

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number  
**WO 2005/105129 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 38/00**
- (21) International Application Number:  
PCT/GB2005/001621
- (22) International Filing Date: 28 April 2005 (28.04.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
2004201774 28 April 2004 (28.04.2004) AU  
2005900650 11 February 2005 (11.02.2005) AU
- (71) Applicant (for all designated States except US): **BTG INTERNATIONAL LIMITED** [GB/GB]; 10 Fleet Place, Limeburner Lane, London EC4M 7SB (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ANDERSON,**


**Robert** [AU/AU]; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3050 (AU). **BEISSBATH, Tim** [DE/DE]; DKFZ (B050) Im Neuenheimer Feld 580, 69120 Heidelberg (DE). **DIN, Jason, Tye** [AU/AU]; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3050 (AU).

(74) Agent: **DOLAN, Anthony, Patrick**; BTG International Limited, 10 Fleet Place, Limeburner Lane, London EC4M 7SB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,

[Continued on next page]

(54) Title: EPITOPES RELATED TO COELIAC DISEASE



(57) Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

WO 2005/105129 A2



TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## EPITOPES RELATED TO COELIAC DISEASE

The invention relates to epitopes useful in the diagnosis and therapy of coeliac disease, including diagnostics, therapeutics, kits, and methods of using the foregoing.

Coeliac disease is caused by an immune mediated hypersensitivity to dietary gluten. Gluten proteins in wheat, rye, barley and in some cases oats are toxic in coeliac disease. Gluten is composed of alpha/beta, gamma and omega gliadins, and low and high molecular weight (LMW and HMW) glutenins in wheat, hordeins in barley, secalins in rye and avenins in oats. Hordeins and secalins are homologous to gamma and omega gliadins and low and high molecular weight glutenins in wheat. Avenins are phylogenetically more distant than hordeins and secalins from wheat gluten.

The goal of research in coeliac disease has been to define the toxic components of gluten by defining the peptides that stimulate gluten-specific T-cells. Precise definition of gluten epitopes permits development of new diagnostics, therapeutics, tests for gluten contamination in food and non-toxic grains that retain the cooking/baking qualities of traditional gluten. Many of these applications require a comprehensive understanding of all rather than the most common toxic peptides in gluten.

Genes encoding HLA-DQ2 and/or HLA-DQ8 are present in over 99% of individuals with coeliac disease compared to approximately 35% of the general Caucasian population. Gluten-derived peptides (epitopes) bound to HLA-DQ2 or HLA-DQ8 stimulate specific T-cells. HLA-DQ2 and DQ8-restricted epitopes include a "core" 9 amino acid sequence that directly interacts with the peptide binding groove of HLA-DQ2 or DQ8 and with cognate T-cell receptors. In general, libraries of overlapping peptides (usually 15 to 20mers) containing all unique 10 or 12mer peptides in an antigen have been used to map HLA class II-restricted T-cells epitopes.

A series of gluten peptides are known to activate gluten specific T-cells in coeliac disease. Previous studies have identified gluten peptides from selected gluten proteins or gluten digests. T-cell clones and lines isolated from intestinal biopsies have been used to screen these gluten components.

Modification of gluten by the enzyme, tissue transglutaminase (tTG) present in intestinal tissue, substantially increases gluten's stimulatory capacity on gluten specific T-cells. Most of the known epitopes for gluten-specific T-cells correspond to tTG-deamidated gluten peptides. Transglutaminase mediates deamidation of specific glutamine residues (to glutamate) in gluten. Glutamine-containing sequences susceptible to deamidation by tTG generally conform to a motif: QXPX or QXX (FYMILVW) (see Vader W. et al 2002 *J. Exp. Med.* 195:643-649, PCT WO 03/066079, and Fleckenstein B. 2002. *J Biol Chem* 277:34109-16). The motif for peptides that bind to HLA-DQ2 and that are susceptible to deamidation by tTG has been used to predict certain gluten epitopes (Vader et al *J Exp Med* 2002 *J. Exp. Med.* 195:643-649, PCT WO 03/066079).

However, other groups have identified epitopes for gluten-specific intestinal T-cell clones and lines using panels of eleven recombinant alpha/beta (11) and five gamma gliadins (Arentz-

Hansen H. 2000. *J. Exp. Med.* 191:603-612, Arentz-Hansen H. 2002. *Gastroenterology* 123:803-809, PCT WO 02/083722), and lysates of purified gluten proteins (Sjostrom H. et al 1998. *Scand. J. Immunol.* 48,111-115; van de Wal, Y. et al 1998. *J. Immunol.* 161(4):1585-1588; van de Wal, Y. et al 1999. *Eur. J. Immunol.* 29:3133-3139; Vader W. et al 2002. *Gastroenterology* 122:1729-1737.).

Our work has exploited the observation that gluten challenge *in vivo* induces HLA-DQ2 restricted CD4+ gluten-specific T-cells in peripheral blood expressing a gut-homing integrin ( $\alpha 4\beta 7$ ). This technique allowed the mapping of the dominant epitope in A-gliadin (57-73 QE65) (Anderson, RP et al 2000. *Nat. Med.* 6:337-342., WO 01/25793). A-gliadin 57-73 QE65 corresponds to two overlapping epitopes identified using intestinal T-cell clones (Arentz-Hansen H. et al 2000. *J. Exp. Med.* 191:603-612, Arentz-Hansen H. et al 2002. *Gastroenterology* 123:803-809). The advantage of *in vivo* gluten challenge to induce gluten specific T-cells is that any food can be consumed and the resulting T-cells induced in blood (quantified in peripheral blood using a simple overnight interferon gamma ELISPOT assay) will have been stimulated *in vivo* by endogenously presented epitopes, rather than primed *in vitro* by a synthetic or purified antigen. Overnight assays of fresh polyclonal peripheral blood T-cells also avoid the potential for artefacts associated with the lengthy purification of T-cell clones.

Interestingly, T-cell clones and lines specific for several gamma-gliadin epitopes (Arentz-Hansen H. 2002. *Gastroenterology* 123:803-809, PCT WO 02/083722) cross-react with the originally defined A-gliadin epitope 57-73 QE65.

Although there is substantial homology within the alpha/beta gliadins, earlier work (see WO 03/104273) has shown that the dominant epitope recognized in HLA-DQ2-associated coeliac disease, "A-gliadin 57-73 QE65", is encoded by a minority of the alpha/beta gliadins present in Genbank.

## SUMMARY OF THE INVENTION

The current study set out to develop a method that would allow mapping of all T-cell epitopes in gluten. Consumption of wheat bread (200g daily for 3 days) or oats (100g daily for 3 days) was used to induce gluten or avenin-specific T-cells in peripheral blood (collected 6 days after beginning the challenge). Peripheral blood mononuclear cells (PBMC) were assessed in overnight interferon gamma ELISPOT assays using a library of gluten and avenin peptides including all unique 12mer sequences included in every Genbank entry for wheat gluten and/or oat avenins. This goal was achieved by establishing an algorithm to design peptides spanning all potential epitopes in gluten proteins in Genbank (2922 20mers included all 14 964 unique 9mers – potential T-cell epitopes), adapting the interferon-gamma ELISPOT assay to a high throughput assay capable of screening over 1000 peptides with a single individual's blood and developing bioinformatics tools to analyse and interpret the data generated.

A series of 41 "superfamilies" of wheat gluten peptides were identified as putative T-cell epitopes. Superfamilies shared motifs in which a limited level of redundancy was allowed. Many of

the most potent families include known T-cell epitopes including the previously described dominant epitope, A-gliadin 57-73.

Through comprehensive mapping of gluten epitopes using PBMC after gluten challenge, the inventors have found a series of novel gliadin, LMW and HMW glutenin, and avenin epitopes for coeliac disease associated with HLA-DQ2 and HLA-DQ8. Novel epitopes were identified for HLA-DQ2 and HLA-DQ8-associated coeliac disease. HLA-DQ2 and HLA-DQ8 associated coeliac disease are genetically and functionally distinct in terms of the range of T-cell epitopes that are recognized. In addition, three peptides present in avenin proteins of oats also activated peripheral blood mononuclear cells (PBMC) following oats challenge in HLA-DQ2+ coeliac subjects, the first time oats epitopes have been defined. Identification of avenin peptides recognized by T-cells following oats challenge *in vivo* provides a molecular basis for the observed occasional relapse of coeliacs following oat exposure (Lundin KEA et al. 2003 Gut 52:1649-52) and may provide a basis for a predictive diagnostic or genetic de-toxification of oats.

The data presented here will provide a comprehensive basis for definition of both common "dominant" and occasional "weak" T-cell epitopes in coeliac disease. This information is the platform for functional applications such as diagnostics, food tests, immunotherapeutics and prophylactics, and for design of non-toxic gluten proteins useful in modified grains.

In particular, through comprehensive mapping of gluten T cell epitopes, the inventors have found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in wheat gliadins and glutenins, having similar core sequences (e.g., SEQ ID NOS: 1-199) and similar extended sequences (e.g., SEQ ID NOS:200-1554, 1555-1655, 1656-1671, and 1830-1903). The inventors have also found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in: oat avenins having similar core sequences (e.g., SEQ ID NOS: 1684-1695) and similar extended sequences (e.g., SEQ ID NO: 1672-1683, 1696-1698, and 1764-1768); rye secalins (SEQ ID NOS: 1769-1786); and barley hordeins (SEQ ID NOS: 1787-1829). Additionally, epitopes bioactive in coeliac disease in HLA-DQ8+ patients have been identified in wheat gliadins having similar core sequences (e.g., SEQ ID NOS: 1699-1721) and similar extended sequences (e.g., SEQ ID NOS: 1722-1763 and 1908-1927). This comprehensive mapping thus provides dominant epitopes recognized by T cells in coeliac patients. Thus, the methods of the invention described herein may be performed using any of these identified epitopes, and analogues and equivalents thereof. That is, the agents of the invention include these epitopes. Additionally, combinations of epitopes, i.e., "combitopes" or single peptides comprising two or more epitopes, have been shown to induce equivalent responses as the individual epitopes, indicating that several epitopes may be utilized for therapeutic, diagnostic, and other uses of the invention. Such combitopes may be in the form of, e.g., SEQ ID NO: 1906. Preferably, the agents of the invention include one or more of the epitopes having the sequences listed recited in SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768,

1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 and analogues and equivalents thereof as defined herein.

Preferred agents that are bioactive in coeliac disease in HLA-DQ8+ patients possess a glutamine in a sequence that suggests susceptibility to deamidation separated by seven residues from a second glutamine also susceptible to deamidation (e.g., as found in QGSFQPSQQ) wherein the deamidated sequences are high affinity binders for HLA-DQ8 following deamidation by tTG (The binding motif for HLA-DQ8 favours glutamate at positions 1 and 9.) In a less preferred embodiment, the agent possesses glutamine residues susceptible to deamidation but not separated by seven residues from a second glutamine susceptible to tTG-mediated deamidation.

The invention thus provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, comprising the steps of: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising an amino acid sequence selected from SEQ ID NOS: 1-1927, preferably selected from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, or an equivalent sequence from a naturally occurring gluten protein, (ii) an analogue of (i) which is capable of being recognised by a T cell receptor that recognises (i), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iii) a product comprising two or more agents as defined in (i) or (ii); and (b) determining *in vitro* whether T cells in the sample recognise the agent, with recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The term "gluten protein" encompasses alpha/beta, gamma and omega gliadins, and low and high molecular weight (LMW and HMW) glutenins in wheat, hordeins in barley, secalins in rye, and avenins in oats. The invention is particularly concerned with gliadins and avenins.

The invention also provides use of the agent for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The finding of epitopes which are modified by transglutaminase also allows diagnosis of coeliac disease based on determining whether other types of immune response to these epitopes are present. Thus the invention also provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to the epitope in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.

The invention provides a method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined above is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The invention also provides a mutant gluten protein whose wild-type sequence can be modified by a transglutaminase to a sequence that comprises an epitope comprising sequence as defined above, but which mutant gluten protein has been modified in such a way that it does not contain sequence which can be modified by a transglutaminase to a sequence that comprises such an epitope comprising sequence; or a fragment of such a mutant gluten protein which is at least 7 amino acids long (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long) and which comprises sequence which has been modified in said way.

The invention also provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises the agent, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

Additionally the invention provides a food that comprises the proteins defined above.

The invention additionally provides the agent, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent. Also provided is an antagonist of a T cell which has a T cell receptor that recognises (i), optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells. Additionally provided is the agent or an analogue that binds an antibody (that binds the agent) for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.

The invention also provides methods of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from: a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs: 1-1927, preferably from the group consisting of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and b) an analogue of a) which is capable of being recognised by a T cell receptor that recognises the peptide of a) and which is not more than 50 amino acids in length. In some embodiments, the agent is HLA-DQ2-restricted, HLA-DQ8-restricted or one agent is HLA-DQ2-restricted and a second agent is HLA-DQ8-restricted. In some embodiments, the agent comprises a wheat epitope, an oat epitope, a rye epitope, a barley epitope or any combination thereof either as a single agent or as multiple agents.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an agent as described above and pharmaceutically acceptable carrier or diluent.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined above, and a pharmaceutically acceptable carrier or diluent.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

The present invention also provides methods of preventing or treating coeliac disease by 1) diagnosing coeliac disease in an individual by either: a) contacting a sample from the host with at least one agent selected from: i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, preferably selected from the group consisting of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease; or b) administering an agent as defined above and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease; and 2) administering to an individual diagnosed as having, or being susceptible to, coeliac disease a therapeutic agent for preventing or treating coeliac disease.

The present invention also provides agents as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

The present invention also provides antagonists of a T cell which has a T cell receptor as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.

The present invention also provides proteins that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined above, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The present invention also provides pharmaceutical compositions comprising an agent or antagonist as defined and a pharmaceutically acceptable carrier or diluent.

The present invention also provides compositions for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

The present invention also provides compositions for antagonising a T cell response to an agent as defined above, which composition comprises an antagonist as defined above.

The present invention also provides mutant gluten proteins whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined above, which mutant gluten protein comprises a mutation which prevents its modification by a transglutaminase to a

sequence which is an agent as defined above; or a fragment of such a mutant gluten protein which is at least 7 amino acids long (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long) and which comprises the mutation.

The present invention also provides polynucleotides that comprise a coding sequence that encodes a protein or fragment as defined above.

The present invention also provides cells comprising a polynucleotide as defined above or which have been transformed with such a polynucleotide.

The present invention also provides mammals that expresses a T cell receptor as defined above.

The present invention also provides methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the host with at least one agent selected from i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, preferably selected from the group consisting of SEQ ID NOS: SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The present invention also provides methods of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The present invention also provides methods of identifying an antagonist of a T cell, which T cell recognises an agent as defined above, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the detecting of any such decrease in said ability indicating that the substance is an antagonist.

The present invention also provides kits for carrying out any of the methods described above comprising an agent as defined above and a means to detect the recognition of the peptide by the T cell.

The present invention also provides methods of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined above which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

The present invention also provides processes for the production of a protein encoded by a coding sequence as defined above which process comprises: a) cultivating a cell described above under conditions that allow the expression of the protein; and optionally b) recovering the expressed protein.

The present invention also provides methods of obtaining a transgenic plant cell comprising transforming a plant cell with a vector as described above to give a transgenic plant cell.

The present invention also provides methods of obtaining a first-generation transgenic plant comprising regenerating a transgenic plant cell transformed with a vector as described above to give a transgenic plant.

The present invention also provides methods of obtaining a transgenic plant seed comprising obtaining a transgenic seed from a transgenic plant obtainable as described above.

The present invention also provides methods of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method as described above, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

The present invention also provides transgenic plant cells, plants, plant seeds or progeny plants obtainable by any of the methods described above.

The present invention also provides transgenic plants or plant seeds comprising plant cells as described above.

The present invention also provides transgenic plant cell calluses comprising plant cells as described above obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny as defined above.

The present invention also provides methods of obtaining a crop product comprising harvesting a crop product from a plant according to any method described above and optionally further processing the harvested product.

The present invention also provides food that comprises a protein as defined above.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows a method to generate all possible peptide epitopes from a group of proteins.

Figure 2 shows Genbank accession numbers for gluten gene products present in the Genbank database on 16th June 2003.

Figure 3A shows an expectation maximization (EM) algorithm to analyze data from ELISpot.

Figure 3B shows a test on a dataset of patients with coeliac disease.

Figure 4 shows an iterative procedure to find minimal set of responsive epitopes.

Figure 5 shows gliadin and glutenin sequences (SEQ ID NOS: 1-1554). In the "consensus" column, letters in lower case use the standard one letter amino acid code, but letters in upper case have a

different meaning: E=[e or q], F=[f or y or w], I=[i or l or v], S=[s or t], R=[r or k or h]. The "sequence" column uses the standard one letter amino acid code.

Figure 6 shows gluten peptides that stimulate gamma interferon in PBMC collected 6 days after gluten challenge in HLA-DQ2+ coeliac disease volunteers (SEQ ID NOS: 1555-1655). The indicated 9mers are common to 200 groups of bioactive "structurally" related 20mer peptides. The gluten sequences are ranked according to the bioactivity X proportion of subjects responding.

Figure 7 shows the results of a wheat challenge experiment (SEQ ID NOS: 1656-1671). These peptides gave high quality responses (indicated 'Y') in ten subjects (A-J) after wheat challenge.

Figure 8 shows Avenin peptides (+/-deamidation by tTG) that stimulate interferon- $\gamma$  in PBMC collected 6 days after gluten challenge in HLA-DQ2+ coeliac disease volunteers (SEQ ID NOS: 1672-1698). Those marked with a \* are optimal unique 20mers inducing IFN- $\gamma$  after oats challenge.

Figure 9 shows the most potent 40 20mers (SEQ ID NOS: 1699-1763) in two HLA-DQ8 (not HLA-DQ2) subjects grouped according to shared core sequences. The core sequence of group 6 (QGSFQPSQQ) corresponds to the alpha-gliadin epitope described by van de Wal *et al* (*J. Immunol.* 1998, 161(4):1585-1588). The maximum response in Subject A was 271 SFC (medium alone, no peptide response: 4 SFC), and in B it was 26 SFC (medium alone, no peptide response: 1 SFC).

Figure 10 shows the amino acid sequence of A-gliadin (SEQ ID NO: 1928) based on amino acid sequencing.

## **DETAILED DESCRIPTION OF THE INVENTION**

The term "coeliac disease" encompasses a spectrum of conditions caused by varying degrees of gluten sensitivity, including a severe form characterised by a flat small intestinal mucosa (hyperplastic villous atrophy) and other forms characterised by milder symptoms.

The individual mentioned above (in the context of diagnosis or therapy) is human. They may have coeliac disease (symptomatic or asymptomatic) or be suspected of having it. They may be on a gluten free diet. They may be in an acute phase response (for example they may have coeliac disease, but have only ingested gluten in the last 24 hours before which they had been on a gluten free diet for 14 to 28 days).

The individual may be susceptible to coeliac disease, such as a genetic susceptibility (determined for example by the individual having relatives with coeliac disease or possessing genes which cause predisposition to coeliac disease).

### ***The agent***

The agent is typically a peptide, for example of length 7 to 50 amino acids, such as 10 to 40, 12 to 35 or 15 to 30 amino acids in length.

The agent may be the peptide represented by any of SEQ ID NOS: 1-1927 or an epitope comprising sequence that comprises any of SEQ ID NOS: 1-1927 which is an isolated oligopeptide

derived from a gluten protein; or an equivalent of these sequences from a naturally occurring gluten protein. In a further set of embodiments of the invention, the agent is any peptide epitope of an oat gluten (*e.g.* any T cell epitope of an avenin).

Preferably, the agent is the peptide represented by any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 or an epitope comprising sequence that comprises any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 which is an isolated oligopeptide derived from a gluten protein; or an equivalent of these sequences from a naturally occurring gluten protein.

Thus the epitope may be a derivative of a naturally occurring gluten protein, particularly from a wheat or oat gluten. Such a derivative is typically a fragment of the gluten protein, or a mutated derivative of the whole protein or fragment. Therefore the epitope of the invention does not include the naturally occurring whole gluten protein, and does not include other whole naturally occurring gluten proteins.

Typically such fragments will be at least 7 amino acids in length (*e.g.*, at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length).

Typically such fragments will be recognised by T cells to at least the same extent that the agents from which they are derived are recognised in any of the assays described herein using samples from coeliac disease patients.

The agent may be the peptide represented by any of SEQ ID NOS: 1-1927, preferably the peptide represented by any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 or a protein comprising a sequence corresponding to any of SEQ ID NOS: 1-1927, preferably comprising a sequence corresponding to any of from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 (such as fragments of a gluten protein comprising any of SEQ ID NOS: 1-1927 and preferably any of from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, for example after the gluten protein has been treated with transglutaminase). Bioactive fragments of such sequences are also agents of the invention. Typically such fragments will be at least 7 amino acids in length (*e.g.*, at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length). Sequences equivalent to any of SEQ ID NOS: 1-1927 or analogues of these sequences are also agents of the invention.

In the case where the epitope comprises a sequence equivalent to the above epitopes (including fragments) from another gluten protein (*e.g.* any of the gluten proteins mentioned herein or any gluten proteins which cause coeliac disease), such equivalent sequences will correspond to a

fragment of a gluten protein typically treated (partially or fully) with transglutaminase. Such equivalent peptides can be determined by aligning the sequences of other gluten proteins with the gluten protein from which the original epitope derives (for example using any of the programs mentioned herein). Transglutaminase is commercially available (e.g. Sigma T-5398).

The agent which is an analogue is capable of being recognised by a TCR which recognises (i). Therefore generally when the analogue is added to T cells in the presence of (i), typically also in the presence of an antigen presenting cell (APC) (such as any of the APCs mentioned herein), the analogue inhibits the recognition of (i), i.e. the analogue is able to compete with (i) in such a system.

The analogue may be one which is capable of binding the TCR which recognises (i). Such binding can be tested by standard techniques. Such TCRs can be isolated from T cells which have been shown to recognise (i) (e.g. using the method of the invention). Demonstration of the binding of the analogue to the TCRs can then be shown by determining whether the TCRs inhibit the binding of the analogue to a substance that binds the analogue, e.g. an antibody to the analogue. Typically the analogue is bound to a class II MHC molecule (e.g. HLA-DQ2) in such an inhibition of binding assay.

Typically the analogue inhibits the binding of (i) to a TCR. In this case the amount of (i) which can bind the TCR in the presence of the analogue is decreased. This is because the analogue is able to bind the TCR and therefore competes with (i) for binding to the TCR.

T cells for use in the above binding experiments can be isolated from patients with coeliac disease, for example with the aid of the method of the invention. Other binding characteristics of the analogue may also be the same as (i), and thus typically the analogue binds to the same MHC class II molecule to which the peptide binds (HLA-DQ2 or -DQ8). The analogue typically binds to antibodies specific for (i), and thus inhibits binding of (i) to such antibodies.

The analogue is typically a peptide. It may have homology with (i), typically at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology with (i), for example over a region of at least 7, 8, 9, 10, 11, 12, 13, 14, 15 or more (such as the entire length of the analogue and/or (i), or across the region which contacts the TCR or binds the MHC molecule) contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux *et al* (1984) *Nucleic Acids Research* **12**, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or align sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information on the world wide web through the Internet at, for example,

“www.ncbi.nlm.nih.gov/”. This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length  $W$  in the query sequence that either match or satisfy some positive-valued threshold score  $T$  when aligned with a word of the same length in a database sequence.  $T$  is referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity  $X$  from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters  $W$ ,  $T$  and  $X$  determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length ( $W$ ) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments ( $B$ ) of 50, expectation ( $E$ ) of 10,  $M=5$ ,  $N=4$ , and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability ( $P(N)$ ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

The homologous peptide analogues typically differ from (i) by 1, 2, 3, 4, 5, 6, 7, 8 or more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology. The substitutions are preferably ‘conservative’. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
	Polar – charged	D E
		K R
AROMATIC		H F W Y

Typically the amino acids in the analogue at the equivalent positions to amino acids in (i) that contribute to binding the MHC molecule or are responsible for the recognition by the TCR, are the same or are conserved.

Typically the analogue peptide comprises one or more modifications, which may be natural post-translation modifications or artificial modifications. The modification may provide a chemical moiety (typically by substitution of a hydrogen, e.g. of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group. Typically the modification is present on the N or C terminus.

The analogue may comprise one or more non-natural amino acids, for example amino acids with a side chain different from natural amino acids. Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L- or a D- amino acid.

The analogue typically has a shape, size, flexibility or electronic configuration that is substantially similar to (i). It is typically a derivative of (i). In one embodiment the analogue is a fusion protein comprising the sequence of any of SEQ ID NOS: 1-1927 and non-gluten sequence. Preferably, the analogue according to this embodiment is a fusion protein comprising the sequence of any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 and non-gluten sequence

In one embodiment the analogue is or mimics (i) bound to a MHC class II molecule. 2, 3, 4 or more of such complexes may be associated or bound to each other, for example using a biotin/streptavidin based system, in which typically 2, 3 or 4 biotin labelled MHC molecules bind to a streptavidin moiety. This analogue typically inhibits the binding of the (i)/MHC Class II complex to a TCR or antibody which is specific for the complex.

The analogue is typically an antibody or a fragment of an antibody, such as a Fab or F(ab')<sub>2</sub> fragment. The analogue may be immobilised on a solid support, particularly an analogue that mimics peptide bound to a MHC molecule.

The analogue is typically designed by computational means and then synthesised using methods known in the art. Alternatively the analogue can be selected from a library of compounds. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class II molecule, such as HLA-DQ2 or -DQ8. Analogues are generally selected from the library based on their ability to mimic the binding characteristics (i). Thus they may be selected based on ability to bind a TCR or antibody which recognises (i).

Typically analogues will be recognised by T cells to at least the same extent as any of the agents (i), for example at least to the same extent as the equivalent epitope is recognised in any of the assays described herein, typically using T cells from coeliac disease patients. Analogues may be recognised to these extents *in vivo* and thus may be able to induce coeliac disease symptoms to at

least the same extent as any of the agents mentioned herein (e.g. in a human patient or animal model).

Analogues may be identified in a method comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope of the invention, recognition of the substance indicating that the substance is an analogue. Such TCRs may be any of the TCRs mentioned herein, and may be present on T cells. Any suitable assay mentioned herein can be used to identify the analogue. In one embodiment this method is carried out *in vivo*. As mentioned above preferred analogues are recognised to at least the same extent as the equivalent epitope, and so the method may be used to identify analogues which are recognised to this extent.

In one embodiment the method comprises determining whether a candidate substance is able to inhibit the recognition of an epitope of the invention, inhibition of recognition indicating that the substance is an analogue.

The agent may be a product comprising at least 2, 5, 10 or 20 agents as defined by (i) or (ii). Typically the composition comprises epitopes of the invention (or equivalent analogues) from different gluten proteins, such as any of the species or variety of or types of gluten protein mentioned herein. Preferred compositions comprise at least one epitope of the invention, or equivalent analogue, from all of the glutens present in any of the species or variety mentioned herein, or from 2, 3, 4 or more of the species mentioned herein (such as from the panel of species consisting of wheat, rye, barley, oats and triticale). Thus, the agent may be monovalent or multivalent.

According to certain embodiments of the invention, the agent does not have or is not based on a sequence disclosed in WO 02/083722 and/or WO 01/25793 and/or WO03/104273 and/or recited in any of SEQ ID NOS: 1555-1577, 1580-1581, 1584-1586, 1594-1599, 1621-1622 and/or is not an agent derived from A-gliadin, the sequence of which is given in Figure 10.

Within SEQ ID NOS: 1-1927, a preferred subset is SEQ ID NOS: 1-1763. Within SEQ ID NOS: 1764-1927, preferred subsets are: (a) oat sequences 1764-1768, (b) rye sequences 1769-1786, (c) barley sequences 1787-1829, (d) wheat sequences 1895-1903, (e) wheat DQ8 sequences 1908-1927, and (f) combitope sequence 1906. Other preferred subsets are: (a) 1764-1768, (b) 1769-1773, (c) 1774-1786, (d) 1787-1792, (e) 1793-1829, (f) 1830-1894, (g) 1895-1903, (h) 1830-1903, (i) 1904-1906, (j) 1908-1916, (k) 1917-1927, and (l) 1908-1913, 1915-1923 and 1925-1927.

Within SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, & 1764-1927, particularly preferred wheat epitopes are SEQ ID NOS: 1656-1671, 1830-1903, and 1907-1927.

Within SEQ ID NOS: 1830-1894 (Table 1), some sequences have N-terminal and C-terminal glycines. The invention extends to these sequences omitting the C-terminal glycine and/or the N-terminal glycine. Preferably, both the C-terminal glycine and the N-terminal glycine are omitted.

### **Diagnosis**

As mentioned above the method of diagnosis of the invention may be based on the detection of T cells that bind the agent or on the detection of antibodies that recognise the agent.

The T cells that recognise the agent in the method (which includes the use mentioned above) are generally T cells that have been pre-sensitised *in vivo* to one or more gluten proteins. As mentioned above such antigen-experienced T cells have been found to be present in the peripheral blood.

In the method the T cells can be contacted with the agent *in vitro* or *in vivo*, and determining whether the T cells recognise the agent can be performed *in vitro* or *in vivo*. Thus the invention provides the agent for use in a method of diagnosis practiced on the human body. Different agents are provided for simultaneous, separate or sequential use in such a method.

The *in vitro* method is typically carried out in aqueous solution into which the agent is added. The solution will also comprise the T cells (and in certain embodiments the APCs discussed below). The term 'contacting' as used herein includes adding the particular substance to the solution.

Determination of whether the T cells recognise the agent is generally accomplished by detecting a change in the state of the T cells in the presence of the agent or determining whether the T cells bind the agent. The change in state is generally caused by antigen specific functional activity of the T cell after the TCR binds the agent. The change of state may be measured inside (e.g. change in intracellular expression of proteins) or outside (e.g. detection of secreted substances) the T cells.

The change in state of the T cell may be the start of or increase in secretion of a substance from the T cell, such as a cytokine, especially IFN- $\gamma$ , IL-2 or TNF- $\alpha$ . Determination of IFN- $\gamma$  secretion is particularly preferred. The substance can typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

Typically the specific binding agent is immobilised on a solid support. After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent that will bind the complex. Typically the second agent binds the substance at a site which is different from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

Thus the second agent may be detected by a third agent that is typically labelled directly or indirectly by a detectable label. For example the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

In one embodiment the detection system which is used is the *ex-vivo* ELISPOT assay described in WO 98/23960. In that assay IFN- $\gamma$  secreted from the T cell is bound by a first IFN- $\gamma$  specific antibody that is immobilised on a solid support. The bound IFN- $\gamma$  is then detected using a second IFN- $\gamma$  specific antibody which is labelled with a detectable label. Such a labelled antibody can be obtained from MABTECH (Stockholm, Sweden). Other detectable labels which can be used are discussed below.

The change in state of the T cell that can be measured may be the increase in the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or a change in cell surface markers on the T cell.

In one embodiment the change of state is detected by measuring the change in the intracellular expression of proteins, for example the increase in intracellular expression of any of the cytokines mentioned above. Such intracellular changes may be detected by contacting the inside of the T cell with a moiety that binds the expressed proteins in a specific manner and which allows sorting of the T cells by flow cytometry.

In one embodiment when binding the TCR the agent is bound to an MHC class II molecule (typically HLA-DQ2 or -DQ8), which is typically present on the surface of an antigen presenting cell (APC). However as mentioned herein other agents can bind a TCR without the need to also bind an MHC molecule.

Generally the T cells which are contacted in the method are taken from the individual in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the samples. The MCs will comprise the T cells and APCs. Thus in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T cells, such as only CD4 T cells, can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art, such as those described in Lalvani *et al* (1997) *J. Exp. Med.* **186**, p859-865.

In one embodiment, the T cells used in the assay are in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they are not cultured before being used in the method. Thus the T cells have not been restimulated in an antigen specific manner *in vitro*. However the T cells can be cultured before use, for example in the presence of one or more of the agents, and generally also exogenous growth promoting cytokines. During culturing the agent(s) are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an

increase in the sensitivity of the method. Thus the T cells can be converted into cell lines, such as short term cell lines (for example as described in Ota *et al* (1990) *Nature* 346, p183-187).

The APC that is typically present in the method may be from the same individual as the T cell or from a different host. The APC may be a naturally occurring APC or an artificial APC. The APC is a cell that is capable of presenting the peptide to a T cell. It is typically a B cell, dendritic cell or macrophage. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus the APC may be present in MCs or PBMCs. The APC is typically a freshly isolated *ex vivo* cell or a cultured cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class II molecules on its surface.

In the method one or more (different) agents may be used. Typically the T cells derived from the sample can be placed into an assay with all the agents which it is intended to test or the T cells can be divided and placed into separate assays each of which contain one or more of the agents.

The invention also provides the agents such as two or more of any of the agents mentioned herein (e.g. the combinations of agents which are present in the composition agent discussed above) for simultaneous separate or sequential use (eg. for *in vivo* use).

In one embodiment agent *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs. When agents that can be recognised by the T cell without the need for presentation by APCs are used then APCs are not required. Analogues which mimic the original (i) bound to a MHC molecule are an example of such an agent.

In one embodiment the agent is provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the agent on its surface. The peptide may have been taken up inside the APC and presented, or simply be taken up onto the surface without entering inside the APC.

The duration for which the agent is contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically  $10^5$  to  $10^7$ , preferably  $5 \times 10^5$  to  $10^6$  PBMCs are added to each assay. In the case where agent is added directly to the assay its concentration is from  $10^{-1}$  to  $10^3 \mu\text{g/ml}$ , preferably 0.5 to  $50 \mu\text{g/ml}$  or 1 to  $10 \mu\text{g/ml}$ .

Typically the length of time for which the T cells are incubated with the agent is from 4 to 24 hours, preferably 6 to 16 hours. When using *ex vivo* PBMCs it has been found that  $0.3 \times 10^6$  PBMCs can be incubated in  $10 \mu\text{g/ml}$  of peptide for 12 hours at  $37^\circ\text{C}$ .

The determination of the recognition of the agent by the T cells may be done by measuring the binding of the agent to the T cells (this can be carried out using any suitable binding assay format discussed herein). Typically T cells which bind the agent can be sorted based on this binding, for example using a FACS machine. The presence of T cells that recognise the agent will be deemed to occur if the frequency of cells sorted using the agent is above a "control" value. The frequency of

antigen-experienced T cells is generally 1 in  $10^6$  to 1 in  $10^3$ , and therefore whether or not the sorted cells are antigen-experienced T cells can be determined.

The determination of the recognition of the agent by the T cells may be measured *in vivo*. Typically the agent is administered to the host and then a response which indicates recognition of the agent may be measured. The agent is typically administered intradermally or epidermally. The agent is typically administered by contacting with the outside of the skin, and may be retained at the site with the aid of a plaster or dressing. Alternatively the agent may be administered by needle, such as by injection, but can also be administered by other methods such as ballistics (e.g. the ballistics techniques which have been used to deliver nucleic acids). EP-A-0693119 describes techniques that can typically be used to administer the agent. Typically from 0.001 to 1000  $\mu\text{g}$ , for example from 0.01 to 100  $\mu\text{g}$  or 0.1 to 10  $\mu\text{g}$  of agent is administered.

In one embodiment a product can be administered which is capable of providing the agent *in vivo*. Thus a polynucleotide capable of expressing the agent can be administered, typically in any of the ways described above for the administration of the agent. The polynucleotide typically has any of the characteristics of the polynucleotide provided by the invention which is discussed below. The agent is expressed from the polynucleotide *in vivo*. Typically from 0.001 to 1000  $\mu\text{g}$ , for example from 0.01 to 100  $\mu\text{g}$  or 0.1 to 10  $\mu\text{g}$  of polynucleotide is administered.

Recognition of the agent administered to the skin is typically indicated by the occurrence of inflammation (e.g. induration, erythema or oedema) at the site of administration. This is generally measured by visual examination of the site.

The method of diagnosis based on the detection of an antibody that binds the agent is typically carried out by contacting a sample from the individual (such as any of the samples mentioned here, optionally processed in any manner mentioned herein) with the agent and determining whether an antibody in the sample binds the agent, such a binding indicating that the individual has, or is susceptible to coeliac disease. Any suitable format of binding assay may be used, such as any such format mentioned herein.

### ***Therapy***

The identification of the immunodominant epitope and other epitopes described herein allows therapeutic products to be made which target the T cells which recognise this epitope (such T cells being ones which participate in the immune response against gluten proteins). These findings also allow the prevention or treatment of coeliac disease by suppressing (by tolerisation) an antibody or T cell response to the epitope(s).

Certain agents of the invention bind the TCR that recognises the epitope of the invention (as measured using any of the binding assays discussed above) and cause tolerisation of the T cell that carries the TCR. Such agents, optionally in association with a carrier, can therefore be used to prevent or treat coeliac disease.

Generally tolerisation can be caused by the same peptides which can (after being recognised by the TCR) cause antigen specific functional activity of the T cell (such as any such activity mentioned herein, e.g. secretion of cytokines). Such agents cause tolerisation when they are presented to the immune system in a 'tolerising' context.

Tolerisation leads to a decrease in the recognition of a T cell or antibody epitope by the immune system. In the case of a T cell epitope this can be caused by the deletion or anergising of T cells that recognise the epitope. Thus T cell activity (for example as measured in suitable assays mentioned herein) in response to the epitope is decreased. Tolerisation of an antibody response means that a decreased amount of specific antibody to the epitope is produced when the epitope is administered.

Methods of presenting antigens to the immune system in such a context are known and are described for example in Yoshida et al. *Clin. Immunol. Immunopathol.* 82, 207-215 (1997), Thureau et al. *Clin. Exp. Immunol.* 109, 370-6 (1997), and Weiner et al. *Res. Immunol.* 148, 528-33 (1997). In particular certain routes of administration can cause tolerisation, such as oral, nasal or intraperitoneal. Tolerisation may also be accomplished via dendritic cells and tetramers presenting peptide. Particular products which cause tolerisation may be administered (e.g. in a composition that also comprises the agent) to the individual. Such products include cytokines, such as cytokines that favour a Th2 response (e.g. IL-4, TGF- $\beta$  or IL-10). Products or agent may be administered at a dose that causes tolerisation.

The invention provides a protein that comprises a sequence able to act as an antagonist of the T cell (which T cell recognises the agent). Such proteins and such antagonists can also be used to prevent or treat coeliac disease. The antagonist will cause a decrease in the T cell response. In one embodiment, the antagonist binds the TCR of the T cell (generally in the form of a complex with HLA-DQ2 or -DQ8) but instead of causing normal functional activation causing an abnormal signal to be passed through the TCR intracellular signalling cascade, which causes the T cell to have decreased function activity (e.g. in response to recognition of an epitope, typically as measured by any suitable assay mentioned herein).

In one embodiment the antagonist competes with epitope to bind a component of MHC processing and presentation pathway, such as an MHC molecule (typically HLA-DQ2 or -DQ8). Thus the antagonist may bind HLA-DQ2 or -DQ8 (and thus be a peptide presented by this MHC molecule) or a homologue thereof.

Methods of causing antagonism are known in the art. In one embodiment the antagonist is a homologue of the epitopes mentioned above and may have any of the sequence, binding or other properties of the agent (particularly analogues). The antagonists typically differ from any of the above epitopes (which are capable of causing a normal antigen specific function in the T cell) by 1, 2, 3, 4 or more mutations (each of which may be a substitution, insertion or deletion). Such

antagonists are termed "altered peptide ligands" or "APL" in the art. The mutations are typically at the amino acid positions that contact the TCR.

For example, the antagonist may differ from the epitope by a substitution within the sequence that is equivalent to the sequence represented by amino acids 64 to 67 of A-gliadin (the sequence of A-gliadin is given in Figure 10). Thus preferably the antagonist has a substitution at the equivalent of position 64, 65 or 67. Preferably the substitution is 64W, 67W, 67M or 65T.

Since the T cell immune response to the epitope of the invention in an individual is polyclonal, more than one antagonist may need to be administered to cause antagonism of T cells of the response which have different TCRs. Therefore the antagonists may be administered in a composition which comprises at least 2, 4, 6 or more different antagonists, which each antagonise different T cells.

The invention also provides a method of identifying an antagonist of a T cell (which recognises the agent), comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response (e.g. using any suitable assay mentioned herein), the detecting of any such decrease in said ability indicating that the substance is an antagonist.

In one embodiment, the antagonists (including combinations of antagonists to a particular epitope) or tolerising (T cell and antibody tolerising) agents are present in a composition comprising at least 2, 4, 6 or more antagonists or agents which antagonise or tolerate to different epitopes of the invention, for example to the combinations of epitopes discussed above in relation to the agents which are a product comprising more than one substance.

#### ***Testing whether a composition is capable of causing coeliac disease***

As mentioned above the invention provides a method of determining whether a composition is capable of causing coeliac disease comprising detecting the presence of a protein sequence which is capable of being modified by a transglutaminase to a sequence comprising the agent or epitope of the invention (such transglutaminase activity may be a human intestinal transglutaminase activity). Typically this is performed by using a binding assay in which a moiety which binds to the sequence in a specific manner is contacted with the composition and the formation of sequence/moiety complex is detected and used to ascertain the presence of the agent. Such a moiety may be any suitable substance (or type of substance) mentioned herein, and is typically a specific antibody. Any suitable format of binding assay can be used (such as those mentioned herein).

In one embodiment, the composition is contacted with at least 2, 5, 10 or more antibodies which are specific for epitopes of the invention from different gluten proteins, for example a panel of antibodies capable of recognising the combinations of epitopes discussed above in relation to agents of the invention which are a product comprising more than one substance.

The composition typically comprises material from a plant that expresses a gluten protein which is capable of causing coeliac disease (for example any of the gluten proteins or plants

mentioned herein). Such material may be a plant part, such as a harvested product (e.g. seed). The material may be processed products of the plant material (e.g. any such product mentioned herein), such as a flour or food that comprises the gluten protein. The processing of food material and testing in suitable binding assays is routine, for example as mentioned in Kricka LJ, J. Biolumin. Chemilumin. 13, 189-93 (1998).

### ***Binding assays***

The determination of binding between any two substances mentioned herein may be done by measuring a characteristic of either or both substances that changes upon binding, such as a spectroscopic change.

The binding assay format may be a 'band shift' system. This involves determining whether the presence of one substance (such as a candidate substance) advances or retards the progress of the other substance during gel electrophoresis.

The format may be a competitive binding method which determines whether the one substance is able to inhibit the binding of the other substance to an agent which is known to bind the other substance, such as a specific antibody.

### ***Mutant gluten proteins***

The invention provides a gluten protein in which an epitope sequence of the invention, or sequence which can be modified by a transglutaminase to provide such a sequence has been mutated so that it no longer causes, or is recognised by, a T cell response that recognises the epitope. In this context the term recognition refers to the TCR binding the epitope in such a way that normal (not antagonistic) antigen-specific functional activity of the T cell occurs.

Methods of identifying equivalent epitopes in other gluten proteins are discussed above. The wild type of the mutated gluten protein is one which causes coeliac disease. Such a mutated gluten protein may have homology with the wild type of the mutated gluten protein, for example to the degree mentioned above (in relation to the analogue) across all of its sequence or across 15, 30, 60, 100 or 200 contiguous amino acids of its sequence. The sequences of other natural gluten proteins are known in the art.

The mutated gluten protein will not cause coeliac disease or will cause decreased symptoms of coeliac disease. Typically the mutation decreases the ability of the epitope to induce a T cell response. The mutated epitope may have a decreased binding to HLA-DQ2 or -DQ8, a decreased ability to be presented by an APC or a decreased ability to bind to or to be recognised (i.e. cause antigen-specific functional activity) by T cells that recognise the agent. The mutated gluten protein or epitope will therefore show no or reduced recognition in any of the assays mentioned herein in relation to the diagnostic aspects of the invention.

The mutation may be one or more deletions, additions or substitutions of length 1 to 3, 4 to 6, 6 to 10, 11 to 15 or more in the epitope, for example across any of SEQ ID NOS: 1-1927; or across

equivalents thereof. Preferably the mutant gluten protein has at least one mutation in the sequence of any of SEQ ID NO: 1-1927. A preferred mutation is at the position equivalent to position 65 in A-gliadin (see Figure 10). Preferably, a naturally occurring glutamine is substituted to histidine, tyrosine, tryptophan, lysine, proline, or arginine.

The invention thus also provides use of a mutation (such any of the mutations in any of the sequences discussed herein) in an epitope of a gluten protein, which epitope is an epitope of the invention, to decrease the ability of the gluten protein to cause coeliac disease.

In one embodiment the mutated sequence is able to act as an antagonist. Thus the invention provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent of the invention, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The invention also provides proteins which are fragments of the above mutant gluten proteins, which are at least 7 amino acids long (e.g. at least 8, 9, 10, 11, 12, 13, 14, 15, 30, 60, 100, 150, 200, or 250 amino acids long) and which comprise the mutations discussed above which decrease the ability of the gluten protein to be recognised. Any of the mutant proteins (including fragments) mentioned herein may also be present in the form of fusion proteins, for example with other gluten proteins or with non-gluten proteins.

The equivalent wild type protein to the mutated gluten protein is typically from a graminaceous monocotyledon, such as a plant of a genus selected from *Triticum*, *Secale*, *Hordeum*, *Triticale* or *Avena*, (e.g. wheat, rye, barley, oats or triticale). For example, the protein may be an  $\alpha$ ,  $\alpha\beta$ ,  $\beta$ ,  $\gamma$  or  $\omega$  gliadin or an avenin.

### **Kits**

The invention also provides a kit for carrying out the method comprising one or more agents and optionally a means to detect the recognition of the agent by the T cell. Typically the different agents are provided for simultaneous, separate or sequential use. Typically the means to detect recognition allows or aids detection based on the techniques discussed above.

Thus the means may allow detection of a substance secreted by the T cells after recognition. The kit may thus additionally include a specific binding moiety for the substance, such as an antibody. The moiety is typically specific for IFN- $\gamma$ . The moiety is typically immobilised on a solid support. This means that after binding the moiety the substance will remain in the vicinity of the T cell which secreted it. Thus "spots" of substance/moiety complex are formed on the support, each spot representing a T cell which is secreting the substance. Quantifying the spots, and typically comparing against a control, allows determination of recognition of the agent.

The kit may also comprise a means to detect the substance/moiety complex. A detectable change may occur in the moiety itself after binding the substance, such as a colour change. Alternatively a second moiety directly or indirectly labelled for detection may be allowed to bind the substance/moiety complex to allow the determination of the spots. As discussed above the second

moiety may be specific for the substance, but binds a different site on the substance than the first moiety.

The immobilised support may be a plate with wells, such as a microtitre plate. Each assay can therefore be carried out in a separate well in the plate.

The kit may additionally comprise medium for the T cells, detection moieties or washing buffers to be used in the detection steps. The kit may additionally comprise reagents suitable for the separation from the sample, such as the separation of PBMCs or T cells from the sample. The kit may be designed to allow detection of the T cells directly in the sample without requiring any separation of the components of the sample.

The kit may comprise an instrument which allows administration of the agent, such as intradermal or epidermal administration. Typically such an instrument comprises plaster, dressing or one or more needles. The instrument may allow ballistic delivery of the agent. The agent in the kit may be in the form of a pharmaceutical composition.

The kit may also comprise controls, such as positive or negative controls. The positive control may allow the detection system to be tested. Thus the positive control typically mimics recognition of the agent in any of the above methods. Typically in the kits designed to determine recognition *in vitro* the positive control is a cytokine. In the kit designed to detect *in vivo* recognition of the agent the positive control may be antigen to which most individuals should response.

The kit may also comprise a means to take a sample containing T cells from the host, such as a blood sample. The kit may comprise a means to separate mononuclear cells or T cells from a sample from the host.

### ***Polynucleotides, cells, transgenic mammals and antibodies***

The invention also provides a polynucleotide which is capable of expression to provide the agent or mutant gluten proteins. Typically the polynucleotide is DNA or RNA, and is single or double stranded. The polynucleotide will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 or more bases or base pairs. The polynucleotide therefore comprises a sequence which encodes the sequence of any of SEQ ID NO: 1-1927 or any of the other agents mentioned herein. To the 5' and 3' of this coding sequence the polynucleotide of the invention has sequence or codons which are different from the sequence or codons 5' and 3' to these sequences in the corresponding gluten protein gene.

5' and/or 3' to the sequence encoding the peptide the polynucleotide has coding or non-coding sequence. Sequence 5' and/or 3' to the coding sequence may comprise sequences which aid expression, such as transcription and/or translation, of the sequence encoding the agent. The polynucleotide may be capable of expressing the agent prokaryotic or eukaryotic cell. In one embodiment the polynucleotide is capable of expressing the agent in a mammalian cell, such as a human, primate or rodent (e.g. mouse or rat) cell.

A polynucleotide of the invention may hybridise selectively to a polynucleotide that encodes a gluten protein from which the agent is derived at a level significantly above background. Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C). However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook *et al* (1989), *Molecular Cloning: A Laboratory Manual*). For example, if high stringency is required, suitable conditions include 0.2 x SSC at 60°C. If lower stringency is required, suitable conditions include 2 x SSC at 60°C.

Agents or proteins of the invention may be encoded by the polynucleotides described herein.

The polynucleotide may form or be incorporated into a replicable vector. Such a vector is able to replicate in a suitable cell. The vector may be an expression vector. In such a vector the polynucleotide of the invention is operably linked to a control sequence which is capable of providing for the expression of the polynucleotide. The vector may contain a selectable marker, such as the ampicillin resistance gene.

The polynucleotide or vector may be present in a cell. Such a cell may have been transformed by the polynucleotide or vector. The cell may express the agent. The cell will be chosen to be compatible with the said vector and may for example be a prokaryotic (bacterial), yeast, insect or mammalian cell. The polynucleotide or vector may be introduced into host cells using conventional techniques including calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

The invention provides processes for the production of the proteins of the invention by recombinant means. This may comprise (a) cultivating a transformed cell as defined above under conditions that allow the expression of the protein; and preferably (b) recovering the expressed polypeptide. Optionally, the polypeptide may be isolated and/or purified, by techniques known in the art.

The invention also provides TCRs which recognise (or bind) the agent, or fragments thereof which are capable of such recognition (or binding). These can be present in the any form mentioned herein (e.g. purity) discussed herein in relation to the protein of the invention. The invention also provides T cells which express such TCRs which can be present in any form (e.g. purity) discussed herein for the cells of the invention.

The invention also provides monoclonal or polyclonal antibodies which specifically recognise the agents (such as any of the epitopes of the invention) and which recognise the mutant gluten proteins (and typically which do not recognise the equivalent wild-type gluten proteins) of the invention, and methods of making such antibodies. Antibodies of the invention bind specifically to these substances of the invention.

For the purposes of this invention, the term "antibody" includes antibody fragments such as Fv, F(ab) and F(ab')<sub>2</sub> fragments, as well as single-chain antibodies.

A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) *Nature* **256**, 495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

The polynucleotide, agent, protein or antibody of the invention, may carry a detectable label. Detectable labels which allow detection of the secreted substance by visual inspection, optionally with the aid of an optical magnifying means, are preferred. Such a system is typically based on an enzyme label which causes colour change in a substrate, for example alkaline phosphatase causing a colour change in a substrate. Such substrates are commercially available, e.g. from BioRad. Other suitable labels include other enzymes such as peroxidase, or protein labels, such as biotin; or radioisotopes, such as <sup>32</sup>P or <sup>35</sup>S. The above labels may be detected using known techniques.

Polynucleotides, agents, proteins, antibodies or cells of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% of the polynucleotide, peptide, antibody, cells or dry mass in the preparation. The polynucleotide, agent, protein or antibody is typically substantially free of other cellular components. The polynucleotide, agent, protein or antibody may be used in such a substantially isolated, purified or free form in the method or be present in such forms in the kit.

The invention also provides a transgenic non-human mammal which expresses a TCR of the invention. This may be any of the mammals discussed herein (e.g. in relation to the production of the antibody). Preferably the mammal has, or is susceptible, to coeliac disease. The mammal may also express HLA-DQ2 or -DQ8 or HLA-DR3-DQ2 and/or may be given a diet comprising a gluten protein which causes coeliac disease (e.g. any of the gluten proteins mentioned herein). Thus the mammal may act as an animal model for coeliac disease.

The invention also provides a method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal of the invention which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product. Such a product may be used to treat or prevent coeliac disease.

The invention provides therapeutic (including prophylactic) agents or diagnostic substances (the agents, proteins and polynucleotides of the invention). These substances are formulated for clinical administration by mixing them with a pharmaceutically acceptable carrier or diluent. For example they can be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous, intraocular, intradermal, epidermal or transdermal administration. The substances may be mixed with any vehicle which is pharmaceutically acceptable and appropriate for the desired route of administration. The pharmaceutically carrier or diluent for injection may be, for example, a sterile or isotonic solution such as Water for Injection or physiological saline, or a carrier particle for ballistic delivery.

The dose of the substances may be adjusted according to various parameters, especially according to the agent used; the age, weight and condition of the patient to be treated; the mode of administration used; the severity of the condition to be treated; and the required clinical regimen. As a guide, the amount of substance administered by injection is suitably from 0.01 mg/kg to 30 mg/kg, preferably from 0.1 mg/kg to 10 mg/kg.

The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The substances of the invention may thus be used in a method of treatment of the human or animal body, or in a diagnostic method practised on the human body. In particular they may be used in a method of treating or preventing coeliac disease. The invention also provide the agents for use in a method of manufacture of a medicament for treating or preventing coeliac disease. Thus the invention provides a method of preventing or treating coeliac disease comprising administering to a human in need thereof a substance of the invention (typically a non-toxic effective amount thereof).

The agent of the invention can be made using standard synthetic chemistry techniques, such as by use of an automated synthesizer. The agent may be made from a longer polypeptide e.g. a fusion protein, which polypeptide typically comprises the sequence of the peptide. The peptide may be derived from the polypeptide by for example hydrolysing the polypeptide, such as using a protease; or by physically breaking the polypeptide. The polynucleotide of the invention can be made using standard techniques, such as by using a synthesiser.

***Plant cells and plants that express mutant gluten proteins or express proteins comprising sequences which can act as antagonists***

The cell of the invention may be a plant cell, such as a cell of a graminaceous monocotyledonous species. The species may be one whose wild-type form expresses gluten proteins, such as any of the gluten proteins mentioned herein. Such a gluten protein may cause coeliac disease in humans. The cell may be of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane. Typically the cell is of the *Triticum* genus, such as *aestivum*, *spelta*, *polonicum* or *monococcum*.

The plant cell of the invention is typically one which does not express one or more wild-type gluten proteins (such as any of the gluten proteins mentioned herein which may cause coeliac disease), or one which does not express one or more gluten proteins comprising a sequence that can be recognised by a T cell that recognises the agent. Thus if the wild-type plant cell did express such a gluten protein then it may be engineered to prevent or reduce the expression of such a gluten protein or to change the amino acid sequence of the gluten protein so that it no longer causes coeliac disease (typically by no longer expressing the epitope of the invention).

This can be done for example by introducing mutations into 1, 2, 3 or more or all of such gluten protein genes in the cell, for example into coding or non-coding (e.g. promoter regions). Such mutations can be any of the type or length of mutations discussed herein (e.g., in relation to homologous proteins). The mutations can be introduced in a directed manner (e.g., using site directed mutagenesis or homologous recombination techniques) or in a random manner (e.g. using a mutagen, and then typically selecting for mutagenised cells which no longer express the gluten protein (or a gluten protein sequence which causes coeliac disease)).

In the case of plants or plant cells that express a protein that comprises a sequence able to act as an antagonist such a plant or plant cell may express a wild-type gluten protein (e.g. one which causes coeliac disease). Preferably though the presence of the antagonist sequence will cause reduced coeliac disease symptoms (such as no symptoms) in an individual who ingests a food comprising protein from the plant or plant cell.

The polynucleotide which is present in (or which was transformed into) the plant cell will generally comprise promoter capable of expressing the mutant gluten protein the plant cell. Depending on the pattern of expression desired, the promoter may be constitutive, tissue- or stage-specific; and/or inducible. For example, strong constitutive expression in plants can be obtained with the CAMV 35S, Rubisco *ssu*, or histone promoters. Also, tissue-specific or stage-specific promoters may be used to target expression of protein of the invention to particular tissues in a transgenic plant or to particular stages in its development. Thus, for example seed-specific, root-specific, leaf-specific, flower-specific etc promoters may be used. Seed-specific promoters include those described by Dalta *et al* (Biotechnology Ann. Rev. (1997), 3, pp.269-296). Particular examples of seed-specific promoters are napin promoters (EP-A-0 255, 378), phaseolin promoters, glutenine promoters,

helianthene promoters (WO92/17580), albumin promoters (WO98/45460), oleosin promoters (WO98/45461) and ATS1 and ATS3 promoters (WO99/20775).

The cell may be in any form. For example, it may be an isolated cell, e.g. a protoplast, or it may be part of a plant tissue, e.g. a callus, or a tissue excised from a plant, or it may be part of a whole plant. The cell may be of any type (e.g. of any type of plant part). For example, an undifferentiated cell, such as a callus cell; or a differentiated cell, such as a cell of a type found in embryos, pollen, roots, shoots or leaves. Plant parts include roots; shoots; leaves; and parts involved in reproduction, such as pollen, ova, stamens, anthers, petals, sepals and other flower parts.

The invention provides a method of obtaining a transgenic plant cell comprising transforming a plant cell with a polynucleotide or vector of the invention to give a transgenic plant cell. Any suitable transformation method may be used (in the case of wheat the techniques disclosed in Vasil V et al, *Biotechnology* 10, 667-674 (1992) may be used). Preferred transformation techniques include electroporation of plant protoplasts and particle bombardment. Transformation may thus give rise to a chimeric tissue or plant in which some cells are transgenic and some are not.

The cell of the invention or thus obtained cell may be regenerated into a transgenic plant by techniques known in the art. These may involve the use of plant growth substances such as auxins, gibberellins and/or cytokinins to stimulate the growth and/or division of the transgenic cell. Similarly, techniques such as somatic embryogenesis and meristem culture may be used. Regeneration techniques are well known in the art and examples can be found in, e.g. US 4,459,355, US 4,536,475, US 5,464,763, US 5, 177,010, US 5, 187,073, EP 267,159, EP 604, 662, EP 672, 752, US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014, US 5,478,744, US 5,179,022, US 5,565,346, US 5,484,956, US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520, US 5,510,318, US 5,204,253, US 5,405,765, EP 442,174, EP 486,233, EP 486,234, EP 539,563, EP 674,725, WO91/02071 and WO 95/06128.

In many such techniques, one step is the formation of a callus, i.e. a plant tissue comprising expanding and/or dividing cells. Such calli are a further aspect of the invention as are other types of plant cell cultures and plant parts. Thus, for example, the invention provides transgenic plant tissues and parts, including embryos, meristems, seeds, shoots, roots, stems, leaves and flower parts. These may be chimeric in the sense that some of their cells are cells of the invention and some are not. Transgenic plant parts and tissues, plants and seeds of the invention may be of any of the plant species mentioned herein.

Regeneration procedures will typically involve the selection of transformed cells by means of marker genes.

The regeneration step gives rise to a first generation transgenic plant. The invention also provides methods of obtaining transgenic plants of further generations from this first generation plant. These are known as progeny transgenic plants. Progeny plants of second, third, fourth, fifth,

sixth and further generations may be obtained from the first generation transgenic plant by any means known in the art.

Thus, the invention provides a method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant of the invention, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

Progeny plants may be produced from their predecessors of earlier generations by any known technique. In particular, progeny plants may be produced by: (a) obtaining a transgenic seed from a transgenic plant of the invention belonging to a previous generation, then obtaining a transgenic progeny plant of the invention belonging to a new generation by growing up the transgenic seed; and/or (b) propagating clonally a transgenic plant of the invention belonging to a previous generation to give a transgenic progeny plant of the invention belonging to a new generation; and/or (c) crossing a first-generation transgenic plant of the invention belonging to a previous generation with another compatible plant to give a transgenic progeny plant of the invention belonging to a new generation; and optionally (d) obtaining transgenic progeny plants of one or more further generations from the progeny plant thus obtained.

These techniques may be used in any combination. For example, clonal propagation and sexual propagation may be used at different points in a process that gives rise to a transgenic plant suitable for cultivation. In particular, repetitive back-crossing with a plant taxon with agronomically desirable characteristics may be undertaken. Further steps of removing cells from a plant and regenerating new plants therefrom may also be carried out.

Also, further desirable characteristics may be introduced by transforming the cells, plant tissues, plants or seeds, at any suitable stage in the above process, to introduce desirable coding sequences other than the polynucleotides of the invention. This may be carried out by the techniques described herein for the introduction of polynucleotides of the invention.

For example, further transgenes may be selected from those coding for other herbicide resistance traits, e.g. tolerance to: Glyphosate (e.g. using an EPSP synthase gene (e.g. EP-A-0,293,358) or a glyphosate oxidoreductase (WO 92/00377) gene); or tolerance to fosametin; a dihalobenzonitrile; glufosinate, e.g. using a phosphinothrycin acetyl transferase (PAT) or glutamine synthase gene (cf. EP-A-0,242,236); asulam, e.g. using a dihydropteroate synthase gene (EP-A-0,369,367); or a sulphonylurea, e.g. using an ALS gene); diphenyl ethers such as acifluorfen or oxyfluorfen, e.g. using a protoporphyrinogen oxidase gene); an oxadiazole such as oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole such as TNP, or a phenopylate or carbamate analogue thereof.

Similarly, genes for beneficial properties other than herbicide tolerance may be introduced. For example, genes for insect resistance may be introduced, notably genes encoding *Bacillus*

*thuringiensis* (*Bt*) toxins. Likewise, genes for disease resistance may be introduced, e.g. as in WO91/02701 or WO95/06128.

Typically, a protein of the invention is expressed in a plant of the invention. Depending on the promoter used, this expression may be constitutive or inducible. Similarly, it may be tissue- or stage-specific, i.e. directed towards a particular plant tissue (such as any of the tissues mentioned herein) or stage in plant development.

The invention also provides methods of obtaining crop products by harvesting, and optionally processing further, transgenic plants of the invention. By crop product is meant any useful product obtainable from a crop plant.

***Products that contain mutant gluten proteins or proteins that comprise sequence capable of acting as an antagonist***

The invention provides a product that comprises the mutant gluten proteins or protein that comprises sequence capable of acting as an antagonist. This is typically derived from or comprise plant parts from plants mentioned herein which express such proteins. Such a product may be obtainable directly by harvesting or indirectly, by harvesting and further processing the plant of the invention. Directly obtainable products include grains. Alternatively, such a product may be obtainable indirectly, by harvesting and further processing. Examples of products obtainable by further processing are flour or distilled alcoholic beverages; food products made from directly obtained or further processed material, e.g. baked products (e.g. bread) made from flour. Typically such food products, which are ingestible and digestible (i.e. non-toxic and of nutrient value) by human individuals.

In the case of food products that comprise the protein which comprises an antagonist sequence the food product may also comprise the wild-type gluten protein, but preferably the antagonist is able to cause a reduction (e.g. completely) in the coeliac disease symptoms after such food is ingested.

***Deamidation***

Where a sequence described herein includes a Gln residue, the invention also provides that sequence where the Gln residue has been deamidated to a Glu residue. One or more (e.g., 1, 2, 3, 4, 5, etc.) Gln residue(s) per sequence may be deamidated, but when there is more than one Gln residue, not all of them must be deamidated. Preferably, the Gln residues that are deamidated are those susceptible to deamidation by transglutaminase.

Examples where Gln may be deamidated are given in the sequence listing. For example, residue 4 of SEQ ID NO:1 can be a Gln residue or a Glu residue, residue 6 of SEQ ID NO:2 can be a Gln residue or a Glu residue, residues 4 and 7 of SEQ ID NO:6 can each independently be Gln or Glu residues, etc. The Gln residues that are susceptible to deamidation, and their deamidated Glu counterparts, are referred to as "Glx" residues.

Where the agent includes more than one Glx residue, these may be arranged in any configuration. For example, the Glx residues may be consecutive residues, and/or may be separated by one or more (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, *etc.*) other residues. As mentioned above, for HLA-DQ8 epitopes, the agent preferably comprises a Glx residue that is separated by seven residues from another Glx residue.

Preferred agents of the invention are deamidated agents, *i.e.*, the agent comprises the one or more Glx residues in the Glu form. This can be achieved in various ways, *e.g.*, by including Glu residues during production, or by converting Gln residues to Glu by deamidation. Conversion of Gln to Glu can be achieved by treating an agent that contains Gln residues that are susceptible to deamidation with a deamidating agent. The one or more Gln residues are preferably deamidated to Glu by transglutaminase, for example as described in the examples.

The skilled person will be able to determine which particular Gln residues in the agent are susceptible to deamidation and thus which residues should be Glu residues arising from deamidation of a Gln residue. For example, Gln-containing sequences susceptible to deamidation by transglutaminase generally conform to a motif: *e.g.*, QXPX, QXPF(Y), QXX(FYMILVW), QXPF, QXX(FY), PQ(QL)P(FY)P. For example, the sequence PQ(QL)P(FY)P facilitates deamidation of the underlined Q at position 2 by transglutaminase.

In particular, agents comprising the deamidated versions of SEQ ID NOs: 1-1927 are preferred (where such sequences are not already deamidated). Most preferably, the agents of the invention comprise the transglutaminase-deamidated versions of SEQ ID NOs: 1-1927 (again, where not already deamidated). Analogues and equivalents of these agents, as defined herein, are also encompassed within the scope of the invention.

## EXAMPLES

The invention is illustrated by the following nonlimiting Examples:

### *Initial gliadin epitope screening library*

In initial experiments involving 29 HLA-DQ2+ individuals with coeliac disease on long-term gluten free diet, interferon-gamma ELISPOT assays were used to screen a previous Pepset (described in WO 03/104273, which is incorporated herein by reference) initially as pools of peptides and then in 15 subjects as individual peptides with and without deamidation by tTG. This Pepset library consisted of 652 20mer gliadin peptides spanning all unique 12mers contained within all Genbank entries described as wheat gliadins found in September 2001. This Pepset library was designed "manually" from gene-derived protein sequences aligned using ClustalW software (MegAlign) arranged into phylogenetic groupings .

Approximately 0.6 micromole of each of 652 of the 20mers was provided. Two marker 20mer peptides were included in each set of 96 (VLQQHNIAHGSSQVLQESTY – peptide 161, and IKDFHVYFRESRDALWKGPG) and were characterized by reverse phase-HPLC and amino acid sequence analysis. Average purities of these marker peptides were 19% and 50%, respectively. Peptides were initially dissolved in acetonitrile (10%) and Hepes 100mM to 10mg/ml. The final concentration of individual peptides incubated with PBMC for the IFN $\gamma$  ELISpot assays was 20 mcg/ml. These peptides were deamidated by incubation with guinea pig tissue tTG (Sigma T5398) in the ratio 100:32 mcg/ml for two hours at 37°C. Peptides solutions were stored at –20°C and freshly thawed prior to use. These studies were conducted in Oxford, UK. ELISpot assays were performed as described for those conducted in Melbourne, Australia (all other studies described herein). “Oxford” data regarding subject responses to individual peptides was pooled with “Melbourne” data for subsequent “minimal” epitope analysis in the “EM algorithm” (see below).

### ***Second round gliadin epitope screening library***

A second round gliadin epitope library was designed according to the bioactive sequences identified from the initial gliadin epitope screening library of 652 20mers. Gliadin 20mers with mean bioactivity equivalent to >5% of the most potent gliadin 20mer (91: P Q P F P P Q L P Y P Q P Q L P Y P Q P) in 15 HLA-DQ2+ subjects assessed with all 652 deamidated 20mers were defined. Since earlier studies (see WO 03/104273) indicated that deamidated pools of this Pepset were more potent than without deamidation, glutamine residues within bioactive 20mers potentially deamidated by tTG were identified according to the motif QXPX, QXZ (FYWILVM) where X is any amino acid except proline, and P is proline, Z is any amino acid, and FYWILVM represent hydrophobic amino acids (consistent with the motifs for tTG-mediated deamidation published by Vader W. et al J Exp Med 2002 J. Exp. Med. 195:643-649, PCT WO 03/066079, and Fleckenstein B. 2002. J Biol Chem 277:34109-16).

12mer peptides were then identified in which each potential deamidation site could be in position 4, 6 or 7 in the 9mer located within HLA-DQ2 binding groove (HLA-DQ2 anchors at these positions show a preference for glutamate). Candidate 12mer core epitope sequences were then flanked with glycine followed by the N-terminal residue present in the parent gliadin polypeptide and at the C-terminal by the C-terminal residue present in the parent gliadin polypeptide followed by glycine (i.e. GXXXXXXXXQXXXXXXXXG).

Peptides were synthesised with glutamine or glutamate in position 9. Peptides (100mcg/ml) (+/- deamidation by tTG) were then assessed in interferon gamma ELISPOT assays using PBMC from 15 HLA-DQ2+ coeliac volunteers after gluten challenge. Results of these assays were analysed according to the EM algorithm (see below). In addition, the most potent distinct peptides were synthesised and purified to >80% (Mimotopes) and assessed in interferon gamma ELISPOT assays using PBMC from 15 HLA-DQ2+ coeliac volunteers after wheat gluten challenge.

### *Complete gluten epitope screening library*

To make practical the design of a substantially larger peptide library spanning all wheat gliadin and glutenin, rye, barley, and oat gluten-like proteins (prolamines), and to confirm data from the previous gliadin peptide library, an iterative algorithm was developed to automate design of a minimal set of 20mers including all unique 12mers (excluding signal peptide sequences) in gluten proteins. The ScanSet algorithm is shown in Figure 1.

The method tests for all possible peptide epitopes from a group of proteins whether they are potential antigens in a range of patients. T-cell epitopes range in size between 9 and 15 AA. To test all possible 12mers in a set of proteins, becomes quickly unfeasible because of the high numbers.

Here we use the fact that, for example, a 20mer peptide can cover up to 9 different 12mers. We therefore developed a combinatorial approach to cover all possible 12mers represented in a family of proteins.

20 amino acid (20mer) long peptides are generated that are tested as antigens, and that cover all 12mer peptide sequences that exist in the group of proteins. We define the length of peptides to generate as  $L$  (e.g. 20) and the length of the epitopes we want to cover as  $S$ . We developed a computer program that generates all uniquely occurring  $L$ mers from a set of proteins. Further, we generate all uniquely occurring  $S$ mers from this set of proteins. Next we select a set of  $N$   $L$ mers that contains all sequences of  $L$ mers. Figure 1 outlines how this algorithm works.

On 16 June 2003, Genbank contained accession numbers for 53 alpha/beta, 53 gamma and 2 omega gliadins, and 77 LMW and 55 HMW glutenins from *T. aestivum*, 59 hordeins, 14 secalins, and 20 avenins (see Figure 2). In total, ScanSet identified 18117 unique 12mers contained in the 225 gluten gene products.

All unique gluten 12mers could be subsumed in 2922 20mers. These 20mers were synthesised in a Pepset peptide library (Mimotopes Inc., Melbourne, Australia). Pepset peptides were synthesized in batches of 96 (Mimotopes Inc., Melbourne Australia). Approximately 0.7 to 1.3 micromole of each of 2922 20mers was provided. Two marker 20mer peptides were included in each set of 96 (one representative peptide from the 94 other peptides on each particular plate, and IKDFHVYFRESRDALWKGPG) and were characterized by reverse phase-HPLC and mass spectroscopy. Average purities of these marker peptides were 36% (range: 5-68%) and 64% (range:55-71%), respectively.

Peptides were initially dissolved in aqueous acetonitrile (50%). Peptides in aqueous acetonitrile were transferred to sterile 96-well plates and diluted in sterile PBS with 1mM calcium (250 mcg/ml) and then incubated with tTG (25 mcg/ml) (Sigma T5398) for 6h 37°C and then stored frozen (-20°C) until use.

Subjects all had biopsy-proven coeliac disease and had followed a strict gluten free diet for at least 6 months. All subjects possessed *HLA-DQB1\*02* (HLA-DQ2) alone (n=100) or *HLA-DQA1\*03* and *HLA-DQB1\*0302* (HLA-DQ8) alone (n=5). In all cases, tTG-IgA was assessed before

gluten challenge and was in the normal range (30% of initial volunteers were found to have elevated tTG-IgA and were excluded since chronic gluten exposure is associated with failure to induce peripheral blood gluten-specific T-cells by short-term gluten challenge). Volunteers consumed Baker's Delight "white bread block loaf" (200g daily for three days) or Uncle Toby's oats (100g daily for three days). All but three subjects completed the three day challenge (one withdrew after first mouthful of bread, and the other two vomited after initial two slices of bread. Data from the latter two were included in subsequent analysis). Blood (300ml) was drawn six days after commencing gluten challenge. Gluten peptide-specific IFN $\gamma$  ELISpot responses have not been found in our previous studies, and so "pre-challenge" blood was not assessed in this set of experiments (Anderson, RP et al 2000. *Nat. Med.* 6:337-342., WO 01/25793, WO 03/104273).

IFN $\gamma$  ELISpot assays (Mabtech, Sweden) were performed in 96-well plates (MAIP S-45, Millipore) in which each well contained 25mcl of peptide solution and 100mcl of PBMC ( $2 \times 10^5$ /well) in RPMI containing 10% heat inactivated human AB serum. After development and drying, IFN $\gamma$  ELISpot plates were assessed using the MAIP automated ELISpot plate counter. Data was then analysed according to a novel algorithm (Expectation Maximization: EM) to define and quantify interferon-gamma responses to 9mer sequences contained within the peptide library (see Figure 3 and below). 9mer peptides were then rationalised according to an algorithm that assumes redundancy in T-cell recognition, the "IterativeCluster" algorithm (see Figure 4 and below), by allowing groups of amino acids with similar chemical properties at any one position in the 9mer, or for glutamate to replace glutamine at any position (assuming deamidation may have occurred).

Since there were data sets from only two HLA-DQ8+ individuals who were not also HLA-DQ2+, and these were utilizing only the 721 wheat gliadin 20mers from the "Complete gluten epitope screening library", bioactive peptides were identified by taking the average rank of peptide-specific IFN $\gamma$  ELISPOT responses in the two subjects. For prediction of likely HLA-DQ8-restricted gliadin epitopes, it was assumed that a glutamine residue susceptible to tTG-mediated deamidation occupied either position 1 or 9 in potential 9mer core regions of epitopes, consistent with the HLA-DQ8 binding motif and the findings of van de Wal et al (van de Wal, Y. et al 1998. *J. Immunol.* 161(4):1585-1588).

***Expectation Maximization (EM) algorithm to analyze data from ELISpot:***

Figure 3 shows an algorithm to analyze data coming from an assay using the ELISpot. T-cell responses to different peptides are measured in 96 well plates using T-cell assays. Assays are performed on many patients using many different peptide antigens. The result of the T-cell assays can be summarized in a table where the rows represent peptides and the columns patients and the individual measurements (counts) are in the table (e.g., see Figure 3B). The purpose of the EM algorithm is to differentiate between response and non response of a patient to a peptide and to estimate a mean rate of response and a proportion of people responding for each peptide.

Responses are measured for a number of different patients ( $i$  will be used to indicate the patient) and for many different peptides ( $j$  will be used to indicate the peptide). Each measurement ( $y_{ij}$ ) represents a count of T-cells from patient  $i$  responding to peptide  $j$ . In order to estimate, whether a measurement for a certain peptide in a patient can be called a response or whether it is more likely to be coming from a background distribution, we propose a model for an incomplete data problem, with  $y_{ij}$  being the observed count of spots and  $z_{ij}$  an unobserved indicator, whether person  $i$  responds to peptide  $j$ .

The observed number of counts  $y_{ij}$  are modelled to come from independent Poisson distributions:  $\text{poisson}(\alpha_i, \lambda_j)$ , if patient  $i$  is responding to peptide  $j$ , i.e.  $z_{ij} = 1$ , and  $\text{poisson}(\alpha_i, \lambda_0)$ , if patient  $i$  is not responding to peptide  $j$ , i.e.  $z_{ij} = 0$ .

- Complete data:  $y_{ij}$  (observed counts),  $z_{ij}$  (response indicator, not observed).
- Parameters:  $\theta = (\alpha_i, \lambda_j, \lambda_0, p_j)$ 
  - $\alpha_i$ : Patients overall responsiveness.
  - $\lambda_j$ : Peptide induced rate of response.
  - $\lambda_0$ : Background rate of response.
  - $p_j$ : Proportion of people responding to peptide  $j$ .

EM algorithm:

- Set variables initially to random values
- E-step: compute likelihood
- M-step: maximize likelihood function
- Iterate E- and M-step

#### ***Iterative procedure to find minimal set of responsive epitopes***

A program to compute a minimal set of peptides for use in a vaccine based on the T-cell responses estimated in the EM algorithm was developed. We measured T-Cell responses to  $L$ mers from a group of proteins. The peptides were generated to cover all possible  $S$ mers. We estimated the following parameters for the response by an EM algorithm: rate of response, number of people responding, proportion of people responding. The proportion of people responding multiplied with the estimated rate of response is used as a criterion to define epitopes which are good antigens. Many of the measured  $L$ mers contain the same  $S$ mer epitopes. In order to find the epitopes ( $S$ mers) which can explain all the responses in  $L$ mers we select the  $S$ mer which is contained in  $L$ mers that in the mean have the highest responses. Then we remove all  $L$ mers that contain this  $S$ mer from our measurements. Next we select the  $S$ mer with the highest responses in the remaining  $L$ mers. We iterate this procedure until no  $S$ mers with responses higher than a specified cutoff exist. We use several iterations with different cutoffs. This process is sketched in Figure 4. The such defined list of clustered  $L$ mers can be used as a basis to define the optimal epitopes and select peptides that function as good antigens.

***HLA-DQ2 epitopes in wheat gluten***

HLA-DQ2 epitopes in wheat gliadins and glutenins were identified using PBMC collected on day 6 after commencing gluten challenge in a total of 76 HLA-DQ2+ individuals in gamma-interferon ELISPOT assays (Initial gliadin epitope library: n=15, Second round gliadin epitope screening library: n=15, Complete gluten epitope screening library: n= 46). All data relating to individual peptide responses in coeliac subjects was pooled and analysed by the EM algorithm.

A series of 9mer sequences were identified and ordered according to the intensity of gamma-interferon responses and the proportion of individuals responding (see Figure 5). Many of the sequences identified could be grouped in "superfamilies" allowing for several different amino acids with similar chemical properties to be present at any one position in the putative epitope (see Figure 6). For example, in "Sequence 1" of Figure 6 (SEQ ID NO: 1555) P (QR) P (QE) LP (FY) PQ, glutamine (Q) or arginine (R) are both accepted at position 2 except that Q generates a substantially more bioactive epitope.

By reviewing the 110 most "active" 9mer sequences identified by the EM algorithm, the "list" of 9mer motifs could be condensed to 41 9mers, many of which overlapped (for example "Sequence 1" and "2" (SEQ ID NOS: 1555 and 1558 respectively) overlap by 7 residues and are both present in A-gliadin 57-73 QE65). In selected cases, high-grade peptides were synthesised and confirmed the bioactivity of peptides identified by the EM algorithm (see Figure 7).

***HLA-DQ2 epitopes in oats avenins***

Avenin peptides were assessed after challenge with oats (n=30 subjects) or after wheat bread (n=8) in HLA-DQ2+ coeliac subjects. ELISPOT responses were found for the peptides found in Figure 8. One of the reactive avenin peptides was homologous to a sequence in wheat gluten (SEQ ID NO: 1590).

***Oats (avenin) high quality peptide studies***

High grade avenin peptides were assessed 3 days after completing oats challenge with pure wheat-free oats, 100g/d for 3 days ("day 6" PBMC interferon gamma ELISPOT responses). These peptides were designed upon peptides previously defined using the screening grade ("first round") avenin peptide library and on potential deamidation sites. There were 25 peptides (as 16mers) with purity verified by HPLC as >80%, and sequences confirmed by mass spectroscopy.

Interferon gamma ELISPOT responses to the high grade avenin peptides following deamidation by tTG were compared in 18 subjects with DQ2+ coeliac disease .

The dominant (>70% maximal response) peptides after oats challenge included: EQQFGQNI FSGFSVQL (SEQ ID NO: 1764) (11/18 subjects), QLRCPAIH SVVQAIIL (SEQ ID NO: 1765) (4/18 subjects), and QYQPYPEQEQPILQQQ (SEQ ID NO: 1766) (3/18 subjects). 2/18 subjects did not have avenin specific responses (defined by SFU (spot forming units) > 3 X blank) and 6/18 subjects mean maximal SFU were less than 10. Two additional peptides elicited positive responses:

QIPEQLRCPAHSVQ (SEQ ID NO: 1767) (3/18 subjects) and EQYQPEQQPFMQPL (SEQ ID NO: 1768) (>40% maximal peptide response in 5/18 subjects). The panel of 25 peptides included several peptides similar to peptide 1490 (SEQ ID NO: 1490) reported in Arentz-Hansen, PLoS Medicine (Oct. 2004, vol. 1, issue 1 (84-92), however, that peptide induced a strong positive response in only one subject, and far weaker response in 5 subjects.

Interferon gamma ELISPOT responses to high grade avenin peptides were absent prior to gluten challenge, and were blocked by pre-treatment of PBMC with anti-HLA DQ but not anti-HLA DR antibody.

### *Rye and barley screening peptide libraries*

Secalin and hordein 20mer first round peptide libraries were assessed 3 days after completing rye (bread, 100g/d for 3 days) or barley (boiled, 100g/d for 3 days) challenge ("day 6" PBMC interferon gamma ELISPOT responses). Although iterative analysis using 2nd and 3rd round peptide libraries to define epitopes has not yet been performed, the 20mers pre-treated with tTG found to induce "potent" responses shared substantial structural similarity to the bioactive peptides identified after wheat challenge. However, the dominant peptide sequences after rye or barley challenge did not include peptides with the PQQQLPY sequence found to be dominant after wheat challenge. The dominant (>70% maximal response) 20mer after rye challenge was usually PQQLFPLPQQPFPPQQPFPP (SEQ ID NO: 1769) (8/14 subjects), or occasionally QPFPPQQPTPIQQPFPPQ (SEQ ID NO: 1770) (4/14), QQPQQLFPPQTQQSSPQQPQQ (SEQ ID NO: 1771) (1/14), PQTQQPQQPFPPQQPQQLF (SEQ ID NO: 1772) (1/14) and/or QEQREGVQILLPQSHQQLVG (SEQ ID NO: 1773) (1/14). Additional peptides noted for greater than 40% maximal response in at least 1 subject include:

FQQPQQPFPPQQQLPLQP (SEQ ID NO: 1774) (3/14, 2 > 70%)  
 PQQPFPPQQPEQIIPQQPQQP (SEQ ID NO: 1775) (5/14, 3 > 70%)  
 QQLPLQPQQPFPPQQPIPQ (SEQ ID NO: 1776) (6/14, 2 > 70%)  
 QQPQQPFPLQPQQPVPQQPQ (SEQ ID NO: 1777) (3/14, 1 > 70%)  
 SIPQQPQQPFPPQQPFPPQSQ (SEQ ID NO: 1778) (4/14, 1 > 70%)  
 QTQQSIPQQPQQPFPPQQPF (SEQ ID NO: 1779) (3/14, 1 > 70%)  
 NMQVGPSPGQVEWPQQQPLPQ (SEQ ID NO: 1780) (2/14, 1 > 70%)  
 VGPSGQVSWPQQQPLPQQPQQ (SEQ ID NO: 1781) (2/14, 2 > 70%)  
 QQPFLQLPQQPFSQPQQPFL (SEQ ID NO: 1782) (1/14, 1 > 70%)  
 FPLQPQQPFPPQQPEQIISQQ (SEQ ID NO: 1783) (5/14, 1 > 70%)  
 PQQPQRPFPAQQPEQIISQQP (SEQ ID NO: 1784) (3/14, 1 > 70%)  
 SPQQPQLPFPQQPQQPFVVVV (SEQ ID NO: 1785) (4/14, 1 > 70%)  
 QQPSIQLSLQQQLNPCKNVL (SEQ ID NO: 1786) (1/14, 1 > 70%)

Typically, the dominant peptides after barley challenge included one of six peptide motifs, or were one of eight other individual 20mers "dominant" in only one of 17 subjects after barley challenge. The six motifs identified:

QQPIPQQPQPY (SEQ ID NO: 1787)

FFPQQQFFPW (SEQ ID NO: 1788)

LQPQQFFPQ (SEQ ID NO: 1789)

PQPQQASPL (SEQ ID NO: 1790)

IIPQQPQQPF (SEQ ID NO: 1791)

YPEQQQPF (SEQ ID NO: 1792)

The barley hordein peptides showing at least 40% maximal peptide response in at least one subject include the following, wherein an asterisk indicates the eight individual peptides showing maximal response in a single individual:

QQQFFPQQPIPQQPQPYPQQ (SEQ ID NO: 1793) (8/17, 2 > 70%)  
 QQPQPFSSQQPIPQQPQPYPQ (SEQ ID NO: 1794) (9/17, 8 > 70%)  
 PQQPVPQQPQPYPQQPQPF (SEQ ID NO: 1795) (5/17, 1 > 70%)  
 PQQFFPQQPIPQQPQPYPQQP (SEQ ID NO: 1796) (6/17, 2 > 70%)  
 YPQQPQFFPQQPIPQQPQPY (SEQ ID NO: 1797) (6/17, 2 > 70%)  
 QPQPYPQQPQPYPQQPQPFQ (SEQ ID NO: 1798) (7/17, 2 > 70%)  
 QPQQPQFFPQQPVPQQPQPY (SEQ ID NO: 1799) (5/17, 2 > 70%)  
 PQPYPQQPQFFPQQPFFCQQ (SEQ ID NO: 1800) (1/17, 1 > 70%)\*  
 QFFPQQQFFPWQPQQFFPQ (SEQ ID NO: 1801) (10/17, 2 > 70%)  
 PFPQQPQQPFPQPPQPFRRQ (SEQ ID NO: 1802) (6/17, 3 > 70%)  
 WQPQQPFPQPPQFFPLQPQQ (SEQ ID NO: 1803) (9/17, 5 > 70%)\*  
 PWQPQQPFPQPPQEPPIPQQPQ (SEQ ID NO: 1804) (1/17, 1 > 70%)  
 QQPFPQPPQPIPYQPQQPFN (SEQ ID NO: 1805) (5/17, 1 > 70%)  
 PQQPQQPFPQPPQFFSWQPQ (SEQ ID NO: 1806) (6/17, 2 > 70%)\*  
 QPQQPFPQPPQPIPYQPQQP (SEQ ID NO: 1807) (4/17, 1 > 70%)\*  
 QSQQQFPQPPQPPQPPQPP (SEQ ID NO: 1808) (1/17, 0 > 70%)  
 PFPQPPQFFSWQPQQPFLQP (SEQ ID NO: 1809) (1/17, 0 > 70%)  
 FPQPQEPFPQQPQQPFFLQP (SEQ ID NO: 1810) (1/17, 0 > 70%)  
 PFPQPPQFFPWQPQQPFPQP (SEQ ID NO: 1811) (6/17, 0 > 70%)  
 FPQYQIPTPLQPQQPFPQQP (SEQ ID NO: 1812) (2/17, 1 > 70%)  
 FPLQPQQPFPQQPQQPFPQQ (SEQ ID NO: 1813) (1/17, 0 > 70%)  
 QQPFFLQPQQPFPQPPQPFQ (SEQ ID NO: 1814) (1/17, 0 > 70%)  
 SPLQPQQPFPQGGSEQIIPQQ (SEQ ID NO: 1815) (1/17, 0 > 70%)

PQQASPLQPQPQQASPLQPQ (SEQ ID NO: 1816) (1/17, 1 > 70%)  
 PQQPPFWPQQPPFPQQPPFGL (SEQ ID NO: 1817) (1/17, 1 > 70%)\*  
 PVLSQQQPCTQDQTPLLQEQ (SEQ ID NO: 1818) (1/17, 1 > 70%)  
 RQLPKYIIPQQPQQPFLLQP (SEQ ID NO: 1819) (1/17, 1 > 70%)  
 QGSEQIIPQQPQQPFPLQPH (SEQ ID NO: 1820) (7/17, 3 > 70%)\*  
 PQGSEQIIPQQPFPLQPQPF (SEQ ID NO: 1821) (2/17, 1 > 70%)  
 QPFPTPQQQFFPYLPQQTFPP (SEQ ID NO: 1822) (4/17, 1 > 70%)  
 PFPQPPQQKYPEQPQQPFPW (SEQ ID NO: 1823) (1/17, 1 > 70%)  
 QKYPEQPQQPFPWQQPTIQL (SEQ ID NO: 1824) (1/17, 1 > 70%)  
 FQQPQQSYVPVQPPFPQPQ (SEQ ID NO: 1825) (3/17, 1 > 70%)  
 QIPYVHPSILQQLNPKVFL (SEQ ID NO: 1826) (1/17, 1 > 70%)  
 LAAQLPAMCRLEGGGGLLAS (SEQ ID NO: 1827) (1/17, 1 > 70%)  
 PYLPEELSPQYQIPTPLQPQ (SEQ ID NO: 1828) (1/17, 1 > 70%)\*  
 VSPHPGQQTTVSPHQGQQTT (SEQ ID NO: 1829) (1/17, 1 > 70%)\*

### ***Second and third round wheat gliadin and glutenin peptide libraries***

The second round wheat gliadin and glutenin library was designed upon the sequences of 20mer wheat gliadin and glutenin peptides that induced at least 5% of the response (interferon gamma ELISPOT) stimulated by the most active transglutaminase (tTG) pre-treated (enzymatically deamidated) 20mer peptide in any subject. All 2nd round 16mer peptides were assessed in at least 18 subjects. The 2nd round library generated from the "Oxford" gliadin 20mer library had been assessed in ten subjects - this data was merged with data generated from the 18 subjects used to assess the new 2nd round (expanded) gliadin/glutenin library. Hence, individual 16mer peptides pre-treated with transglutaminase were assessed in either 18 (novel gliadin/glutenin sequences based on "Melbourne" 20mer library) or 28 subjects (gliadin sequences based on "Oxford" 20mer library). All 16mers identified for the second round Oxford library also fulfilled the selection criteria for the Melbourne second round library.

The second round peptide library data was analysed according to the "dominance" of peptide responses in the interferon gamma ELISPOT in individual subjects i.e. the percent response of an individual's PBMC to a specific peptide normalized against that individual's maximal peptide-induced response. Sequences of peptides that stimulated at least 40% of the maximal peptide-specific response in at least one subject are shown in Table 1 below. The dataset supports the consistency and "dominance" of peptides conforming to the sequences identified using the first round 20mer peptide library using the Expectation Maximization (EM) algorithm described above.

*Table 1: Peptides confirmed in Second Round Library as at least 40% as active as the peptide with maximal activity in any one subject. Ranked according to potency of peptide family*

Peptide	SEQ ID NO:	>70%	40-70%	10-40%	<10%
G-QLPYPQPQLPYPQP-G	1830	18/28	4/28	3/28	3/28
G-LQPFPPQPQLPYPQP-G	1831	14/28	8/28	Nil	6/28
G-LQPFPPQPQLPFPQP-G	1832	4/28	8/28	5/28	10/28
G-LQPFPPQPQLPYLQP-G	1833	1/28	1/28	12/28	14/28
G-LQPFPPQPQLPYSQP-G	1834	2/28	3/28	12/28	11/28
G-LQPFPPQPQLSYSQP-G	1835	Nil	1/28	2/28	25/28
G-QQPFPPQPQQPFPWQ-G	1837	9/28	8/28	5/28	6/28
G-QQPFPPQPQQPIPVO-G	1838	8/28	5/28	7/28	8/28
G-QQPFPPQPQQPFSQQ-G	1839	4/28	7/28	8/28	9/28
G-QQPFPPQPQQPFCQQ-G	1840	2/28	2/28	13/28	11/28
G-GLERPWQQQLPQP-G	1841	2/18	1/18	Nil	15/18
G-QTFPHQPQQAFPQP-G	1842	1/28	2/28	Nil	25/28
LQQQCSFVAMPQRLAR	1843	1/28	1/28	11/28	15/28
QGQQGYYPISPQQSGQ	1844	1/18	1/18	1/18	15/18
PGQQSGYYPTSPQQS	1845	1/18	1/18	Nil	16/18
QGQPGYYPTSPQQIGQ	1846	1/18	1/18	1/18	15/18
GQQSGYYPTSPQQSG	1847	1/18	Nil	2/18	15/18
QQGYYPPTSPQQSGQQ	1848	Nil	1/18	Nil	17/
QGQQGYYPPTSPQQPPQ	1849	Nil	1/18	Nil	Nil
QQGYYPISPQQLGQQ	1850	Nil	1/18	Nil	Nil
YVFPDCSTINVPYANI	1851	1/18	1/18	1/18	15/18
IIMQQEQEQQRQGVQI	1852	1/28	Nil	8/28	19/28
VAHAIIIMHQQQQQEQE	1853	Nil	1/28	2/28	25/28
G-QPIPQQPQQPFPPLQ-G	1854	1/28	Nil	5/28	
G-FPQLQQPQQPFPQQ-G	1855	1/28	Nil	1/28	26/28
G-FPQTQQPQQPFPQQ-G	1856	Nil	1/28	2/28	25/28
G-QPLSQQPQQTFPQQ-G	1857	Nil	1/28	Nil	27/28
G-QQPQQQPQQPFPQQ-G	1858	Nil	1/28	5/28	22/28
G-FPQPQQPQQPFPQQ-G	1859	Nil	1/28	3/28	25/28
G-FPQPQQPQQSFPQQ-G	1860	Nil	1/28	1/28	26/28
G-QPQQTFPQQPQLPF-G	1861	1/18	Nil	2/18	15/18
G-MQVDPSGQVQWPQQ-G	1862	1/18	Nil	Nil	17/18
G-IQVDPSGQVQWPQQ-G	1863	1/18	Nil	Nil	17/18
G-MQADPSGQVQWPQQ-G	1864	1/18	Nil	Nil	17/18
G-MQVDPSQVQWPQQ-G	1865	1/18	Nil	Nil	17/18
G-QQEQQILQQILQQQ-G	1866	1/18	Nil	Nil	17/18
VPLYRTTTSVPFVGT	1867	1/18	Nil	Nil	17/18
LQTLPSMCNVYIPPYC	1868	1/18	Nil	Nil	17/18
LALQTLPAMCNVYIPP	1869	1/18	Nil	Nil	17/18
DAIRALIYSIVLQEQQ	1870	1/18	Nil	Nil	17/18
G-QQQFSQPQQPFPQP-G	1871	Nil	5/28	7/28	16/28
G-FFPQPQQQFPQPQQ-G	1872	Nil	1/28	10/28	17/28

G-FPQQPQQQFFPQPQQ-G	1873	Nil	1/28	Nil	27/28
G-QQPFFPQPQQQFFPQP-G	1874	Nil	1/28	12/28	15/28
G-QPQFFLPQLPYQP-G	1875	Nil	4/28	9/28	15/28
G-QQPFFPQPQQQLPQP-G	1876	Nil	3/28	6/28	19/28
G-LPFFPQQPQQPLPQP-G	1877	Nil	2/18	4/18	12/18
G-QQAFPPQPQQTFPHQ-G	1878	Nil	3/28	8/28	17/28
G-QQPFTQPQQPTPIQ-G	1879	Nil	1/28	4/28	23/28
G-QQIFPQPQQTFPHQ-G	1880	Nil	1/28	10/28	17/28
G-QQQFIQPQQPFPQQ-G	1881	Nil	2/28	11/28	15/28
G-QPFFLPQPQQPFPQQ-G	1882	Nil	2/28	7/28	19/28
G-QPFPWQPQQPFPQQ-G	1883	Nil	2/28	8/28	18/28
G-QPTPIQPQQPFPQQ-G	1884	Nil	2/28	5/28	21/28
G-QVSFQQPQQQYPSF-G	1885	Nil	2/28	4/28	22/28
G-FFQQPQQQYPSQQ-G	1886	Nil	1/28	1/28	26/28
G-GKSQVLQQSTYQLL-G	1887	Nil	2/18	1/18	15/18
<b>GQVVNNHGQTVFNDIG</b>	1888	Nil	1/18	4/18	
G-QPQLPFPQPQQQF-G	1889	Nil	1/28	2/28	25/28
G-QPFPQPQQQLPFP-G	1890	Nil	1/28	2/28	25/28
G-HQQPGQRQQGYPT-G	1891	Nil	1/18	1/18	16/18
G-HQQFPQQQIPVVQP-G	1892	Nil	1/18	1/18	16/18
<b>LEAVTSIALRRLPTMC</b>	1893	Nil	1/18	1/18	
G-QQPQFSQQQIPVI-G	1894	Nil	1/18	Nil	17/18

The third round peptide library consisted of 74 peptides based upon structurally distinct sequences in the second round library found to induce at least 10% of the maximal response to any peptide in any subject. These peptides corresponded to wild-type (non-deamidated) sequences virtually identical to those used in the second round library. The distinct feature of this library was that it consisted of peptides with purity verified by HPLC as >80%, and with sequences confirmed by mass spectroscopy.

Interferon gamma ELSIPOT responses to the 3rd round library peptides following deamidation by tTG were compared in 14 subjects. Once again, sequences including the PQPQLPY motif were “dominant” in 9/14 subjects. However PFPQPQQPFPW (SEQ ID NO: 1895) stimulated >70% of maximal response in 1/14 subjects, PFPQPQQPFPQ (SEQ ID NO: 1896) in 1/14, PQPFLPQLPYQP (SEQ ID NO: 1897) in 1/14, QPFPQPQQPQQP (SEQ ID NO: 1898) in 4/14 (including 3 subjects in whom PQPQLPY peptides were not potent epitopes) SGQGVSSQQSSQQQ (SEQ ID NO: 1899) in 2/14 (including one in which PQPQLPY peptides were not potent), QYEVIRSLVLRRLPTNM (SEQ ID NO: 1900) and GLARSQMLQQSICHVG (SEQ ID NO: 1901) each in one (the same) subject in whom PQPQLPY peptides were not potent epitopes, RTTTSVPEFGVTGVGA (SEQ ID NO: 1902) in 1/14 subjects and AIHTVIHSIIMQQEQQ (SEQ ID NO: 1903) in 1/14 subjects.

Many of the sequences tested in third round were structurally related and individual subject's responses were present or absent according to the "relatedness" of certain sequences, suggesting redundancy of peptides recognized by gluten specific T cells induced by in vivo gluten challenge.

Interferon gamma ELISPOT responses to 3rd round peptides were absent before gluten challenge, and were blocked by pre-treatment of PBMC with anti-HLA DQ but not HLA DR antibody.

### *Combitopes*

The issue of epitope redundancy and the potential utility in diagnostics and therapeutics of peptides designed to combine "unique" dominant epitopes was addressed by comparing interferon gamma ELISPOT responses after wheat (n=16 HLA DQ2 coeliac disease subjects), rye (n=17) or barley (n=13) challenge to the sequences: QLQPFPPQPELPYPQPQL (SEQ ID NO: 1904) ("P04724E"), QPEQPFPPQPEQPFPPWQP (SEQ ID NO: 1905) ("626fEE"), and QLQPFPPQPELPYPQPFPQPEQPFPPQPEQPFPPWQP (SEQ ID NO: 1906) ("Combitope"). After rye and barley challenge the sum of the median ELISPOT responses (spot forming units) to P04724E and 626fEE were almost identical (99%, and 102%, respectively) to the response to a similar (optimal) concentration of the Combitope. However, after wheat challenge (n=16 subjects), median P04724E response was 89% of that to Combitope, and median 626fEE responses was 70% of the response to Combitope. These findings would be consistent with substantial redundancy of these related epitope sequences, P04724E and 626fEE, after wheat challenge but not after rye or barley, and that combining dominant epitope sequences within longer peptides does not reduce their biological availability. Hence, combitopes derived from selected potent epitopes may be efficient delivery devices for T cell epitope-based therapeutics and diagnostics in coeliac disease.

### *Epitopes in wheat gliadin associated with HLA-DQ8+ coeliac disease*

Epitopes in wheat gliadins were identified using PBMC after gluten challenge in two individuals, one HLA-DQ8 homozygous, and one HLA-DQ8 heterozygote. Induced T-cell responses in other HLA-DQ8 (not DQ2) coeliac individuals responded weakly to gluten challenge and their data did not allow detailed analysis.

Deamidated 20mers including the core sequence: QGSFQPSQQ (SEQ ID NO: 1907), corresponding to the known HLA-DQ8-restricted alpha-gliadin epitope (in which Q1 and Q9 are deamidated by tTG for optimal activity), induced moderately strong peptide responses. However, a series of "core" peptides were associated with more potent responses in 20mers derived from gamma and omega gliadins (see Figure 9). The most potent peptides possessed glutamine in a sequence that would suggest susceptibility to deamidation separated by seven residues from a second glutamine also susceptible to deamidation (as found in QGSFQPSQQ (SEQ ID NO: 1907)) suggesting that these deamidated sequences would become high affinity binders for HLA-DQ8 following deamidation by tTG. (The binding motif for HLA-DQ8 favours glutamate at positions 1 and 9.) A further group of

20mers possessed glutamine residues susceptible to deamidation but not separated by seven residues from a second glutamine susceptible to tTG-mediated deamidation.

### *HLA DQ8 coeliac disease gliadin and glutenin epitopes*

Five subjects with coeliac disease that possess HLA DQ2 and HLA DQ8 alleles underwent wheat gluten challenge. PBMC from two subjects initially challenged were used to screen the first round "Melbourne" wheat gliadin 20mer library. The 20mer sequences identified using PBMC from these two HLA DQ8 CD subjects were dissected further by screening, in five HLA DQ8+ DQ2- CD subjects including the two original subjects, a second round library based on reactive 20mers in the 1<sup>st</sup> round library. The 2<sup>nd</sup> round library consisted of *screening grade* overlapping 16mers, and 13mers predicted to correspond to tTG-mediated deamidation products of epitopes with the potential for deamidation of glutamine at position 1 and/or position 9 (consistent with the HLA DQ8 peptide binding motif). In addition, the 1400 glutenin (HMW and LMW) tTG-pretreated 20mers in the "Melbourne" wheat gluten library were also screened in these five subjects.

The most potent and consistently dominant gliadin 16mers were the related sequences VYIPPYCTIAPFGIFG (SEQ ID NO: 1908) (3/5 subjects >70% response to maximal gliadin 16mer) and AMCNVYIPPYCAMAPF (SEQ ID NO: 1908) also dominant in 3/5 subjects (4/5 subjects produced dominant responses to one or both of these peptides). In addition, a series of peptides derived from previously identified bioactive 20mers whose responses in the ELISPOT were enhanced or permissive to specific glutamine residues being deamidated were identified: (QE)QPTPIQP(QE) (SEQ ID NO: 1909), (QE)QPFPLQP(QE) (SEQ ID NO: 1910), (QE)QPIPVQP(QE) (SEQ ID NO: 1911), (QE)QPQQPFP(QE) (SEQ ID NO: 1912), (QE)QP(QE)LPFP(QE) (SEQ ID NO: 1913), (QE)GSFQPSQ(QE) (SEQ ID NO: 1914) (previously published HLA DQ8 epitope, van der Wal 1998), (QE)LPFP(QE)QP(QE) (SEQ ID NO: 1915), and (QE)QPFPP(QE)QP(QE) (SEQ ID NO: 1916).

Screening the glutenin 20mer library identified a further series of sequences that were dominant in at least one of the five subjects. Dominant 20mer peptides shared the motifs or had the sequences: PQQQQQQLVQQQ (SEQ ID NO: 1917), QGIFLQPH(LQ)I(AS)QLEV (SEQ ID NO: 1918), QPGQGQQG(HY)Y (SEQ ID NO: 1919), QSRYEAIRAII(FY)S (SEQ ID NO: 1920), RTTTSVPFD (SEQ ID NO: 1921), QPFFWRQQP (SEQ ID NO: 1922), Q(PS)(PS)(FI)(PS)QQQQ (SEQ ID NO: 1923), (QPLR)GYPTSPQ (SEQ ID NO: 1924) (previously identified HLA DQ8 epitope, van der Wal 2001), QGSYYPGQASPQ (SEQ ID NO: 1925), GYYPTSSLQPEQGQQGYPT (SEQ ID NO: 1926), and QGQQLAQGGQQGQPAQVQQG (SEQ ID NO: 1927). Glutenin peptides were assessed after pre-treatment with transglutaminase. Hence, the requirement for deamidation for these epitopes is not known.

A comprehensive library of "uncharacterised" screening grade peptides including all unique 12mer sequences encoded by genes present in Genbank defined as (bread making) wheat (*Triticum*

aestivum), rye, barley, or oats gluten, gliadin, glutenin, secalin, hordein, or avenin have been assessed using T cells from HLA DQ2+ (and in some cases HLA DQ8+) coeliac disease volunteers six days after commencing in vivo gluten challenge. A relatively consistent pattern of epitope hierarchy has been identified in HLA DQ2 coeliac disease that is similar to but not identical after consumption of other grains toxic in coeliac disease. Peptides with the sequence PQPQLPY are dominant after wheat challenge in at least two thirds of HLA DQ2+ coeliac disease, but other epitopes are occasionally dominant while PQLPY peptides are essentially inactive in fewer than one in six HLA DQ2+ subjects with coeliac disease. The contribution of rare dominant epitopes will be better assessed after screening large numbers (e.g. >30) subjects (in progress). Epitope hierarchy after rye and barley consumption is similar to that after wheat with the exception that deamidated peptides similar to the gliadin/hordein/secalin sequences PQPQQPFP or PFPQQPQQP are usually dominant rather than PQPQLPY (a sequence unique to wheat alpha-gliadins). Combitopes that comprise serial and partially overlapping gluten epitopes are as active or more active than single epitopes alone and offer a means of efficiently delivering multiple gluten epitopes for T cell recognition. Such combitopes are therefore useful in design and delivery of peptide therapies in coeliac disease that target multiple unique T cell epitopes.

**REFERENCES**

1. Molberg O, et al. *Nature Med.* 4, 713-717 (1998).
2. Quarsten H, et al. *Eur. J. Immunol.* 29, 2506-2514 (1999).
3. Greenberg CS et al. *FASEB* 5, 3071-3077 (1991).
4. Mantzaris G, Jewell D. *Scand. J. Gastroenterol.* 26, 392-398 (1991).
5. Mauri L, et al. *Scand. J. Gastroenterol.* 31, 247-253 (1996).
6. Bunce M, et al. *Tissue Antigens* 46, 355-367 (1995).
7. Olerup O, et al. *Tissue antigens* 41, 119-134 (1993).
8. Mullighan CG, et al. *Tissue-Antigens.* 50, 688-92 (1997).
9. Plebanski M et al. *Eur. J. Immunol.* 28, 4345-4355 (1998).
10. Anderson DO, Greene FC. The alpha-gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes. *Theor Appl Genet* (1997) 95:59-65.
11. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Van der Wal Y, Kooy YMC, Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. *J Exp Med.* 2000; 191:603-12.
12. Vader LW, de Ru A, van der Wal, Kooy YMC, Benckhuijsen W, Mearin ML, Drijfhout JW, van Veelen P, Koning F. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. *J Exp Med* 2002; 195:643-649.
13. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Papadopoulos G, Koning F. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. *J Immunol.* 1998; 161:1585-8.
14. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Molberg O, Lundin KEA, Sollid L, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F. *Proc Natl Acad Sci USA* 1998; 95:10050-10054.
15. Vader W, Kooy Y, Van Veelen P et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. *Gastroenterology* 2002, 122:1729-37
16. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadin rich in proline residues. *Gastroenterology* 2002, 123:803-809.

Each of the PCT publications, U.S. patents, other patents, journal references, and any other publications cited or referred to herein is incorporated herein by reference in their entirety.

**WE CLAIM:**

1. A method of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from:

(a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs: 1-1927, and equivalents thereof; and

(b) an analogue of (a) which is capable of being recognised by a T cell receptor that recognises the peptide of (a) and which is not more than 50 amino acids in length.

2. A method of claim 1 wherein the agent is HLA-DQ2-restricted.

3. A method of claim 1 wherein the agent is HLA-DQ8-restricted.

4. A method of claim 1 wherein one agent is HLA-DQ2-restricted and a second agent is HLA-DQ8-restricted.

5. A method of claim 1 wherein the agent comprises a wheat epitope.

6. A method of claim 1 wherein the agent comprises an oat epitope.

7. A method of claim 1 wherein one agent comprises a wheat epitope and one agent comprises an oat epitope.

8. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an agent as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.

9. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 1, and a pharmaceutically acceptable carrier or diluent.

10. A method of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.

11. A method of preventing or treating coeliac disease comprising:  
diagnosing coeliac disease in an individual by either:

a) contacting a sample from the host with at least one agent selected from:

i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, and equivalents thereof; and

ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and

determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease; or

- b) administering an agent as defined in claim 1 and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease; and

administering to an individual diagnosed as having, or being susceptible to, coeliac disease a therapeutic agent for preventing or treating coeliac disease.

12. Use of an agent for the preparation of a medicament for treating or preventing coeliac disease, wherein the agent comprises:

(a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs: 1-1927 and equivalents thereof; and

(b) an analogue of (a) which is capable of being recognised by a T cell receptor that recognises the peptide of (a) and which is not more than 50 amino acids in length.

13. A use of claim 12 wherein the agent is HLA-DQ2-restricted.

14. A use of claim 12 wherein the agent is HLA-DQ8-restricted.

15. A use of claim 12 wherein one agent is HLA-DQ2-restricted and a second agent is HLA-DQ8-restricted.

16. A use of claim 12 wherein the agent comprises a wheat epitope.

17. A use of claim 12 wherein the agent comprises an oat epitope.

18. A use of claim 12 wherein one agent comprises a wheat epitope and one agent comprises an oat epitope.

19. A use of claim 12 wherein the agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.

20. A use of claim 12 wherein the agent is present within a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 12, and a pharmaceutically acceptable carrier or diluent.

21. A use of claim 12 wherein the agent is present within a composition for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1.

22. An agent as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

23. An antagonist of a T cell which has a T cell receptor as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.

24. An agent as defined in claim 1 or an analogue that binds an antibody that binds to an epitope of an agent as defined in claim 1 for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.

25. A protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined in claim 1, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

26. An agent as defined in claim 1 or an antagonist as defined in claim 9.

27. A pharmaceutical composition comprising an agent as defined in claim 1 or an antagonist as defined in claim 9 and a pharmaceutically acceptable carrier or diluent.

28. A composition for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.

29. A composition for antagonising a T cell response to an agent as defined in claim 1, which composition comprises an antagonist as defined in claim 9.

30. A mutant gluten protein whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gluten protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined in claim 1; or a fragment of such a mutant gluten protein which is at least 7 amino acids long and which comprises the mutation.

31. A polynucleotide that comprises a coding sequence that encodes a protein or fragment as defined in claim 25 or 30.

32. A polynucleotide according to claim 31 that additionally comprises one or more regulatory sequences operably linked to the coding sequence, which regulatory sequences are capable of securing the expression of the coding sequence in a cell.

33. A polynucleotide according to claim 32 wherein the regulatory sequence(s) allow expression of the coding sequence in a prokaryotic or mammalian cell.

34. A polynucleotide according to any one of claims 31 to 33 which is a vector or which is in the form of a vector.

35. A cell comprising a polynucleotide as defined in any one of claims 31 to 34 or which has been transformed with such a polynucleotide.

36. A cell according to claim 35 which is a prokaryotic cell or a mammalian cell.

37. A mammal that expresses a T cell receptor as defined in claim 1.

38. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:

(a) contacting a sample from the host with at least one agent selected from:

i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, and equivalents thereof; and

ii) an analogue of (i) which is capable of being recognised by a T cell receptor that recognises (i) and which is not more than 50 amino acids in length; and

(b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

39. Use of an agent as defined in claim 38 for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

40. A method or use according to claim 38 or 39 wherein the agent is an analogue (iii) which comprises (i) or (ii) bound to (a) an HLA molecule, or (b) a fragment of an HLA molecule capable of binding (i) or (ii).

41. A method or use according to claim 40 wherein the HLA molecule or fragment is in a complex comprising four HLA molecules or fragments of HLA molecules.

42. Use according to any one of claims 39-41 wherein the method comprises administering the agent to the skin of an individual and detecting the presence of inflammation at the site of administration, the detection of inflammation indicating that the T cells of the individual recognise the agent.

43. A method according to claim 39, 41 or 42 wherein the sample is blood sample.

44. A method according to claim 38, 40, 41 or 43 wherein the T cells are not restimulated in antigen specific manner *in vitro* before the said determining.

45. A method or use according to any one claims 38-44 in which the recognition of the agent by the T cells is determined by detecting the secretion of a cytokine from the T cells.

46. A method or use according to claim 45 in which the cytokine is IFN- $\gamma$ .

47. A method or use according to claim 45 or claim 46 in which the cytokine is detected by allowing the cytokine to bind to an immobilised antibody specific to the cytokine and then detecting the presence of the antibody/cytokine complex.

48. A method or use according to any one of claims 38 to 44 wherein said determining is done by measuring whether the agent binds the T cell receptor.

49. A method for identifying an analogue as defined in a claim 38, 40 or 41 comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope comprising sequence as defined in claim 38, recognition of the substance indicating that the substance is an analogue.

50. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to an epitope of an epitope comprising sequence as defined in claim 38 in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.

51. A method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined in claim 38 is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

52. A method according to claim 51 wherein the said determining is done by contacting the composition with an antibody specific for the sequence which is capable of being modified to the oligopeptide sequence, binding of the antibody to a protein in the composition indicating the composition is capable of causing coeliac disease.

53. A method of identifying an antagonist of a T cell, which T cell recognises an agent as defined in claim 1, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the detecting of any such decrease in said ability indicating that the substance is an antagonist.

54. A kit for carrying out a method or use according to any one of claims 38 to 48 comprising an agent as defined in claim 38, 40 or 41 and a means to detect the recognition of the peptide by the T cell.

55. A kit according to claim 54 wherein the means to detect recognition comprises an antibody to IFN- $\gamma$ .

56. A kit according to claim 55 wherein the antibody is immobilised on a solid support and optionally the kit also comprises a means to detect the antibody/IFN- $\gamma$  complex.

57. Use of an agent or antagonist as defined in claim 56 or a wild type sequence as defined in claim 30 to produce an antibody specific to the agent, antagonist or wild type sequence.

58. Use of a mutation in an epitope of a gluten protein, which epitope is as defined in claim 38, to decrease the ability of the gluten protein to cause coeliac disease.

59. Method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined in claim 37 which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

60. A therapeutic product as identified in the method of claim 59 for use in a method of preventing or treating coeliac disease.

61. A method of diagnosing coeliac disease, or susceptibility to coeliac disease in an individual comprising administering an agent as defined in claim 38 and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease.

62. A cell according to claim 35 which is a cell of a graminaceous monocotyledonous species.

63. A cell according to claim 62 which is a cell of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane.

64. A process for the production of a protein encoded by a coding sequence as defined in claim 31 which process comprises:

(a) cultivating a cell according to any one of claims 35, 36, 62 or 63 under conditions that allow the expression of the protein; and optionally

(b) recovering the expressed protein.

65. A method of obtaining a transgenic plant cell comprising:

(a) transforming a plant cell with a vector according to claim 34 to give a transgenic plant cell.

66. A method of obtaining a first-generation transgenic plant comprising:

(b) regenerating a transgenic plant cell transformed with a vector according to claim 34 to give a transgenic plant.

67. A method of obtaining a transgenic plant seed comprising:

(c) obtaining a transgenic seed from a transgenic plant obtainable by step (b) of claim 66.

68. A method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method according to claim 66, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

69. A method according to claim 68 comprising:

(d) obtaining a transgenic seed from a first-generation transgenic plant obtainable by the method according to claim 67, then obtaining a second-generation transgenic progeny plant from the transgenic seed;

and/or

(e) propagating clonally a first-generation transgenic plant obtainable by the method according to claim 66 to give a second-generation progeny plant;

and/or

(f) crossing a first-generation transgenic plant obtainable by a method according to claim 66 with another plant to give a second-generation progeny plant;

and optionally

(g) obtaining transgenic progeny plants of one or more further generations from the second-generation progeny plant thus obtained.

70. A transgenic plant cell, plant, plant seed or progeny plant obtainable by a method according to any one of claims 65 to 69.

71. A transgenic plant or plant seed comprising plant cells according to claim 62 or 63.

72. A transgenic plant cell callus comprising plant cells according to claim 62 or 63 obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny as defined in any one of claims 62, 63, or 65 to 69.

73. A plant or callus according to any one of claims claim 70 to 72 which is of a species as defined in claim 62 or 63.

74. A method of obtaining a crop product comprising harvesting a crop product from a plant according to any one of claims 70 to 73 and optionally further processing the harvested product.


75. A method according to claim 74 wherein the plant is a wheat plant and the harvested crop product is grain; optionally further processed into flour or another grain product.

76. A crop product obtainable by a method according to claim 74 or 75.

77. A food that comprises a protein as defined in any claim 25 or 30.

78. A food according to claim 77 in which a protein as defined in claim 25 or 30 is used instead of wild-type gluten.

**Figure 1**



**Figure 2**

<b>Alpha/beta gliadins (n=53)</b>	<b>Gamma gliadins (n=53)</b>	<b>LMW glutenins (n=77)</b>	<b>HMW glutenins (n=55)</b>	<b>Hordeins (n=59)</b>	<b>Secalins (n=14)</b>	<b>Avenins (n=20)</b>
S07361	AAA34272	AAB35353	A03353	A24095.1	A23277	S29209
P18573	S07398	AAB48474	A24266	A25677	AAB37403	S29208
P04728	PS0094	AAB48475	A30843	AAA32942	AAB37404	S29207
P04727	P21292	AAB48476	AAA62315	AAA32943	AAB37405	S06455
P04726	P08453	AAB48477	AAB02788	AAA32944	AAB37406	P80356
P04725	P08079	AAB48478	AAB23624	AAA32955	AAB37407	P27919
P04724	P06659	AAB48479	AAB23625	AAA32967	AAB58403	P14812
P04723	P04730	BAA22613	AAB23626	AAA92333	AAG35598	JQ1048
P04722	P04729	BAA22614	AAB23627	AAB28161	CAA26449	JQ1047
P04721	JS0402	BAA23162	AAB23628	AAB71678	S18235	JQ1046
P02863	JA0153	BAB78737	AAD32223	AAB71679	S18236	JG0015
EEWTA	EEWTG	BAB78738	AAF23506	B24095	S70327	B36433
E22364	CAC94871	BAB78739	AAF23507	B25677	S70328	AAB32025
D22364	CAC94870	BAB78740	B30843	BAA11642	S70329	AAB23365
CAB76964	CAC94869	BAB78741	CAA26847	CAA25509		AAA32716
CAB76963	CAC94868	BAB78742	CAA27052	CAA25912		AAA32715
CAB76962	CAC11089	BAB78743	CAA31395	CAA25913		AAA32714
CAB76961	CAC11088	BAB78744	CAA31396	CAA25914		AAA32713
CAB76960	CAC11087	BAB78745	CAA32115	CAA26889		1502200A
CAB76959	CAC11080	BAB78746	CAA43331	CAA31861		1411172A
CAB76958	CAC11079	BAB78747	CAA43361	CAA37729		
CAB76957	CAC11078	BAB78748	CAA59340	CAA42642		
CAB76956	CAC11065	BAB78749	CAC40684	CAA48209		
CAB76955	CAC11064	BAB78750	CAC40685	CAA51204		
CAB76954	CAC11057	BAB78751	CAC40686	CAA59104		
CAA35238	CAC11056	BAB78752	CAC40687	CAA60681		
CAA26385	CAC11055	BAB78753	CAC83002	P02864		
CAA26384	CAB75404	BAB78754	CAC83003	P06470		
CAA26383	BAA11251	BAB78755	CAC83018	P06471		
CAA10257	AAN32705	BAB78756	CAC84118	P06472		
C22364	AAK84880	BAB78757	CAC84119	P17990		
BAA12318	AAK84780	BAB78758	CAC84120	P17991		
B22364	AAK84779	BAB78759	CAC84121	P17992		
AAN32704	AAK84778	BAB78760	CAC84122	P80198		
AAB23109	AAK84777	BAB78761	EEWTHW	S07189		
AAB23108	AAK84776	BAB78762	JC2099	S07365		
AAA96525	AAK84775	BAB78763	JC4966	S07975		
AAA96524	AAK84774	BAB78764	JN0689	S07976		
AAA96523	AAK84773	CAA30570	JN0690	S08312		
AAA96522	AAK84772	CAA31685	P02861	S18350		
AAA96276	AAF42989	CAA59313	P02862	S20519		
AAA34283	AAD30556	CAA59338	P08488	S52390.1		
AAA34282	AAD30440	CAA59339	P08489	T04369		
AAA34281	AAB31090	CAA59340	P10387	T04473		
AAA34280	AAA34289	CAA76890	P10388	T04474		
AAA34279	AAA34288	EEWT1	S02262	T05718		
AAA34278	AAA34287	P10385	S04832	T05737		
AAA34277	AAA34286	P10386	S15720	T06211		
AAA34276	AAA34285	P16315	S18733	1103203A		

AAA17741	AAA34274	S01992	S29176	1103203B		
A27319	1802407A	S04325	S29177	1103203C		
A22364	1507333A	S57645	S29178	1210226A		
1307187B	1209306A	S57654	S29179	1307151A		
	<b>Omega gliadins (n=2)</b>					
		S57655	AAN78346	1307151B		
	A59156	S57656	AAO74630	1604464A		
	AAG17702	T05910		A24095.2		
		T05923		AAP31051		
		T06505.1		CAA48209.2		
		T06505.2		S52390.2		
		T06506				
		T06508				
		T06980				
		T06981				
		T06982				
		AAP44992				
		AAP44991				
		AAP44989				
		AAO53259				
		CAD58622				
		CAD58619				
		CAD58621				
		A03353				
		AAO53264				
		AAO53265				
		AAO53266				
		AAO53267				
		CAA76890				
TOTAL:	All gliadins					
20mers	721	645	786	416	155	199
12mers	4465	3945	4799	2672	957	1279
9mers	3739	3164	3630	2413	811	1207

**FIGURE 3****Figure 3A****M-Step:**

$$\begin{aligned} \frac{dQ(\theta, \theta^{(c)})}{dp_j^{(c)}} = 0 & \rightarrow p_j^{(c+1)} = \frac{\sum_i \hat{z}_{ij}^{(c)}}{n} \\ \frac{dQ(\theta, \theta^{(c)})}{d\alpha_i^{(c)}} = 0 & \rightarrow \alpha_i^{(c+1)} = \frac{\sum_j [\hat{z}_{ij}^{(c)} y_{ij} + (1 - \hat{z}_{ij}^{(c)}) y_{ij}]}{\sum_j [\lambda_j^{(c)} \hat{z}_{ij}^{(c)} + \lambda_0^{(c)} (1 - \hat{z}_{ij}^{(c)})]} \\ \frac{dQ(\theta, \theta^{(c)})}{d\lambda_j^{(c)}} = 0 & \rightarrow \lambda_j^{(c+1)} = \frac{\sum_i \hat{z}_{ij}^{(c)} y_{ij}}{\sum_i \alpha_i^{(c)} \hat{z}_{ij}^{(c)}} \\ \frac{dQ(\theta, \theta^{(c)})}{d\lambda_0^{(c)}} = 0 & \rightarrow \lambda_0^{(c+1)} = \frac{\sum_{ij} (1 - \hat{z}_{ij}^{(c)}) y_{ij}}{\sum_{ij} \alpha_i^{(c)} (1 - \hat{z}_{ij}^{(c)})} \end{aligned}$$

**E-Step:**

$$\hat{z}_{ij}^{(c+1)} = E(z_{ij} | y_{ij}) = pr(z_{ij} = 1 | y_{ij}) = \frac{p_j^{(c)} pr(y_{ij} | \alpha_i \lambda_j^{(c)})}{p_j^{(c)} pr(y_{ij} | \alpha_i \lambda_j^{(c)}) + (1 - p_j^{(c)}) pr(y_{ij} | \alpha_i \lambda_0^{(c)})}$$

Compute:

$$\begin{aligned} Q(\theta, \theta^{(c)}) = \sum_{ij} \{ & \hat{z}_{ij}^{(c)} \log p_j + (1 - \hat{z}_{ij}^{(c)}) \log(1 - p_j) + y_{ij} \hat{z}_{ij}^{(c)} \log(\alpha_i \lambda_j) \\ & + y_{ij} (1 - \hat{z}_{ij}^{(c)}) \log(\alpha_i \lambda_0) - \hat{z}_{ij}^{(c)} \alpha_i \lambda_j - (1 - \hat{z}_{ij}^{(c)}) \alpha_i \lambda_0 \} \end{aligned}$$

**Figure 3B**

Patient:  $i = 1 \dots 29$   
 Peptide:  $j = 1 \dots 652$   
 Plate:  $m = 1 \dots 7$





Figure 4




Figure 5

Group	Consensus	SEQ ID NO:	Sequence	SEQ ID NO:
1	gEIpFpEpE	1	gqlypypape lypypapg	200
			gqlypypapa lypypapg	201
2	EIpFpEpEI	2	ylqlqpfppaqlpypapql p	202
			papfppaqlpypapql pypap	203
			pymqlqpfppaqlpypapql	204
			qlqpfppaqlpypapql	205
			gqlypypapel pypapg	206
			gqlypypaql pypapg	207
			papfppaqlpypapql pypap	208
			mqlqpfppaqlpypapql py	209
			qlqpfppaqlpypapql	210
			pqlypypaql pypapqlpyp	211
			pqlypypaql pypapqfrp	212
			lqpfppaqlpypapel pypf	213
			lqlqpfppaqlpypapql py	214
			papfppaqlpypapql pypap	215
			3	EEpFpFEpE
pqaqaqaqfppaqaqfppwapa	217			
qpfppaqaqfppwapa qpfpa	218			
qpfppaqaqfppwapa qpfpa	219			
5	FpEpEEpIp	4	qqaqfppaqaqfppaqaqip	220
			pqaqaqaqfppaqaqip vqaq	221
			pqaqaqaqfppaqaqip vqaq	222
			gqaqfppaqaqip vqaq	223
			gqaqfppaqaqip vqaq	224
			pqaqaqaqfppaqaqip vqaq	225
			qpfppaqaqfppwapaqaqfpa	226
6	FpEpEEpFp	5	pqaqaqaqfppaqaqfppwapa	227
			pqaqaqaqfppaqaqfpp w	228
			qpfppaqaqfppwapaqaqfpa	229
			gqaqfppaqaqfppwapa	230
			gqaqfppaqaqfppwapa	231
			pqaqaqaqfppaqaqfpp w	232
			qpfppaqaqfppwapaqaqfpa	233
			qqaqaqfppaqaqfppwapa	234
			qqaqaqfppaqaqfppwapa	235
			qqaqaqfppaqaqfppwapa	236
			qqaqaqfppaqaqfppwapa	237
			7	EpEIpFpEp
papfppaqlpypapqlpypap	239			
pymqlqpfppaqlpypapql	240			
qlqpfppaqlpypapql	241			
gqlypypapel pypapg	242			
glqpfppaqlpypapg	243			
lqlqpfppaqlpypapqfr	244			
qlqpfppaqlpypapq	245			

			gqlypypaqqlpypqpg	246
			pqpfppqlypypaqqlpypqpg	247
			lqlqpfppaqqlpypqpgqpf	248
			lqlqpfppaqelypypqgeelpypqaelypypqapqpf	249
			mqlyqpfppaqqlpypqpgqlpy	250
			glqpfppaqelypypqpg	251
			qlqpfppaqelypypqpgql	252
			pqlypypaqqlpypqpgqlpyp	253
			qlqpfppaqqlpypqpgq	254
			glqpfppaqqlpypqpg	255
			pqlypypaqqlpypqpgqpf	256
			lqpfppaqelypypqgeelpy	257
			lqlqpfppaqqlpypqpgqlpy	258
			glqpfppaqqlpypqpg	259
			pqpfppqlypypaqqlpypqpg	260
			ypaqqlpypqpgqpfppqgsy	261
			gsgaqelypypqpgsg	262
			lqlqpfppaqqlpypqpgqlpypqaelypypqapqpf	263
8	EEpFpEpEI	7	qapqapfpqapqlpfpqaseq	264
			fpqapqapfpqapqlpfpqas	265
9	pEEpFSEEG	8	gqapfpqpeapfsgqg	266
			gqapfpqppapfsgqg	267
10	gFpEpEIpF	9	gsqfpqaelypypgsg	268
11	pEEEpEEpF	10	apqlpfpqppapqapqpfpg	269
			gqppqapqapfpgqg	270
			gqppqapqapfpgqg	271
12	IEEpEEpFp	11	lqapqapfpqapqqlpqpqg	272
			lqapqapfpqapqqlpqpqg	273
			apqapfpqlqapqapfpqpg	274
			pfpqlqapqapfpqapqqlp	275
			gfpqlqapqapfpqpg	276
			gfpqlqapqapfpqpg	277
13	pEpEpFIpE	12	lqpfppapqflpqlpypqpg	278
			lqlqpfppapqflpqlpypqpg	279
14	EEISpcmdI	13	lqqilqaaqltpcmdvvlqgh	280
			ilqqilqaaqltpcmdvvlqg	281
15	FEEEpFpEE	14	qspqqsfsyqapqfpqapyp	282
			yqapqfpqapypqapypsqg	283
			pqqsfsyqapqfpqapypqpg	284
16	EpFpEpEIp	15	ylqlqpfppaqqlpypqapqlp	285
			pymqlqpfppaqqlpypqapql	286
			qlqpfppaqqlpypqapql	287
			glqpfppaqelypypqpg	288
			lqlqpfppaqqlpypqapqpf	289
			qlqpfppaqelypypqapq	290
			lqlqpfppaqqlpypqapqpf	291
			lqlqpfppaqelypypqaelypypqaelypypqapqpf	292
			mqlyqpfppaqqlpypqapqlpy	293
			glqpfppaqelypypqpg	294

			ql qfppqelp ypqqql	295
			ql qfppqqlp ypqqqp	296
			gl qfppqqlp ypqqp	297
			l qfppqelp ypqqelpypf	298
			qqpqqfppqqlp fpqqseq	299
			lql qfppqqlp ypqqqlpy	300
			fpqqpqqfppqqlp fpqq	301
			gl qfppqqlp fpqqp	302
			gl qfppqelp ylqqp	303
			pylql qfppqqlp ysqqqp	304
			gl qfppqelp ysqqp	305
			lql qfppqqlp ylqqpfr	306
			lql qfppqqlp ylqqpfr	307
			lql qfppqqlp ysqqpfr	308
			gsg qfppqelp gsg	309
			lql qfppqqlp ypqqqlpypqqqlpypqqpfp	310
			gl qfppqqlp ysqqp	311
			qfppqqlp ysqqpqrppq	312
			lql qfppqqlp ysqqpqr	313
			gl qfppqqlp ylqqp	314
			qfpsqlpylql qfppqqlp	315
			pfpsqqpymql qfppqqlp	316
			pfpsqlpylql qfppqqlp	317
			pfpsqqpylql qfppqqlp	318
			pfpsqqpylql qfppqqlp	319
17	pEEpEEEFp	16	pqqpfppqqqqqfpp qqqqp	320
			gqpfppqqpqqfpp qpp	321
			qqpqqpfppqqqqqfpp qqqq	322
			gqpfppqqpqqqfpp qpp	323
			gfppqqpqqfpp qqqqg	324
			pqqpfppqqqqqfpp qqqqp	325
			gfppqqpqqfpp qqqqg	326
			gqpfppqqpqqqfpp qpp	327
			qqpqqpfppqqqqqfpp qqqq	328
			pqqpqqpfppqqqqqfpp qpp	329
			gfppqqpqqqfpp qqqqg	330
18	pFSEEEEpI	17	gqppfsqqqqpv lpqq	331
			lqqspfsqqqqpv lpqqqp	332
			pfsqqqqppfsqqqqpv lpq	333
			qqqpilsqqppfsqqqqpv l	334
			qppfsqqqqpv lpqqspfsq	335
			qqqvlppqqppfsqqqqpv ll	336
			qqqpilsqqppfsqqqqpv l	337
			qqqpfsqqqqpvlpqqppf	338
			pfsqqqqppfsqqqqpvlpqq	339
			qqqpilpqlpfsqqqqpv lp	340
			qppfsqqqqpv lppqqspf	341
			gqppfsqqqqpv lpqq	342
			qspfsqqqqpv lpqqqpvi	343
			qppfsqqqqpv lpqqspfsq	344
			qqqpfsqqqqpv ipqqpsf	345

			lppfsqqlppfsqqqqpvlp	346
			qqqqppfsqqqqpvlpqsp	347
			sqqqpilsqqppfsqqqqpvl	348
			pfssqqqqpvlqqqipfvhp	349
19	pEEpSpIEp	18	ftqqqqtpiqpqqpfpqqp	350
			pftqqqqtpiqpqqpfpqq	351
			fpeqsqqpftqqqqtpiqp	352
20	EpEEpIpIE	19	pqqpqqpfpqqqpipvqqp	353
			pqqpqqpfpqqqpipvqqp	354
			gqqpfpqqqpipvqqg	355
			gqqpfpqqqpipvqqg	356
			pqqpqqpfpqqqpipvqqp	357
			pqqqpipvqqpqqsfqqsg	358
			qqqpipvqqpqqsfqqsg	359
21	EpEEpEIpF	20	qqpfpqqqpqlpfpqqpqq	360
			qqqpqqpfpqqqpqlpfp	361
			qqpqqpfpqqqpqlpfpqq	362
			qqpqqpfpqqqpqlpfpqq	363
			pqqqpqlpfpqqpqqpfpq	364
			pqqpfpqqqpqlpfpqqpqq	365
			gqqpfpqqqpqlpfg	366
			qqpfpqqqpqlpfpqqpqq	367
			gqqpfpqqqpqlpfg	368
			gfpqqqpqlpfpqqg	369
			gfpqqqpqlpfpqqg	370
22	EpEIpFpEg	21	gsgpqqpelpypqsg	371
23	FpEpEIpFg	22	gsgpfpqqpelpyqsg	372
24	pEEpFcEEg	23	gqqpfpqqpqqpfcqqg	373
			gqqpfpqqpqqpfcqqg	374
25	FpEpEEEEp	24	gffpqqpqqpfpqqqq	375
			gqqpfpqqpqqpfpqq	376
			sqqpqqpfpqqpqqpfpqq	377
			gqqpfpqqpqqpfpqq	378
			sqqpqqpfpqqpqqpfpqq	379
			qpfpqqpqqpfpqqpqqsf	380
			gffpqqpqqpfpqqqq	381
			sqqpqqpfpqqpqqpfpqq	382
			gffpqqpqqpfpqqqq	383
			gqqpfpqqpqqpfpqq	384
26	gEpSpIEpE	25	gqptpiqqpfpfpqqg	385
			gqptpiqqpfpfpqqg	386
27	FIPeIpFpE	26	lqpfppqpflpqlpypqqp	387
			flpqlpypqqpfpqqpyp	388
			gqpqpflpelpypqqp	389
			pqpflpqlpypqqpfpqq	390
			pqpflpqlpypqqpfpqq	391
			gqpqpflpqlpypqqp	392
			lqlqpfppqpflpqlpypq	393
28	FIEEEcSRI	27	svlqqlnpckvflqqqshv	394
			kvflqqqshvamsqrlarp	395
29	pFpEpEEpF	28	qpfppqpfpwqpqqpfpq	396

			pqqpqqpfpqpqqpfpwqqp	397
			pqqpqqpqqpfpqpqqpfpw	398
			qpfpqpqqpfpwqpqqpfpq	399
			gqqpfpqpqqpfpwqq	400
			gqqpfpqpqqpfpwqq	401
			pqqpqqpqqpfpqpqqpfpw	402
			qpfpqpqqpfpwqpqqpfpq	403
			qpqqpfpqpqqpfpwqq	404
			qpqqpfpqpqqpfpwqq	405
			gqqpfpqpqqpfpqqq	406
			gqqpfpqpqqpfpqqq	407
			gqqpfpqpqqpfpqqq	408
			gqvqwpqqpfpqpqqpfpce	409
			pqqqqpfpqpqqpfpqqqq	410
			wpqqqpfpqpqqpfpqqqq	411
			psgqvqwpqqpfpqpqqpfp	412
			gqqpfpqpqqpfpqqq	413
			pqqqqpfpqpqqpfpcepprt	414
			qpqqpfpqpqqpfpwqq	415
			qpqqpfpqpqqpfpwqq	416
			qqqqpfpqpqqpfpqqpprti	417
			qqqqpfpqpqqpfpqqppqi	418
			qqqqpfpqpqqpfpcepprti	419
30	FIEpEEpFp	29	qqflqpqqpfpqpqqpypq	420
			gqqqfiqpqqpfpqq	421
			pqqqfiqpqqpfpqpqqty	422
			gqqqfiqpqqpfpqq	423
			qqqfiqpqqpfpqpqqty	424
			fsqpqqpqqqfiqpqqpfpq	425
			pqqqfiqpqqpfpqpqqty	426
			pqqpflqpqqpfpqpqqpfp	427
			pqqqflqpqqpfpqpqqpfp	428
			pqqqflqpqqpfpqpqqpfp	429
31	pEEEEIaRg	30	gqqpqqqqlahgtflqphki	430
			qqpqqqqlahgtflqphqia	431
32	EpEEpFpEp	31	pqqpqqpfpqpqqpfpwqq	432
			pqqpqqpqqpfpqpqqpfpw	433
			qpfpqpqqpfpqpqqpfp	434
			pqqpqqpfpqpqqpfpvqpq	435
			pqqpqqpfpqpqqpfpvqpq	436
			pqqpqqpqqpfpqpqqpfpw	437
			qppqpfpqpqqpqlpfpqqseq	438
			qpqqpfpqpqqpfpwqq	439
			lqpqqpfpqpqqpfpqqpqq	440
			qpqqpfpqpqqpfpwqq	441
			fpqpqqpfpqpqqpqlpfpqq	442
			pqqpqqpfpqpqqpfpvqpq	443
			plqpqqpfpqpqqpfpqpqq	444
			sqppqpfpqpqqpfpqpqq	445
			sqppqpfpqpqqpfpqpqq	446
			pqqpfpqpqpqqpfpqpqq	447

			q1pfpq qeqqefpqp qqqqq	448
			hqppqqfpqtq qeqqefpqp	449
			pqtq qeqqefpqp qqt fqqq	450
			qqq qeqqefpqp qqqqlpfp	451
			pqqpfpqqq qeqqefpqp q	452
			q qeqqefpqp qqqqlpfpqq	453
			sq qeqqefpqp qqqqqsfq	454
			qqqqpfpqqq qeqqefpqp q	455
			q qeqqefpqp qqqqlpfpqq	456
			pqqpfpqqq qeqqefpqp qqqqlpfpq	457
			lqqqqefpqp qqqqlpfpqq	458
			qqqqpfpqqq qeqqefpqp q	459
			qqqqpfpqlq qeqqefpqp q	460
			qqqqefpqp qqqfpwqp	461
			sk qeqqefpqp qqqqqsfq	462
			sq qeqqefpqp qqqfpqqqq	463
			qqqqefpqp qqqfpwqp	464
			pfpqlq qeqqefpqp qqqqlp	465
			qsk qeqqefpqp qqqqqsfp	466
			fplqqqqpfpq qeqqefpqp	467
			qqqqqqpfpqq qeqqefpqp	468
			qqqqpfpqqq qeqqefpqp q	469
			qqqqpfpqqk qeqqefpqp q	470
			plqqqqpfpq qeqqefpqp q	471
			qqfpqtq qeqqefpqp qqt f	472
			qqqqpfpqqk qeqqefpqp	473
33	pFpIEpEEp	32	qqqqpfpqlq qeqqefpqp	474
			qqqfplqqeap fpqqq	475
			pqqpqqpfpplqqeap fpqqq	476
			qqqfplqqeap fpqqq	477
			pqqqlqqpfpplqqeap fpqqq	478
			pqqpqqpfpplqqeap fpqqq	479
			seqiipqqlqqpfpplqqeap	480
34	EpEEaFpEp	33	gqt fph qeqaefpqp g	481
			qt fph qeqaefpqp qqt fph	482
			gqt fph qeqaefpqp g	483
			pqqt fph qeqaefpqp qqt f	484
35	pEFpSEIpF	34	ppqqpypqqpfpqlpy lql	485
			qqpypqqpfpqlpy lqlap	486
36	pFpEpEEEEI	35	lqqpqqpfpqqpql pqqqq	487
			qqqpfqqeapfpqqqq	488
			lqqpqqpfpqqpql pqqqq	489
			pfpqlqqpqqpfpqqpql p	490
			qqqpfqqeapfpqqqq	491
			qpfqqpqqpfpqqpqqsf	492
37	ppEIpFpEp	36	pqqpfpqlpyqp qlpypqp	493
			pqqpfpqlpyqp qlpypqp	494
			qpfqqpqlpyqp qpfrpqp	495
			pqqpfpqlpyqp qlpypqp	496
			pqqpfpqlpyqp qpfrpqp	497
			pqqpfpqlpyqp qpfrpqp	498

			pqpfppqlpypqpsfppqg	499
			gqpqfppelpypqg	500
			gqpqfppqlpypqg	501
			pfppqfppqlpypqppf	502
			gsgppelpypqgsg	503
			pfppqfppqlpypqgsf	504
			pqpfpqqlpypqppfspqg	505
38	mEIEpFpEp	37	pymqlqppqqlpypqql	506
			mqlqppqqlpypqqlpy	507
			mqlqppqqlpypqqlp	508
			pfpsqppymqlqppqqlp	509
			pfpsqppymqlqppqqlp	510
			pfpsqppymqlqppqqlp	511
39	EESScRIImE	38	pqlarsqmwqqsschvmqg	512
			qqlarsqmlqqsschvmqgg	513
			pqlarsqmwqqsschvmqg	514
			rlarsqmlqqsschvmqggc	515
			rpqmwqqsschvmqggccqg	516
			mwqqsschvmqggccqqlqg	517
			sqmlqqsschvmqggccqql	518
			qqsschvmqggccqqlqgip	519
			qqsschvmqggccqqlqgip	520
			rlarsqmwqqsschvmqggc	521
			arsqmlqqsschvmqggccq	522
40	EEFSEpEEE	39	gqqsfsqpeqefpqpqg	523
			gqqsfsqpeqefpqpqg	524
			gqqsfsqpeqefpqpqg	525
			sqqpqqsfsqpeqefpqpqg	526
			sqqpqqsfsqpeqefpqpqg	527
			qqsfsqpeqefpqpqg	528
			qsqpqqsfsqpeqefpqpqg	529
			qpqqsfsqpeqefpqpqg	530
41	pEEEFpEpE	40	gffpqppeqefpqpqgg	531
			sqqpqqsfsqpeqefpqpqg	532
			sqqpqqsfsqpeqefpqpqg	533
			ppqpfpqpqqsfsqpeqefpqpqg	534
			ppqpfpqpqqsfsqpeqefpqpqg	535
			qpfpqpqqsfsqpeqefpqpqg	536
			qpfpqpqqsfsqpeqefpqpqg	537
			gffpqppeqefpqpqgg	538
			sqqpqqsfsqpeqefpqpqg	539
			gffpqppeqefpqpqgg	540
			qpfpqpqqsfsqpeqefpqpqg	541
			gffpqppeqefpqpqgg	542
			ppqpfpqpqqsfsqpeqefpqpqg	543
			gffsqppeqefpqpqgg	544
			ppqpfpqpqqsfsqpeqefpqpqg	545
			gffpqppeqefpqpqgg	546
			sqqpqqsfsqpeqefpqpqg	547
			sqqpqqsfsqpeqefpqpqg	548
			qqsfsqpeqefpqpqg	549

			qsqqppqqqfsqppqqqfppqq	550
			ppqqqfppqq qppqqpfpqqppq	551
			qpqqqfsqppqqqfppqq qpp	552
			qqppqqpfpqqppqqqfppqq	553
			ppqqppppfpqqppqqqfppqq	554
			gffsqppqqqfppqq qq	555
			tfphqqppqqqfppqq qppqqpf	556
			qtfphqqppqqqfppqq qppqq	557
			gfpqqppqqqfppqq qq	558
			sqppqqqfppqq qppqqsfppq	559
			qtcphqqppqqqfppqq qppqq	560
42	pIpEIEpRn	41	pvpqLqpknpSqppqeqvp	561
			avrvpvpqLqpknpSqppq	562
43	SScISgIER	42	me tscisglerpwqqqplpp	563
44	FEEEpIppE	43	pwqqqplppq qsfSqppfs	564
			pwqqqplppq qsfSqppfs	565
			erpwqeqplppqhtlfpqqq	566
			etrcipglerpwqqqplppq	567
			shipglerpwqqqplppqqt	568
			mrcipglerpwqqqplppq	569
			scisglerpwqqqplppqqs	570
			pwqqqplppqqtLfpqqqpf	571
			erpwqeqplppq qsfSqpp	572
			scisglerpwqqqplppqqs	573
			rpwqqqplppqqtfpqqppf	574
			pwqeqplppqhtlfpqqqpf	575
			ekpwqqqplppq qppqpcsq	576
			pwqqqplppq qsfSqppfs	577
			etscipglerpwqeqplppq	578
45	EpIpEEpSF	44	sqpppfsqqqqqplppqpsf	579
			qplppqpsf sqppppfsqqq	580
			qqqqqplppqpsf sqppppf	581
			ppfsqqqqqplppqpsf sq	582
			qplppqpsf sqppppfsqqq	583
			sqpppfsqqqqqplppqpsf	584
			qqqqqplppqpsf spg	585
			qqqqqplppqpsf sqppppf	586
			qqqqqplppqpsf spg	587
46	IIFSSIIIEE	45	qqsryeairairvystilqe q	588
			aivystilqe qqvqgsiq	589
47	EpIISEEpp	46	qqqpilsqpp fsqqqqpvl	590
			fsqqpppfsqqqpilsqpp	591
			fsqqpppfsqqqpilsqpp	592
			qqqpilsqpp fsqqqqpvl	593
			qqpppfsqqqpilsqpp fs	594
			sqqqpilsqpp fsqqqqpv	595
			qqpppfsqqqpilsqpp fs	596
48	EgIEIIRpI	47	vmqqeqqgqilrpl fqlv	597
			qqqqqgqilrpl fqlvqq	598
49	pFSSIIagI	48	csiikapfssvvgi gqyr	599
			csiikapfssvvgi gq	600

50	FcSSSIapI	49	yippy <del>stti</del> apvgifgtn	601
			vyippy <del>stti</del> apvgifgtn	602
51	RIamSERIa	50	qqcshvamsqrlarsqmwqq	603
			kvflqqqcs <del>h</del> vamsqrlarp	604
			qcs <del>h</del> vamsqrlar <del>p</del> qmwqq <del>s</del>	605
52	EpESFppEE	51	flpqlpyp <del>qpqs</del> fppqppyp	606
			pppflpqlpyp <del>qpqs</del> fppq <del>q</del>	607
			pppflpqlpyp <del>qpqs</del> fppq <del>q</del>	608
			pppfp <del>pp</del> qlpyp <del>qpqs</del> fppq <del>q</del>	609
			g <del>qpqs</del> f <del>pp</del> e <del>q</del> ppypq <del>q</del>	610
			lpqlpyp <del>qpqs</del> f <del>pp</del> q <del>q</del> ppyp <del>q</del>	611
			g <del>qpqs</del> f <del>pp</del> q <del>q</del> ppypq <del>q</del>	612
53	siilqEqqq	52	rydaicaitysiilqe <del>qqq</del> g	613
			airaiiysiilqe <del>qqq</del> gfvq	614
			iraiivysiilqe <del>qqq</del> gfvqp	615
			iiysiilqe <del>qqq</del> gqgsvesq	616
			airaiiysiilqe <del>qqq</del> vqgs	617
			aiiysiilqe <del>qqq</del> gfvqp <del>q</del>	618
			ryeairaiivysiilqe <del>qqq</del> v	619
			iraitysiilqe <del>qqq</del> gfvqa	620
			vysiil <del>qqqq</del> q <del>qqqq</del> q <del>q</del> gs	621
			aiiysiilqe <del>qqq</del> vqgsiqs	622
			siraiivysiil <del>qqqq</del> q <del>qqq</del>	623
			aiiysiilqe <del>qqq</del> vqgsiqs	624
			aiifsiilqe <del>qqq</del> gfvqp <del>q</del>	625
			siilqe <del>qqq</del> gqgsvesq <del>eq</del>	626
			rhesiraiiysiil <del>qqqq</del> q	627
			yysiilqe <del>qqq</del> gfvqp <del>qqq</del>	628
			airaiiysiilqe <del>qqq</del> vqgs	629
			yeairaiiysiilqe <del>qqq</del> gf	630
54	ESEEpEEpF	53	hqpqqqf <del>qt</del> qpqq <del>pf</del> ppq	631
			pp <del>qt</del> qpqq <del>pf</del> ppqq <del>tf</del> ppq	632
			qpqp <del>qt</del> qpqq <del>pf</del> ppqq <del>q</del>	633
			qpqpqp <del>pf</del> ppqqqp <del>fp</del> qt	634
			qpqpqp <del>pf</del> qpqpqp <del>pf</del> ppq	635
			gfp <del>qt</del> qpqp <del>pf</del> ppqq	636
			gfp <del>qs</del> qpqp <del>pf</del> ppqq	637
			ppqpqp <del>pf</del> qpqpqp <del>pf</del> ppq	638
			qpqp <del>pf</del> qpqpqp <del>pf</del> ppqlqp	639
			qpqpqp <del>pf</del> qpqpqp <del>pf</del> ppq	640
			qpqpqp <del>pf</del> qpqpqp <del>pf</del> ppq	641
			pp <del>qt</del> qpqp <del>pf</del> ppqpqp <del>pf</del>	642
			qpqp <del>pf</del> qpqpqp <del>pf</del> ppqp <del>tf</del>	643
			gqpqp <del>pf</del> qpqpqp <del>pf</del> g	644
			qpqp <del>pf</del> qpqpqp <del>pf</del> ppqp <del>q</del>	645
			gfp <del>qs</del> qpqp <del>pf</del> ppqq	646
			qpqp <del>pf</del> qpqpqp <del>pf</del> ppskqp	647
			qpqp <del>pf</del> qpqpqp <del>pf</del> ppsqqp	648
			gfp <del>qt</del> qpqp <del>pf</del> ppqq	649
			gqpqp <del>pf</del> qpqpqp <del>pf</del> g	650
			gqpqp <del>pf</del> qpqpqp <del>pf</del> g	651

			gqqpfpqtqqppqfg	652
			pfpqtqqppqfpqlqqpqq	653
55	EIEEpEEpI	54	qpfpqlqqppqplpqqppq	654
			gfpqlqqppqplpqqg	655
			qqpppfpqlqqppqplpqq	656
			gfpqlqqppqplpqqg	657
56	IpEEpEEpF	55	gqppqqppqppfplqq	658
			fpelqqppqqppqppfplqq	659
			fpelqqppqqppqppfplqq	660
			gqppqqppqppfplqq	661
			gqlqqppqqppqppfg	662
			gqlqqppqqppqppfg	663
57	FpEEpEEpF	56	qqppqqppqppfpqqppqp	664
			fpqqppqppfpqqppfpqq	665
			qqflqqppfpqqppqppypq	666
			plqqppqppfpqqppqppq	667
			qlpfpqqppqppfpqqppqppq	668
			tqqppqppfpqqppqppfpqtq	669
			qtqqppqppfpqqppqppfpqt	670
			pqqppqppqlpfpqqppqppfpq	671
			qqppqqppqppfpqtqqppq	672
			qqppqqppqppfpqtqqppq	673
			gqppqqppqppfpqqg	674
			fpelqqppqppfpqqppqppq	675
			pqqppqlqqppqppfpqqppqppf	676
			plqqppqppfpqqppqppfpqqpp	677
			gqppqppfpqqppqppfg	678
			gqppqqppqppfpqqg	679
			gqppqqppqppfpqqg	680
			ypqqppfpqqppqppfpqqppf	681
			qqtfpqqppqlpfpqqppqppf	682
			pqqppqlqqppqppfpqqppqppyp	683
			plqqppqppfpqqppqppfpqqppq	684
			gqppqppfpqqppqppfg	685
			rqqppqqppqppfpqqppqppf	686
			gqppqqppqppfpqqg	687
			qqppqqppqppfpqqppqppf	688
			qqppqppfpqqppqppfpqtqqp	689
			fpqqppqppfpqqppqppfpqt	690
			fpqqpprqqppqqppqppfpqt	691
			pfqqppqppfpqqppq	692
			pfqqppqppfpqqppqppfpq	693
			gqppqlpfpqqppqppfg	694
			gqppqlpfpqqppqppfg	695
			pqqppqppfpqqppqppfpqqq	696
			qqppqppfpqqppqppfpqqpp	697
			lqqppqppfpqqppqppfpqqppq	698
			pqqppqlqqppqppfpqqppqppyp	699
			prqqppqqppqppfpqqppqpp	700
58	SpIEpEEpF	57	gqppqpqqppqppfpqqg	701
			ftqqppqppqpqqppqppfpqqpp	702

			pftqppqp tpiqqppf pqq	703
			tpiqqppf pqqppppppf	704
			gqp tpiqqppf pqqg	705
59	pFSEEpEEI	58	gqpfSqppqi fpqqg	706
			qqpfSqppqi fpqqqt fp	707
			qqqqpfpqqppfSqppqi	708
			hqpfSqppqi fpqqqt fp	709
			gqpfSqppqi fpqqg	710
			pflqphqpfSqppqi fpqp	711
			gppqppfSeqppqi fg	712
			qqqpflqphqpfSqppqi f	713
			qqqpfSqppqi fpqqqt	714
			gppqppfSqppqi fg	715
60	gEEIFpEpE	59	gqgifpqp qt fphqg	716
			gqgifpqp qt fphqg	717
61	EpEEpEEpF	60	pqqppppppf pppppppw	718
			pqqppppppf pppppppw	719
			ppqp fp pppppppf ppppp	720
			ppqp fp pppppppf ppppp	721
			ppppppf ppppppplfp	722
			ppqp fp pppppppf ppppp	723
			qqqqpfp pppppppf ppppp	724
			tpiqqppfp pppppppf	725
			piqqppfp pppppppf p	726
			qqfp pppppppf ppppppp	727
			gqppfp pppppppf g	728
			qqppppfp pppppppf ppp	729
			lqqpppplp pppppppf pq	730
			gfp pppppppf pqqg	731
			gfp pppppppf pqqg	732
			qqpfp pppppppf pqlqqp	733
			ppppfp pppppppf ppppp	734
			ppppppf pppppppliqpy	735
			ppqpfp pppppppf pqlqq	736
			gqppfp pppppppf g	737
			gqpplp pppppppf g	738
			p pppppppf pppppppliqp	739
			qqpfp pppppppf pqsqqp	740
			tfhqppqqvp pppppppf	741
			gqqqfp pppppppf g	742
			gqqplp pppppppf g	743
			tfhqppqqvfp pppppppf	744
			qqplp pppppppf pqsqqp	745
			gqqqfp pppppppf g	746
			qqvp pppppppf lqqppf	747
			qqplp pppppppf pqsqqp	748
			qqvp pppppppf lqqppf	749
62	FpEEpEEpI	61	ppqaqlp fpqqppppl pppp	750
			qaqlp fpqqppppl ppppp	751
63	pSSEppFp	62	qqpfpqqppppssqppfp q	752
			qqppppssqppfp qqhqpp	753

			ppfsqqqqpssqqppfpqqh	754
64	FpEEpEIpF	63	pqqpfpqqqt fpqqpqlpf	755
			fpqqqt fpqqpqlpf pqqp	756
			qqt fpqqpqlpf pqqpqqpf	757
			pqqpfpqqqt fpqqpqlpf	758
65	pFpFEpEEp	64	qpfqpqqqpfpwqpqqp fpq	759
			qpfqpqqqpfpwqpqqp fpq	760
			qpfqpqqqpfpwqpqqp fpq	761
			qqpfpwqpqqp fpqqg	762
			pfwqpqqp fpqtqqsfplq	763
			qqpfpwqpqqp fpqqg	764
66	pEESFpREg	65	qqqifpqqeqtfphgg	765
			qqqafpqqeqtfphgg	766
			qqqifpqqqqt tfphgg	767
			qqqt fpqqeqtfphgg	768
			qqqafpqqqqt tfphgg	769
			qqqt fpqqqqt tfphgg	770
67	SFpREpEEa	66	qqifpqqqqt fphqqqa fp	771
			qqtfphqqqa fpqqg	772
			qtfphqqqa fpqqqt fph	773
			qqtfphqqqa fpqqg	774
			pqqtfphqqqa fpqqqt f	775
68	FSEEEpSFS	67	pqqqpp fsqqppsfs qqpp	776
69	aFpEpEESF	68	qqqafpqqeqtf phgg	777
			qafpqqqt f phqqqqqfpq	778
			qafpqqqt f phqqqqqfpq	779
			qqqafpqqqt f phgg	780
			qtfphqqqa f pqqqt f ph	781
			qqafpqqqt f phqqqqqfp	782
			pqqtfphqqqa f pqqqt f	783
70	SEEpFSEpE	69	qqfpeqsqppftqpq qptpi	784
			fpeqsqppftqpq qptpiq	785
71	IEpFpEpEp	70	lqpfpqp flpqlpypq	786
			lqlqpfpqp fppqlpypq	787
			lqlqpfpqp flpqlpypq	788
			lqlqpfpqp fppqlpypq	789
			mqqlqpfpqp fppqlpypq	790
			pfpsqqpymqlqpfpqp f	791
			fpsqqpylqlqpfpqp fl	792
			pfpsqqpylqlqpfpqp f	793
			sqppylqlqpfpqp fppq	794
			pfpsqqpymqlqpfpqp f	795
72	pFpRpEIpF	71	qqpylqlqpfprpqlpypq	796
			glqpfprpqlpypqpg	797
			lqlqpfprpqlpypqppfr	798
			glqpfprpqlpypqpg	799
73	EEIFpEpEE	72	qqqifpqqeqtfphgg	800
			qqqifpqqqqt fphgg	801
			qqifpqqqt fphqqqa fp	802
			pqqifpqqqt fphqqqa f	803
			qqifpqqqt fphqqqa f	804

			qqpfsqqpqqifpqqqtffp	805
			hqpfsqqpqqifpqqqtffp	806
			qqqqpfsqqpqqifpqqqt	807
74	EpEESFpER	73	pqqqfiqpqqpqqqtypqrpq	808
			qqqqqfiqpqqpqqqtypqrp	809
			qpfpqppqqqtypqrpqqpfp	810
			pqqpfpqppqqqtypqrpqqp	811
			pqqqfiqpqqpqqqtypqrpq	812
			qppfpqppqqqtypqrpqqpf	813
			qppfpqppqqqtypqrpqqpf	814
75	FpERpEEpF	74	qqtypqrpqqpfpqtqqpqq	815
			qpfpqppqqqtypqrpqqpfp	816
			qqtypqrpqqpfpqtg	817
			qqtypqrpeqqpfpqtg	818
			qppfpqqppqqqtypqrpqqpf	819
			qppfpqqppqqqtypqrpqqpf	820
			qqtypqrpqqpfpqtqqpqq	821
			qtypqrpqqpfpqtqqpqq	822
76	IEpFpEpEI	75	ylqlappfpapqlpypapqlp	823
			pymqlappfpapqlpypapql	824
			qlappfpapqlpypapql	825
			glappfpapel pypapq	826
			lqlappfpapqlpypapqpr	827
			qlappfpapel pypapqp	828
			lqlappfpapqlpypapqpr	829
			lqlappfpapel pypapel pypapel pypapqpf	830
			mqlappfpapqlpypapqlpy	831
			glappfpapel pfpapq	832
			qlappfpapel pypapql	833
			qlappfpapql pypapqp	834
			glappfpapql pypapq	835
			lappfpapel pypapel pypf	836
			lqlappfpapql pypapqlpy	837
			glappfpapql pfpapq	838
			glappfpapel pylapq	839
			pylqlappfpapql pypapqp	840
			glappfpapel pypapq	841
			lqlappfpapql pylapqpr	842
			lqlappfpapql pylapqpr	843
			lqlappfpapql pypapqpr	844
			lqlappfpapql pypapql pypapql pypapqpf	845
			glappfpapql pypapq	846
			lqlappfpapql pypapqpr	847
			glappfpapql pylapq	848
			glappfpapel sysapq	849
			qfqsqlylqlappfpapqlp	850
			lqlappfpapql sysapqpr	851
			lqlappfpapql sysapqpr	852
			gsglappfpapel gsg	853
			pfpqqpymqlappfpapqlp	854
			glappfpapql sysapq	855

			pfpsqlpylqlqpfppqlp	856
			pfpsqppyqlqpfppqlp	857
			pfpsqppyqlqpfppqlp	858
77	EpFpESEES	76	pfpwqppqpfppqtqqs fplq	859
			qpfppqtqqs fplqppqppfpp	860
			fpwqppqpfppqtqqs fplqpp	861
78	ESScIpgIE	77	metscipgle rpwqqqplqq	862
			etscipgle rpwqqqplppq	863
79	pIIpRgppF	78	sqqqpilprgppf sqqtqp v	864
80	EpEEEEfpEp	79	gffp qpeqefppp qqq	865
			gqqpfp qpeqefppp g	866
			sqqppppfp qppqqfppp qq	867
			gqqpfp qpeqefppp g	868
			sqqppppfp qppqqfppp qq	869
			ppqpfpq qppqqfppp qppq	870
			qpfpp qppqqfppp qppqqqs f	871
			gqpfpq qpeqefppp g	872
			qppqqfpfpq qppqqfppp qq	873
			gqqqfs qpeqefppp g	874
			gffp qppqqefppp qqq	875
			sqqppppfp qppqqfppp qq	876
			gffp qppqqfppp qqq	877
			gqqqfs qppqqfppp g	878
			gqpfpq qpeqefppp g	879
			gqqpfp qppqqfppp g	880
			qppqqfppp qppqqppfppp	881
			gqt fph qpeqefppp g	882
			gfpq qpeqefppp qqq	883
			ppqpfpq qppqqfppp qppq	884
			gqqqfs qpeqefppp g	885
			gffs qppqqefppp qqq	886
			p qppqqfppp qppqqqs fpqq	887
			gfpq qppqqefppp qqq	888
			sqqppqqqfs qppqqfppp qq	889
			sqqppqqqfs qppqqfppp qq	890
			qqfs qpeqefppp qq	891
			qsqqppqqqfs qppqqfppp q	892
			qppqqqfs qppqqfppp qppq	893
			gqpfpq qppqqfppp g	894
			qppqqppfpq qppqqfppp qq	895
			ppqpqqppfpq qppqqfppp q	896
			t.fppppqt.cph qppqqfppp	897
			gffs qppqqfppp qqq	898
			t fph qppqqfppp qppqqpp f	899
			qt fph qppqqfppp qppqqq	900
			gfpq qppqqfppp qqq	901
			s qppqqfppp qppqqqs fpqq	902
			qt.cph qppqqfppp qppqqpp	903
			gqt.fph qppqqfppp g	904
81	nmEadpSgE	80	nmqadpsgg vqwpqqpp flq	905
			at a nmqadpsgg vqwpqqpp	906

82	gaIcSSISn	81	fdeeknst galcsslsn gas	907
83	EFpEEEEIpI	82	qppfpqqhq qfpqqqipv vq	908
			qqplfpqqhq qfpqqqipv v	909
			qfpqqqipv vqpsvlqqlnp	910
84	EEEpIIIEE	83	sqqqqpfpq qqaplllqqpp	911
			qqqapillqqppfsqhqqpv	912
			qqqpfq qqaplllqqppfs	913
			qqqqppfsqq qqapillqqp	914
			pfsq qqapvllqq qipfvhp	915
			qqqpfq qqaplllqqppfs	916
85	SEEpEESFp	84	qqpl sqapqatfp qqqt fp	917
			hqpf sqapqatfp qqqt fp	918
			qpfpqhqpf sqapqatfp q	919
			qqpl sqapqatfp qqg	920
			pvpqhqpf sqapqatfp qp	921
			qqpl sqapeatfp qqg	922
			qqlvqlqqpl sqapqatfp	923
			pqlqqpl sqapqatfp qqg	924
86	FRREpEESF	85	phqt fhhapqatfp pqqqaty	925
			qt fhhapqatfp pqqeatyph	926
			qt fhhapqatfp pqqqatyph	927
			qrtipqhqf fhhapqatfp	928
87	RFFFpSSpR	86	sqqqghwyyptspk lsgqqq	929
88	REpEEEEFSE	87	tfp hqqqqqfsqqqqqqqf	930
			qt fphqqqqqfsqqqqqqq	931
89	SIEEIIIEE	88	qqq tlqqilqqq lipcrdvv	932
			tlqqilqqq lipcrdvvlqq	933
			qqqqqqqqq tlqqilqqq lip	934
90	IEEpIppEE	89	pwlaqplppqq tlpqqllqqp	935
			sniiisflkpw lqqplppqq	936
91	pISpEESqE	90	qqqqgyypispqqsgqqqqp	937
92	pEpFpEpEp	91	pypqapfpapap fppqlpy	938
			pfpqqpypqapfpapap f	939
			pqqapfpapap fppqlpypq	940
93	EpEpFpEpE	92	pypqapfpapap fppqlpy	941
			qqpfpqqpyp qapqfpapq	942
			pfpqqpyp qapqfpapap f	943
			pqqapfpapap fppqlpypq	944
94	FpEEpEESF	93	pqqqfiqqqqp fpqqpqqty	945
			qqqfiqqqqp fpqqpqqty p	946
			pqqqfiqqqqp fpqqpqqty	947
			pqqpqqp fpqqpqqsf pqqp	948
			qqp fpqqpqqsf pqqg	949
			qp fpqqpqqty pqrpqapfp	950
			qqpqqp fpeqqpqqsf g	951
			qqpqqp fpqqpqqsf g	952
			pqqp fpqqpqqsf pqqpqqp	953
			pqqp fpqqpqqty pqrpqap	954
			qqp fpqqpqqsf pqqg	955
			qqpqqp fpeqqpqqtf g	956
			pfpqqpqqp fpqqpqqsf pq	957

			gqpqqpfpqapqatfg	958
			qqpfpqapqatyqarpqapf	959
			qqpfpqapqatyqarpqapf	960
95	EESFSEpp	94	pwqqqplppqqsfsqappfs	961
			pwqqqplppqqsfsqappfs	962
			erpwqqqplppqqsfsqapp	963
			pqsfsqappfsqqqqqplp	964
			qqsfsqappfsqqqqqplp	965
			qplppqqsfsqappfsqqqq	966
			pwqqqplppqqsfsqappfs	967
96	FpEEpFpEE	95	ypqapfpqapqapfpqapff	968
			yqqapfpqapypqapypsqq	969
			lpqpyaqpylpyqapfpqa	970
			pqsfsyqqapfpqapypqa	971
			pfqapypqapypsqqpyps	972
			qelqspqqlypqapypqapy	973
			yapylpyqapfpqapqap	974
			qqpfpqapypqapypsqqpy	975
97	EpSSEpIS	96	qpsqqplsqqhqapqqqi	976
			qppfsqqqapssqqplsqq	977
98	EpIEERESF	97	glerpwqqaplqqketfpqa	978
99	ISpEEIqEg	98	qqgyypispqqlgagqsgq	979
100	EEEccERIp	99	qsschvmqqccqrlpqi	980
101	agEgEEgFF	100	gqqagqqqqyyptspqqlg	981
102	EEEpFpEpE	101	gqvqwpqapfpqapqpfce	982
			pqqapfpqapqapfsqqpqa	983
			wpqapfpqapqapfcqqpqa	984
			qqqapfpqapqapqapfpqap	985
			psgqvqwpqapfpqapqpf	986
			pqqapfpqapqapfcqqpqt	987
			qqqapfpqapqapfcqqpqrti	988
			psgqvqwpqapqapfpqapqap	989
			qqqapfpqapqapfsqqpqqi	990
			gqvqwpqapqapfpqapqap	991
			psgqvqwpqapqapfpqapqap	992
			qqqapfpqapqapfcqqpqrti	993
			vdpsgqvqwpqapqapfpqapq	994
103	EIEFpEEEE	102	psgqvqwpqapqapfpqapqap	995
			niqvdpqgqvqwpqapqapfp	996
			gqvqwpqapqapfpqapqap	997
			psgqvqwpqapqapfpqapqap	998
			ttaniquvdpqgqvqwpqapq	999
			vdpsgqvqwpqapqapfpqapq	1000
			qivfpsgqvqwpqapqapfp	1001
			gqvqwpqapqapfpqapq	1002
			gqvqwpqapqapfpqapq	1003
104	EpIEEIceE	103	qstyqplqqlccqqlwqi	1004
			qstyqplqqlccqqlwqi	1005
			qstyqplqqlccqqlwqi	1006
105	pFpEpEFpS	104	ppqapypqapqfpsqlylql	1007
			gqqapfpqapypqapqfpsq	1008

			qqpfppqqpypqpfps qlp	1009
			qqpypqpfps qlpylqlqp	1010
106	aIESIpSmc	105	feeirnlalqtlpsmcnvyi	1011
			rnlalqtlpsmcnvyippyc	1012
			eirnlalqtlpsmcnvyipp	1013
107	RIFEIpERI	106	elccqhlwqipekl qcqaih	1014
			elccqhlwqipekl qcqaih	1015
			glccqhlweiipekl qg	1016
			glccqhlwqipekl qg	1017
			lccqhlwqipekl qcqaihn	1018
108	pFpESEESF	107	pfpwqppqpfqtqqsflq	1019
			qpfqtqqsflqpqqpfpq	1020
			fpwqppqpfqtqqsflqp	1021
			pfqtqqsflqpqqpfpqq	1022
109	EgFFEpSEE	108	gqgffqpsqqnpqaqsfq	1023
			gqgffqpsqqnpqaqg	1024
			qqypsgqgffqpsqqnpqaq	1025
			qqypsgqgffqpsqqnpqaq	1026
			gqgffqpsqqnpqaqg	1027
			psgqgffqpsqqnpqaqsf	1028
			qqypsgqgffqpsqqnpqaq	1029
110	ESIFESScR	109	ars qtlwqssch vmqqccr	1030
111	ISSIFSIII	110	llqqckpvs lvsslwsiiip	1031
			lvsslwsiiippsdcqvmrq	1032
			lvsslwsiiippsdcqvmrq	1033
112	ESFpEpEES	111	gqqtfpqpeqt fphqg	1034
			qqtfpqpeqt fphqppqqfp	1035
			gqqtfpqpeqt fphqg	1036
			qqpqtfpqpeqt fphqppq	1037
			phqt fhhqppqtfpqpeqt y	1038
			qqplsqqpqtfpqpeqt fp	1039
			qtfpqpeqt yphqppqqfpq	1040
			hqpfqqpqtfpqpeqt fp	1041
			qqtfpqpeqt fphqppqqvp	1042
			qtfpqpeqt yphqppqqfpq	1043
			qt fhhqppqtfpqpeqt yph	1044
			hhqppqtfpqpeqt yphqpp	1045
			qqtfpqpeqt fphqppqqfs	1046
			qtfpqpeqt yphqppqqfpq	1047
			qt fhhqppqtfpqpeqt yph	1048
			hhqppqtfpqpeqt yphqpp	1049
113	mEnSRIpGI	112	menshipgl erpsrqqlpp	1050
			menshipgl erlsqqqlpp	1051
			menshipgl egpsqqqlpp	1052
114	EEcSpIaIp	113	kvflqqcspvaip yrlars	1053
115	pFSEEEIp	114	qppfsqqqqt pfsqqqqip v	1054
			sqqqqpfsqqqqip vihps	1055
			qqqqtpfsqqqqip vihpsv	1056
116	ESRcIpGIE	115	etrcipgle rpwqqqlppq	1057
			metrcipgle rpwqqqlpp	1058
117	IpSIERpIE	116	metshipslekplqqqlpl	1059

			cashipslekplq qqpplplq	1060
118	aEIpFpEEp	117	qqpfpqpqq aqlpfpqqp qq	1061
			ppqaqlpfpqqp qqpplpqpq	1062
			qaqlpfpqqp qqpplpqpqq	1063
			qqpfpqpqq aqlpfpqqp qq	1064
			qpfpqpqq aqlpfpqqp qqp	1065
119	SIIIRSIpn	118	qppaqyevir slvrltlnm	1066
			qyevir slvrltlnmcnvy	1067
			qyevir slvrltlnmcnvy	1068
120	aEIEgIRSI	119	qpqqp aqlegirsl vlktlp	1069
			iiqqqp aqlegirsl vlkt	1070
121	EEpaEIEgI	120	qlaqqgliiqp qppaqlegi	1071
			qp qppaqlegi rslvlktlp	1072
			iiqp qppaqlegi rslvlkt	1073
122	SpIampERI	121	ckvflqqqc spvampqrl ar	1074
			lqqqc spvampqrl ar	1075
			vflqqc spvampqrl arsqm	1076
			qqqc spvampqrl arsqmwq	1077
			c spvampqrl arsqmwqqs	1078
			qc spvampqhl arsqmwqqs	1079
			ckvflqqqc spvampqrl ar	1080
			qqqc spvampqrl arsqmwq	1081
			vflqqqc spvampqhl arsq	1082
			vflqqqc spvampqrl arsq	1083
			spvampqrl arsqmlqqssc	1084
123	EInpcRnFI	122	qqlnpcknfl lqqckpvsiv	1085
			slqqslqqqlnpcknfl lq	1086
			qpslqq qvnpcknfl lqqck	1087
			iqqslqq qlnpcknfl lqqc	1088
			iqpslqq qvnpcknfl lqqc	1089
			lqqqvnpcknfl lqqcklvs	1090
124	IEpEEIaEI	123	qgtflqqqvaql elmtsia	1091
125	EFSEEEIp	124	qqp qfsqqqqip vihpsvlq	1092
			qppfsqqqqp qfsqqqqip v	1093
126	FpEpEpFpp	125	lqlqp fpqpqp fpp qlpypq	1094
			qpfpqqp yppqp fpp qlp	1095
			pypqpqp fpqpqp fpp qlpy	1096
			lqlqp fpqpqp fpp qlpypq	1097
			mqlqp fpqpqp fpp qlpypq	1098
			qqpfpqqp yppqp fpp ql	1099
			pfpqpqp fpp qlpypqpppf	1100
			pfpqpqp fpp qlpypqpqs f	1101
			ppqpqp fpqpqp fpp qlpypq	1102
			sqppylqlqp fpqpqp fpp q	1103
			pfpqpqp yppqp fpp qlpy	1104
127	FpEpEEpFc	126	qqqp fpqpqp fpc qqg	1105
			qqvqwpqqqp fpqpqp fpc e	1106
			wppqpqp fpqpqp fpc qqppq	1107
			qqqp fpqpqp fpc qqg	1108
			ppqpqp fpqpqp fpc eqpqr t	1109
			qqqp fpqpqp fpc qppqr t i	1110

			fpqpqqpfcqqpqrtipqph	1111
			qqqpfpqpqqpfcqqpqrti	1112
128	EEIpEIpEE	127	ccqqlpqipeqsryearai	1113
			sschvmqqqccqqlpqi	1114
			qccqqlpqi	1115
			qccqqlpqi	1116
			qccqqlpqi	1117
			qccqqlpqi	1118
			hvmqqqccqqlpqi	1119
			qccqqlpqi	1120
			qccqqlpqi	1121
			cqqlpqi	1122
129	pEESEEIIP	128	fpqpqlpfpqqseqiipqql	1123
			ppqqseqiipqqlqppfplqp	1124
			ppqqseqiipqqlqppfplqp	1125
			fpqpqlpfpqqseqiipqql	1126
130	pnnnSpSnR	129	plnnnnsppnnspnsnhhns	1127
			nnsppnnspnsnhhnsppnn	1128
			plnnnnsppnnspnsnhhns	1129
			nnsppnnspnsnhhnsppnn	1130
			nnsppnnspnsnhhnsppnn	1131
131	mEEEEEEER	130	iimqqeqqeqrqqvqi	1132
			ivhsiiimqqeqqeqrqqvqi	1133
			ivhsiiimqqeqqeqrqq	1134
			siivhsiiimqqeqqeqrqqvq	1135
			ivhsiiimqqeqqeqrqqvqi	1136
132	EEmpcRnF	131	qqmnpcknflqqcnhsvlv	1137
			iqsflqqmnpcknflqqc	1138
			qsflqqmnpcknflqqcn	1139
			iqpylqqmnpcknyllqqc	1140
			iqpylqqmnpcknyllqqc	1141
			lqqmnpcknyllqqcnpvs	1142
133	cnInIpIFR	132	tmcnvnplyr ttrvpfgv	1143
			tsfalrtlptmcnvnplyr	1144
134	IISIIpRS	133	cnhsvlvsslvsiilprsd	1145
			hsvlvsslvsiilprsdq	1146
			lvsslvsiilprsdqvmqq	1147
135	EIaEIpEES	134	schvmqqqccqqla	1148
			qccqqla	1149
136	RpFIEEpIp	135	mesniisflkpwlqqlpp	1150
			sniiisflkpwlqqlppqq	1151
137	pFpEpEEpE	136	qqpfpqpqpqlpfpqpqp	1152
			ppqpfpqpqpqpqpqpqp	1153
			qlpfpqpqpqpqpqpqp	1154
			qpqpqpqpqpqpqpqp	1155
			qpqpqpqpqpqpqpqp	1156
			sqqpqpqpqpqpqpqp	1157
			qpqpqpqpqpqpqpqp	1158
			qpqpqpqpqpqpqpqp	1159
			ppqpfpqpqpqpqpqpqp	1160
			skqpqpqpqpqpqpqpqp	1161

			qskqpqqpfpqpqqpqsfp	1162
			gqqpfpqpqqpqlpfg	1163
			qqpfpqpqqpqlpfpqqpqq	1164
			gqqpfpqpqqpqpfg	1165
			gqqpfpqpqqpqlpfg	1166
			qqpfpqpqqpqpfpqlqqp	1167
			gqqpfpqpqqpqsfg	1168
			qqvqwpqqqqpfpqpqqpqq	1169
			pqqpfpqpqqpqpfpqlqq	1170
			gqqpfpqpqqpqpfg	1171
			gqqpfpqpqqpqsfg	1172
			qqpfpqpqqpqpfpqsqqp	1173
			pfpqpqqpqsfpqqqpli	1174
138	FpEpEEpEE	137	pqqpfpqpqqpqpfpqpqq	1175
			qlpfpqpqqpfpqpqqpqq	1176
			pqqpfpqpqqpqpfpqpqq	1177
			qpfpqpqqpfpqpqqpqsfg	1178
			sqqpqqpfpqpqqpqsfpq	1179
			qqqpfpqpqqpqpfpqpqq	1180
			skqpqqpfpqpqqpqsfpq	1181
			qfpqpqqpqlqpqqpf	1182
			qskqpqqpfpqpqqpqsfp	1183
			qqfpqpqqpqpfpqpqqpqq	1184
			gqqpfpqpqqpqpfg	1185
			gfpqpqqpqsfpqqg	1186
			qqpqqpfpqpqqpqpfpqp	1187
			gfpqpqqpqpfpqpqq	1188
			pqpqqpfpqpqqpqsfpqq	1189
			gqqpfpqpqqpqsfg	1190
			gfpqpqqpqpfpqpqq	1191
			fpqpqqpqqqlqpqpfpq	1192
			qqpfpqpqqpqpfpqlqqp	1193
			pqqpfpqpqqpqpfpqpqq	1194
			gqqpfpqpqqpqsfg	1195
			qqvqwpqqqqpfpqpqqpqq	1196
			pqqpfpqpqqpqpfpqlqq	1197
			gqqpfpqpqqpqpfg	1198
			gqqpfpqpqqpqsfg	1199
			qqpfpqpqqpqpfpqsqqp	1200
			gfpqpqqpqsfpqqg	1201
			pfpqpqqpqsfpqqqpli	1202
			gqqpfpqpqqpqsfg	1203
			gqqpfpqpqqpqpfg	1204
			tfpqpqqpfpqpqqpqpfp	1205
			qtfpqpqqpfpqpqqpqq	1206
			sqpqqpfpqpqqpqsfpqq	1207
			qtcqpqpqqpfpqpqqpqp	1208
			gqqpfpqpqqpqpfg	1209
			qfpqpqqpqqqlqpqpfp	1210
			qfpqpqqpqqqlqpqpfp	1211
139	EEEEIEccE	138	lqqssyqqlqqlccqqlfqi	1212

			qssyqq1qq1ccqqlfqipe	1213
140	pEESFpEES	139	pqqsfpqqs qqsqqpfaqpq	1214
			pqpqqipvqppqqsfpqqs q	1215
			qpqqipvqppqqsfpqqs qq	1216
			vqpqqsfpqqs qqsqqpfaq	1217
141	IFpEpEpEF	140	rpqqlypqpqpqy sqpqqpi	1218
			qpfqpqqlypqpqpqy sqpqq	1219
142	EEpFpEEpE	141	qapfpqapq apfpqpqpip	1220
			qqflqp qapfpqapq apypq	1221
			plqp qapfpqapq apfpqpq	1222
			pqqqfiqp qapfpqapq aty	1223
			p qapfpqapq qqfpqpqpq	1224
			pqqqfpqpqpq qapfpqapq	1225
			tqap qapfpqapq apfpqtq	1226
			p qapfpqapq qpqqpfpqpq	1227
			qqpfpqt qqp qapfpqapq q	1228
			qtqap qapfpqapq apfpqt	1229
			qap qapfpqapq qqfpqpqpq	1230
			qapfpqapq apfpqt qpqpq	1231
			tpi qp qapfpqapq qpqpqf	1232
			qapypqapq apfpqt qpqpq	1233
			qqqfiqp qapfpqapq atyp	1234
			plqp qapfpqapq qpqpqfp	1235
			pqqqfiqp qapfpqapq aty	1236
			qapfpqpqp qapfpqapq qq	1237
			fplqp qapfpqapq apfpqp	1238
			pqqpflqp qapfpqapq apf	1239
			plqp qapfpqapq apfpqpq	1240
			qap qapfpqapq apfg	1241
			yp qapfpqapq apfpqpqpff	1242
			pqqp qapfpqapq qsfqpqp	1243
			p qapfpqapq qqfpqpqpq	1244
			qapfpqapq qpsqqppfpq	1245
			pqqqflqp qapfpqapq apy	1246
			plqp qapfpqapq apfpqpq	1247
			pqqpfpqpqp qapfpqapq	1248
			qap qapfpqapq apfg	1249
			rpfpqp qapypqapq apf	1250
			qap qapfpqapq qsfq	1251
			qap qapfpqapq qsfq	1252
			p qapfpqapq qsfqpqpqp	1253
			qapfpqapq apypqpqpqp	1254
			qp qapfpqapq apfpqt qap	1255
			qapfpqt qqp qapfpqapq q	1256
			fpqp qapypqapq apfpqt	1257
			p qapfpqapq atypqpqpqp	1258
			qap qapfpqapq qqfpqpqpq	1259
			pfpeqp qapypqapq	1260
			qap qapfpqapq qt fg	1261
			pfqpqp qapfpqapq qsfqp	1262
			qap qapfpqapq qt fg	1263

			yaqpylpyppqqpfpqqpqqp	1264
			ppqqpqqpfpqqpqqpqqpqqp	1265
			qqpqqpfpqqpqqpqqpqqp	1266
			ppqqpqqpfpqqpqqpqqpqqp	1267
			qqpqqpfpqqpqqpqqpqqp	1268
			qqpfpqqpqqpqqpqqpqqp	1269
			qqpfpqqpqqpqqpqqpqqp	1270
			lqpqqpfpqqpqqpqqpqqp	1271
			ppqqpfpqqpqqpqqpqqpqqp	1272
143	EIaEIEImS	142	qgtflqqpqqvaqlelmtsia	1273
			ppqqqqalahqiaqlevmtsi	1274
			qphqiaqlevmtsialrilp	1275
			phqiaqlevmtsfalrtlpt	1276
			hqiaqlevmtsialrilptm	1277
			gtllqphqiaqlevmtsial	1278
			qiaqlevmtsfalrtlptmc	1279
			tllqphqiaqlelmtsialr	1280
			flqphqiaqlevmtsiaprt	1281
			qgtflqphqiaqlevmtsia	1282
			qiaqlevmtsialrilptmc	1283
144	FEIpEESEc	143	elccqhlwqipeqsqcaih	1284
			hlwqipeqsqcaiqnvvha	1285
			qhlwqipeqsqcaihkvvh	1286
			elccqhlwqipeqsqcaih	1287
145	EEEEEEIc	144	qsgqqlsqsqqqsqqqqlgqc	1288
			qsdqgvsqsqqsqqqqlgqc	1289
			qgvsqsqqsqqqqlgqcsfq	1290
			filsvsqppqqsqsqqqqlgqq	1291
			qcvsqpqqsqqqqlgqqppq	1292
			qqsgqgvsqsqqsqqqqlgq	1293
			cvsqpqqsqqqqlgqqppqq	1294
			yqpqqsqqqqlgqcsfqppq	1295
			qsqqsqqqqlgqcsfqppqq	1296
			qpqqsqsqqqqlgqqppqqqq	1297
			qlgqcvsqppqqsqqqqlgqq	1298
			qlgqcvsqppqqsqqqqlgqq	1299
146	SIIEpSIIE	145	isivqpsilqqlnqckvflq	1300
			ppqqqisivqpsvlqqlnqck	1301
			qqqlppqqqisivqpsilqql	1302
147	FSaSSSIRF	146	plysattsvrfgvgtgvgay	1303
			vplysattsvrfgvgtgvga	1304
148	REEEEEEEI	147	aiimhqeeqqqqqlqqqqqqq	1305
			gqmhqeeqqqqqlqqqq	1306
			hqeeqqqqqlqqqqqqqqqq	1307
			iimhqeeqqqqqlqqqqqqql	1308
			gqmhqeeqqqqqlqqqq	1309
149	IIEEEEISpc	148	lqqilqqqltpcmdvvlqqh	1310
			qqqqqqqqilqqilqqqltpc	1311
			ilqqilqqqltpcmdvvlqq	1312
150	EEIIPEEEE	149	qqvlpqqqipfvhpsilqql	1313
			qlppfsqqqqqvlpqqqqipf	1314

151	FSEEEEpFp	150	fsqqqqp q fsqqqqpfp qqq	1315
			fsqqqqp q fsqqqqpfp qqq	1316
			ppfsqqqqp q fsqqqqpfp q	1317
152	cIpgIERpF	151	met s cipglerpwqqqlppq	1318
			etr cipglerpwqqqlppq	1319
			mr cipglerpwqqqlppqq	1320
			met r cipglerpwqqqlpp	1321
			mdt s cipglerpwqqqlpp	1322
			et s cipglerpwqqqlppq	1323
153	EEEcIpIam	152	mvflqqqcipvamqrclars	1324
			lnpckvflqqqcipvamqrc	1325
154	EIaEIpREI	153	vmqqccqqlaqiprql qca	1326
			qccqqlaqiprql qcaaihs	1327
			mqqccqqlaqiprql qcaa	1328
			qlaqiprql qcaaihsvvhs	1329
155	EEpREpEE	154	hhqqqpiqqqphqfpqq qpc	1330
156	RpmFIEpEE	155	ypqqrpmqlppqqpisqqqa	1331
			sfppqqppypqqrpmqlppqq	1332
			ypqqrpmqlppqqpisqqqa	1333
157	IEEEmpcR	156	iqsflqqqmpcknflqqc	1334
			qsflqqqmpcknflqqcn	1335
			iqpylqqqmpcknyllqqc	1336
			ppqqppaiqsflqqqmpck	1337
			iqpylqqqmpcknyllqqc	1338
			lqqqmpcknyllqqcnpvs	1339
158	SRIISpRgR	157	srllsprgkelhtpqeqfpq	1340
			srllsprgkelhtpqeqfpq	1341
159	REEEEEEEp	158	iilhqqqqqqp ssqvslqq	1342
160	dcEImEEEc	159	ilprsdcqvmqqqc cqq laq	1343
			smilprsdcqvmqqqc cqq l	1344
			vsiilprsdcqvmqqqc cqq	1345
161	SEpEIpFSE	160	qpylqlqpf s q p q l p y s q p q	1346
			lqlqpf s q p q l p y s q p q p f r	1347
			sqqpylqlqpf s q p q l p y s q	1348
			lqlqpf s q p q l p y s q p q p f r	1349
162	EIpFSEEE	161	qqqpilpqlpfsqqqqpvlp	1350
			plisqqqqlpfsqqqqp qfs	1351
			psflqqqpilpqlpfsqqqq	1352
163	EEpFpIEpE	162	ppqpqqpflppqppfpqqp	1353
			ppqpqqpflppqppfpqqp	1354
			ppqlqqpflppqppfpqqp	1355
			ppqpqqpflppqppfpqqp	1356
			ppqpflppqqsflwqsqqp	1357
			seqiipqqlqqpflppqpp	1358
			ppqpflppqqsflwqsqqp	1359
164	RFdaIRaII	163	pripeqsrydairaiiysiv	1360
			qsrydairaiiysivlqeqq	1361
			qsrydairaiiysivlqeqq	1362
			pripeqsrydairaiiysiv	1363
165	ESRFdaIRa	164	pripeqsrydairaiiysiv	1364
			qsrydairaiiysivlqeqq	1365

			peqsrydairaitypiilqe	1366
			qccqqlpripeqsrydaira	1367
			eqsrydairaitysiiilqeq	1368
			qccqqlpripeqsrydaira	1369
			qsrydaira iiysivlqeqq	1370
			pripeqsrydaira iiysiv	1371
166	EpSpEpEEI	165	flqqppqpsppqqqv vqiis	1372
			sqppflqqppqpsppqqqv v	1373
			ppqpsppqqqv vqiispatp	1374
167	SIREEpIIP	166	qppfslhqppvlpqqqipyv	1375
			qppfslhqppvlpqqqipyv	1376
			qpilppppfslhqppvlpq	1377
			qpilppppfslhqppvlpq	1378
168	ppFSIREEp	167	qqqqqpilppppfslhqpp	1379
			qppfslhqppvlpqqqipyv	1380
			qppfslhqppvlpqqqipyv	1381
			qpilppppfslhqppvlpq	1382
			qpilppppfslhqppvlpq	1383
169	FpIIIEEEE	168	dairaitypiilqeqqgfv	1384
170	FSEEEppF	169	pfsqqqqppfsqqqqpvlpq	1385
			qqppfsqqqqppfsqqplis	1386
			qpsfsqqqqppfsqqqqpfs	1387
			qqqqpftqqqqppfsqqppi	1388
			ppfsqqqqpsfsqqqqppfs	1389
			qqqqppfsqqqqppfsqqqq	1390
			sqqqqappfsqqqqppfsqq	1391
			fsqqqqppfsqqqqppysqq	1392
			psfsqqqqppftqqqqppf	1393
			vlpqqppfsqqqqppfsrsst	1394
			isqqqqappfsqqqqppfsq	1395
			ppfsqqqqppfsqqqqpfs	1396
			fsqqqqppfsrssthssqqpp	1397
			isqqqqppfsqqqqppfsq	1398
			qppyfsqqqqppysqqqqppf	1399
			qrqlppfsqqqqppfsqqqq	1400
			fsqqqqppfsqqqqppysqq	1401
			eqqqppfsqqqqppfsqqqqp	1402
			pfsqqqqppfsqhqqppvlpq	1403
			ysqqqqppysqqqqppfsqq	1404
			qqqqqqqqpftqqqqppfsq	1405
			fsqqqqppfsqqqqppftq	1406
			qqqqppfsqqqqppfsqqqq	1407
			ftqqqqppfsqqqpsisqqqq	1408
			niqqqqppfsqqqqppfsqq	1409
			qqqqpftqqqqppfsqqspi	1410
171	EREEpIIPe	170	sqhqppvlpqqqipsvqpsi	1411
			qqplfsqkqqppvlpqqpafs	1412
			plfsqkqqppvlpqqppfsqq	1413
			sqqqpppfsqhqqppvlpqq	1414
			pfsqqqqppfsqhqqppvlpq	1415
172	EEppFSEES	171	fsqqqqppfsqqtqpvlpqqs	1416

			ftqqqqppfsqqspisqqqq	1417
			qqqppftqqqqppfsqqspi	1418
173	EEEEEEEEp	172	qqqqqqqqqp lsqvsfqppq	1419
			qqqqqqqqqp lsqvcfqqsq	1420
			pfsqqqqqqqqppfsqqq	1421
			gsgqqqqqqqqp gsg	1422
			ppfsqqqqqqqp fpqqpsf	1423
			qqqqspfsqqqqqqppfl	1424
			spisqqqqqqqqppftq	1425
			sqqqqqqqqppflqqqqppf	1426
			gqqqqqqqqqp lsqvg	1427
			qqqqqqqqqqppssqv	1428
			qqqqppftqqqqqqqqqp f	1429
			gqqqqqqqqqp lsqvg	1430
			qqqqqqqqqp ssqvsfqppq	1431
			qqqqqqqqqp ftqqqqppfsq	1432
			qqppfsqqqqqqqqqp fpqq	1433
			qqqqqqqqqqqp lsqvcf	1434
			qqqqqqqqqqqp lsqvsf	1435
			ilhqqhqqqqqqqqqqqp	1436
			qqppfsqqqqqqqqqp pfsq	1437
			qqqqqqqqqp lsqvsfqppq	1438
			hhhqqqqqqqqqp lsqvsf	1439
			aiilhqqqqqqqqqqqp ls	1440
174	EEEEppFS	173	pfsqqqqqqqqppfsqqq	1441
			sqqqppfsqqqqppfsqqq	1442
			isqqqqppfsqqqqppfsq	1443
			psfsqqqqppftqqqqppf	1444
			fsqqqqppfsqqqqppftq	1445
			qqppfsqqqqqqqqppfsq	1446
175	pSIEpSIIE	174	qipsvqpsilqqlnpcklfl	1447
			pvlpqqqipsvqpsilqqln	1448
176	pEEEEIgEEp	175	qqqlgqcsfqppqqqlgqqp	1449
			qlssqvsfqppqqqlgqqp q	1450
			sfqppqqqlgqqpqqqqqqv	1451
			qpqqqlgqqpqqqqqqqlq	1452
			sfqppqqqlgqqpqqqqqqv	1453
			qqqlgqcsfqppqqqlgqqp	1454
			csfqppqqqlgqqpqqqqqq	1455
177	csFEEpEEE	176	qqqlgqcsfqppqqqlgqqp	1456
			lgqcsfqppqqqlgqqwpqq	1457
			sqqqllqcsfqppqqqlgqq	1458
			qsqqqlgqcsfqppqqqlgq	1459
			qqqlgqcsfqppqqqlgqqp	1460
			csfqppqqqlgqqpqqqqqq	1461
178	REIccERIF	177	gplrelccqhlwqipg	1462
			qstyqllrelccqhlwqipe	1463
			qstyqllrelccqhlwqipe	1464
			gplrelccehlwqipg	1465
			qstyqllrelccqhlwqipe	1466
179	IEEEpIIpE	178	peppfslqqppvlpqspfs	1467

			qqp ilpeppfs lqqqpvlpq	1468
			psflqqq pilpqlpfsqqqq	1469
			pfsqqqpsflqqq pilpqlp	1470
180	ERppFSEEE	179	qrppfsqqqqqpvlpqqppf	1471
			lqqppfsqqrppfsqqqqq	1472
			qrppfsqqqqqpvlpqqppf	1473
			lqqppfsqqrppfsqqqqq	1474
181	mIFIEEEcI	180	svlqq lnpcmvflqqqci pv	1475
			mvflqqqci pvamqrclars	1476
182	EEERpFIEp	181	qqsfpgqqrpfiqpslqqql	1477
			qqqqqqsfpgqqrpfiqps	1478
			fpqqrpfiqpslqqqlnpc	1479
183	SFpEIpgeI	182	gyyp tfpqlpgql qppaqqq	1480
184	IEEEIIPeI	183	ggqvqwlqeqlvpql g	1481
			psgqvqwlqqqlvpql qqpl	1482
			ggqvqwlqeqlvpql g	1483
			ggqvqwlqqqlvpql g	1484
			psgqvqwlqqqlvpql qqpl	1485
185	ppFIEpSIE	184	fpqqppfiqpslqqqv npc	1486
			ppqqppfiqpslqqqv npc	1487
			qqppqsfppqqppfiqpslq	1488
186	IIPeEpaFS	185	qqpl fsqkqqpvlpqqpafs	1489
			kqqpvlpqqpafsqqqvtl	1490
			qqqvtlvpqqpafsqqqhqql	1491
187	pEpEEeIpE	186	lqqppqpfppppqqlppqq	1492
			qqppfpqppqqlppq	1493
			lqqppqpfppppqqlppqq	1494
			qqppfpqppqqlppq	1495
			qqfpqppqqlppppqsf	1496
			ppppqqlppppqsfppq	1497
188	gSanmEIdp	187	gtanmqvdpssqvqwpqqq	1498
			gtanmqvdpssqvqwpqqq	1499
			gtanmqvdpssqvqwpqqq	1500
189	EEEgmRIFI	188	qqqqqqqqqgmhiflplsqq	1501
			imqqqqqqqqqgmhiflpl	1502
			qqqqgmhiflplsqqqqvqg	1503
190	RIIRaIIIR	189	cgaihkvvhaiilhqqkqq	1504
			qaihkvvhaiilhqqkqq	1505
191	IpIFgSSSS	190	lrtlpmmcsvnvpvygttts	1506
			lptmcgvnvpvygtttsvpf	1507
			vpvygtttsvpfgvgtqvg	1508
			csvnvpvygtttsvpfgvgt	1509
192	pEEIqEEpE	191	pppqqlgqqqqqevpvaf	1510
			qcsfqqppqqqlqqppqqe	1511
193	ESgEEeIIE	192	qqvsqqqqqsgqqqlvqcsf	1512
			qsgqqqlvqcsfqqppqqql	1513
194	FppEIpFpE	193	ppp fppqlpypqqqlpypq	1514
			ppp fppqlpypqqqlpypq	1515
			qp fppqlpypqqpfrppq	1516
			ppp fppqlpypqqqlpypq	1517
			lqlqpfppqpp fppqlpypq	1518

			ppq fppqlpypq pqp frpqq	1519
			ppq fppqlpypq ppp fspqq	1520
			lqlqpfppqpq fppqlpypq	1521
			ppq fppqlpypq pqs fppqq	1522
			mqlqpfppqp fppqlpypq	1523
			gqpqp fppelpypqpg	1524
			gqpqp fppqlpypqpg	1525
			pfppqpq fppqlpypq pppf	1526
			pfppqpq fppqlpypq pqs f	1527
			ppqpq fppqpq fppqlpypq	1528
			ppq fppqlpypq ppp fspqq	1529
			gsg fppelpypqgsg	1530
			ppqpq fppqlpypq tqpfpp	1531
			ppq fppqlpypq tqpfppq	1532
			qp fppqlpypq tqpfppqp	1533
195	cSpIampER	194	ckvflqqq cspvampqr lar	1534
			lqqq cspvampqr lar	1535
			vflqq cspvampqr larsqm	1536
			lnpckvflqqq cspvampqr	1537
			qqq cspvampqr larsqmwq	1538
			csqvampqr larsqmwqqss	1539
			q cspvampqh larsqmwqqss	1540
			ckvflqqq cspvampqr lar	1541
			qlnpckvflqq cspvampqr	1542
			qqq cspvampqr larsqmwq	1543
			vflqqq cspvampqh larsq	1544
			vflqqq cspvampqr larsq	1545
196	dEESgEgEE	195	sgqrqqdqsgqqqppgqrq	1546
197	EIEESIIFg	196	tppqqlqqsilwgipallr	1547
198	pFSEEEIpI	197	qqppfsqqelpi lpqppfs	1548
			qqpppfsqqppfsqqelpi	1549
			fsqqppfsqqelpi lpqpp	1550
199	SSRIpgIER	198	metshipglekpsqqqplpl	1551
			metsrvplekpwqqqplpp	1552
200	SIaIRSIpm	199	lmt sialrtlpmmcsvnpv	1553
			hlevmt sialrtlpmmcsvn	1554

**Figure 6**

- Sequence 1: P(QR)P(QE)LP(FY)PQ (SEQ ID NO: 1555)  
 Optimal responding peptide: PQLPYQPQLPYQPQPFPRP (SEQ ID NO: 1556)  
 High grade peptide: QLQPFQPELPYPQPQP (SEQ ID NO: 1557)  
 Groups included: 1,2,7,8,10,16,22,23,72
- Sequence 2: P(FY)P(QR)P(QE)LP(FY) (SEQ ID NO: 1558)  
 Optimal responding peptide: PQLPYQPQLPYQPQPFPRP (SEQ ID NO: 1559)  
 High grade peptide: QLQPFQPELPYPQPQP (SEQ ID NO: 1560)  
 Groups included: 1,2,7,8,10,16,22,23,72, 76 PART
- Sequence 3: (PIAT)FPQ(PT)(QE)Q(PTS)(FITY) (SEQ ID NO: 1561)  
 Optimal responding peptide: QFFPQPQQFFWQPQQFFPQ (SEQ ID NO: 1562)  
 High grade peptides: GQQPFQPEQFPWQG (SEQ ID NO: 1563)  
 GQQPFQPEQPIPVQG (SEQ ID NO: 1564)  
 Groups included:  
 3,5,6,9,20,24,29,60,69,70,73,74,77,102PT,108,112
- Sequence 4: PQ(PT)(QE)Q(PTS)(FIY)(PS)(VWHQL) (SEQ ID NO: 1565)  
 Optimal responding peptide: QFFPQPQQFFWQPQQFFPQ (SEQ ID NO: 1566)  
 High grade peptide: GQQPFQPEQFPWQG (SEQ ID NO: 1567)  
 GQQPFQPEQPIPVQG (SEQ ID NO: 1568)  
 Groups included: 3,5,6,9,20,60,66,69,73,74,77,PART 86  
 (3 AND 4 OVERLAP)  
 Status: Similar to Sequence 3
- Sequence 5: (KQW)(QR)P(QE)Q(SPIT)(FLY)PQ (SEQ ID NO: 1569)  
 Optimal responding peptide: QPQLPFPQQPQQPQQPFPQ (SEQ ID NO: 1570)  
 High grade peptide: GFPQTQQPEQFPQQG (SEQ ID NO: 1571)  
 Groups included: 11,12,32,54,55,56,59,61,62,65
- Sequence 6: P(FIYL)(PS)(QE)(QR)P(QE)Q(PT) (SEQ ID NO: 1572)  
 Optimal responding peptide: PLQPQQPFPQQPQQPFPQPQ (SEQ ID NO: 1573)  
 High grade peptide: GQPFPEQPPFPQQG (SEQ ID NO: 1574)  
 Groups included: 32PT,54,55,56,57,61,62,63PT,75,85.94PT
- Sequence 7: FLP(QE)LPYPQ (SEQ ID NO: 1575)  
 Optimal responding peptide: LQLQFPQPQPFLPQLPYPQ (SEQ ID NO: 1576)  
 High grade peptide: PQQPFLPELPYPQPQS (SEQ ID NO: 1577)  
 Groups included: 13,27,71 PART
- Sequence 8: LQQIL(QE)QQL (SEQ ID NO: 1578)  
 Optimal responding peptide: LQQILQQQLTPCMDVVLQQH (SEQ ID NO: 1579)  
 High grade peptide: NO  
 Groups included: 14,89
- Sequence 9: FSYQ(EQ)QFPFQQ (SEQ ID NO: 1580)  
 Optimal responding peptide: PQQSFSYQQPFPQQPYPQQ (SEQ ID NO: 1581)  
 High grade peptide: NO  
 Groups included: 15,96PT
- Sequence 10: FPS(QE)(LQ)PY(LM)Q (SEQ ID NO: 1582)  
 Optimal responding peptide: PFPQQPYLQLQFPQPQLP (SEQ ID NO: 1583)  
 High grade peptide: NO  
 Groups included: 16PT,35,38,71PT, 76PT,92PT,93PT
- Sequence 11: (PQSH)QP(QE)Q(QE)(LF)(PS)Q (SEQ ID NO: 1584)  
 Optimal responding peptide: QQPQQPFPQQPQQPFPQQ (SEQ ID NO: 1585)  
 High grade peptide: GFFPQPEQEFPQQG (SEQ ID NO: 1586)

35/40

Groups included: 17,25,36,40,41,80,88

- Sequence 12: P(FW)(SP)(EQ)Q(EQT)QP(VILSF) (SEQ ID NO: 1587)  
 Optimal responding peptide: QQQQPPFSQQQQPVLPQQSP (SEQ ID NO: 1588)  
 (similar to but more active than PFSQQQSF in WO 02/083722)  
 PSGQVQWPQQQQPFPQPQP (SEQ ID NO: 1589)  
 High grade peptide: QQPPFSEQEQPVLPQG (SEQ ID NO: 1590)  
 Groups included: 18,79,84PT,97,102PT,103PT,115
- Sequence 13: (IL)QP(QE)QPFQ (SEQ ID NO: 1591)  
 Optimal responding peptide: FTQPQQPTPIQPQQPFPQP (SEQ ID NO: 1592)  
 (similar to but more active than IIQPQQPAQ in WO 02/083722)  
 High grade peptide: GQQQFIQPEQPFPQOG (SEQ ID NO: 1593)  
 Groups included: 19 (PART),26,30,58
- Sequence 14: QQP(EQ)LPFPQ (SEQ ID NO: 1594)  
 Optimal responding peptide: QQPQQPFPQPQQPQLPFPQQ (SEQ ID NO: 1595)  
 High grade peptide: NO  
 Groups included: 21,64
- Sequence 15: QPQQP(EQ)LPF (SEQ ID NO: 1596)  
 Optimal responding peptide: QQPQQPFPQPQQPQLPFPQQ (SEQ ID NO: 1597)  
 High grade peptide: NO  
 Groups included: 21
- Sequence 16: PQP(EQ)QP(EQ)LP (SEQ ID NO: 1598)  
 Optimal responding peptide: QQPQQPFPQPQQPQLPFPQQ (SEQ ID NO: 1599)  
 High grade peptide: NO  
 Groups included: 21
- Sequence 17: VFLQQQCSPV (SEQ ID NO: 1600)  
 Optimal responding peptides:  
 GROUP 28: SVLQQLNPCKVFLQQQCShV (SEQ ID NO: 1601)  
 GROUP 122: CKVFLQQQCSPVAMPQRLAR (SEQ ID NO: 1602)  
 GROUP 114: KVFLQQQCSPVAIPYRLARS (SEQ ID NO: 1603)  
 High grade peptide: NQ  
 Groups included: 28,114,122
- Sequence 18: (M)(WL)(QW)QSSCHVMQ (SEQ ID NO: 1604)  
 Optimal responding peptides:  
 GROUP 39: PQLARSQMWWQSSCHVMQQ (SEQ ID NO: 1605)  
 GROUP 110: ARSOTLWQSSCHVMQQCCR (SEQ ID NO: 1606)  
 High grade peptide: NO  
 Groups included: 39,110
- Sequence 19: QPQQQQLAH (SEQ ID NO: 1607)  
 Optimal responding peptide: QQPQQQQLAHGTFLOPHQIA (SEQ ID NO: 1608)  
 High grade peptide: NO  
 Groups included: 31
- Sequence 20: FPLQPQQP(FL)PQ (SEQ ID NO: 1609)  
 Optimal responding peptide: PQQLQQPFPPLQPQQPFPQP (SEQ ID NO: 1610)  
 High grade peptide: NO  
 Groups included: 33
- Sequence 21: FPP(QE)(LQ)PYPQ (SEQ ID NO: 1611)  
 Optimal responding peptide: PPFPPPELPYPQPQFRPQQ (SEQ ID NO: 1612)  
 High grade peptide: PFPQFPFPQLPYPQPQS, (SEQ ID NO: 1613)  
 GQQQFPFPPEQPYPQOG (SEQ ID NO: 1614)  
 Groups included: 37,52,71,92PT,93PT,105

36/40

- Sequence 22: LCC(QE)(HQR)L(PW)(QE)IP (SEQ ID NO: 1615)  
Optimal responding peptide: QSTYQPLQQQLCCQQLWQIPE (SEQ ID NO: 1616)  
High grade peptide: NO  
Groups included: 39PT,100,104,107,178
- Sequence 23: P(WLS)(QL)(QE)QPL(PQ)(PQ) (SEQ ID NO: 1617)  
Optimal responding peptide: ERPWQEQLPQPHTLFPQQQ (SEQ ID NO: 1618)  
High grade peptide: NO  
Groups included: 44,78,90,95PT,98,116,117,113
- Sequence 24: QPLP(QE)QPSF (SEQ ID NO: 1619)  
Optimal responding peptide: PPFSSQQQQPLPQQPSFSQQ (SEQ ID NO: 1620)  
High grade peptide: NO  
Groups included: 45,95PT
- Sequence 25: PF(SP)QQQQP(LVI) (SEQ ID NO: 1621)  
Optimal responding peptide: PPFSSQQQQPLPQQPSFSQQ (SEQ ID NO: 1622)  
High grade peptide: NO  
Groups included: 45 PART
- Sequence 26: IVYSTILQE (SEQ ID NO: 1623)  
Optimal responding peptide: QQSRYEAIRAIVYSTILQEQ (SEQ ID NO: 1624)  
High grade peptide: NO  
Groups included: 46
- Sequence 27: PFSQ(QE)QP(IS)(LF)S (SEQ ID NO: 1625)  
Optimal responding peptide: FSQQQPFSQQQPILSQQPP (SEQ ID NO: 1626)  
High grade peptide: NO  
Groups included: 47 PART,68
- Sequence 28: QGIQILRPL (SEQ ID NO: 1627)  
Optimal responding peptide: QEQQQGIQILRPLFQLVQGG (SEQ ID NO: 1628)  
High grade peptide: NO  
Groups included: 48
- Sequence 29: PFSSVVAGI (SEQ ID NO: 1629)  
Optimal responding peptide: CSIIKAPFSSVAGIGGQYR (SEQ ID NO: 1630)  
High grade peptide: NO  
Groups included: 49
- Sequence 30: YCSTTIAPV (SEQ ID NO: 1631)  
Optimal responding peptide: YIPPYCSTTIAPVGIFGTN (SEQ ID NO: 1632)  
High grade peptide: NO  
Groups included: 50
- Sequence 31: HVAMSQRLA (SEQ ID NO: 1633)  
Optimal responding peptides: QQCSHVAMSQRLARSQMWWQ (SEQ ID NO: 1634)  
High grade peptide: NO  
Groups included: 51
- Sequence 32: YSIIILQ(QE)(QE)(QE)QGF (SEQ ID NO: 1635)  
Optimal responding peptide: RYDAICAITYSIIILQEQQQG (SEQ ID NO: 1636)  
High grade peptide: NO  
Groups included: 53
- Sequence 33: FPHQPQEQAFFQ (SEQ ID NO: 1637)  
Optimal responding peptide: QQIFPQPQQTFPHQPQQAFFQ (SEQ ID NO: 1638)  
High grade peptide: GQTFPHQPQEQAFFQPG (SEQ ID NO: 1639)  
Groups included: 67

37/40

- Sequence 34: PS(GS)(QE)V(QE)WPQ (SEQ ID NO: 1640)  
Optimal responding peptide: ATANMQADPSGQVQWPQQQP (SEQ ID NO: 1641)  
High grade peptide: NO  
Groups included: 81,102PT
- Sequence 35: GALCSSLSN (SEQ ID NO: 1642)  
Optimal responding peptide: FDEEKNSTGALCSSLSNQAS (SEQ ID NO: 1643)  
High grade peptide: NO  
Groups included: 82
- Sequence 36: QFP(QE)Q(QE)IPV (SEQ ID NO: 1644)  
Optimal responding peptide: QPPFPQQHQQFPQQQIPVVQ (SEQ ID NO: 1645)  
High grade peptide: NO  
Groups included: 83
- Sequence 37: P(FY)P(QE)QP(YF)PQ (SEQ ID NO: 1646)  
Optimal responding peptide: QQFPQQPYPQQPYPSQQPY (SEQ ID NO: 1647)  
High grade peptide: NO  
Groups included: 96
- Sequence 38: QAGQG(QE)(QE)GY (SEQ ID NO: 1648)  
Optimal responding peptide: GQQAGQGQQGYPTSPQQLG (SEQ ID NO: 1649)  
High grade peptide: NO  
Groups included: 101
- Sequence 39: TLPSMCNVY (SEQ ID NO: 1650)  
Optimal responding peptide: FEEIRNLALQTLPSMCNVYI (SEQ ID NO: 1651)  
High grade peptide: NO  
Groups included: 106
- Sequence 40: FQPSQ(QE)NPQ (SEQ ID NO: 1652)  
Optimal responding peptide: QQYPSGQGFFQPSQQNPQQAQ (SEQ ID NO: 1653)  
High grade peptide: NO  
Groups included: 109
- Sequence 41: IRSLVLKTL (SEQ ID NO: 1654)  
Optimal responding peptide: QPQQPAQLEGIRSLVLKTL (SEQ ID NO: 1655)  
High grade peptide: NO  
Groups included: 119,120,121

**Figure 7**

Gliadin Sequence	SEQ ID NO:	High quality peptide	A	B	C	D	E	F	G	H	I	J
1,2	1656	QLQFFPQQLPYQPQP	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1657	GQQFFPQPEQPFVWQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1658	GQQFFPQPEQPIPVQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1659	GQQFFPQPEQPFVWQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
5	1660	GFPQTQQPEQPFVWQG		Y	Y				Y	Y		Y
5	1661	GFPQTQQPEQPFVWQG		Y	Y				Y	Y		Y
6	1662	GQPFPEQPPQPFVWQG								Y		
7	1663	PQPQFFLPQLPYQPQS	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
11	1664	GFFPQPEQEFPVWQG		Y	Y	Y	Y		Y			Y
11	1665	GFFPQPEQEFPVWQG		Y	Y	Y	Y		Y			Y
12	1666	GQPPFSEQEQVLPQG					Y		Y		Y	
12	1667	GQPPFSEQEQVLPQG					Y		Y		Y	
13	1668	GQQQFIQPEQPFVWQG		Y	Y	Y		Y	Y	Y		Y
21	1669	PQPQFFPQLPYQPQS	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
21	1670	GQQQFFPPEQPFVWQG		Y	Y						Y	Y
33	1671	GQTFPHQPEQAFFVWQG		Y	Y				Y		Y	Y

**Figure 8**

Avenin 20mer	SEQ ID NO:	Predicted core sequence(s)	SEQ ID NO:	Lambda	Proportion
TTTVQYDPSEQYQPYPEQQQ	1672	DPSEQYQPY	1684	33.58	0.145
QFDPSEQYQPYPEQQQPILQ	1673	PYPEQQQPI DPSEQYQYP	1685 1686	122.34	0.103
*VQYDPSEQYQPYPEQQQPFV	1674	PYPEQQQPF DPSEQYQYP	1687 1688	122.34	0.105
TVQYNPSEQYQPYPEQQQEPF	1675	PYPEQQQEPF DPSEQYQYP	1689 1690	146.42	0.051
YQPYPEQQQPILQQQQMLLQ	1676	PYPEQQQPI	1691	52.56	0.126
EQYQPYPEQQQPFVQQQPPF	1677	PYPEQQQPF	1692	90.39	0.053
SEQYQPYPEQQPFMQPLLQ	1678	PYPEQQPFM	1693	19.07	0.226
*CRRLEQIPEQLRCPAHSVV	1679	RRLEQIPEQ	1694	61.47	0.069
*QIPEQLRCPAHSVVQAAIL	1680			94.84	0.033
*NNKREQQFGQNI FSGFSVQL	1681			104.78	0.077
*QILRQAICQVTRQCCRQLA	1682			34.01	0.055
*VPFLRSQILRQSTCHVMRRQ	1683			92.47	0.067

Sequence 1: PYPEQ(QE)QP(IF) (VLM) (SEQ ID NO:1695)  
 Optimal responding peptide: QFDPSEQYQPYPEQQQPILQ (SEQ ID NO:1696)  
 High grade peptide: NO  
 POTENCY: 6/30 RESPONDERS, RESPONSE RATE 122.3  
 (HOMOLOGOUS TO WHEAT Sequence 12: GQPPFSEQEQPVLPQG (SEQ ID NO:1590))

Sequence 2: CRRLEQIPEQLRCPAHSVV (SEQ ID NO:1697)

Sequence 3: QFGQNI FSGFSVQLLSEALG (SEQ ID NO:1698)  
 POTENCY: 12/30 RESPONDERS, RESPONSE RATE 11.2

**Figure 10**

VRVPVPQLQP QNPSQQQPQE QVPLVQQQOF PGQQQQFPPQ  
 QPYPQPQFPF SQQPYLQLQP FPQPQLPYPQ PQSFPPQQPY  
 POPQPQYSQP QQPISQQQAQ QQQQQQQQQQ QQQILQQILQ  
 QQLIPCMDVV LQQHNIAHAR SQVLQQSTYQ LLQELCCQHL  
 WQIPEQSQCQ AIHNVVHAI LHQQQKQQQQ PSSQVSFQQP  
 LQQYPLGQGS FRPSQQNPOA QGSVQPQQLP QFEEIRNLAL  
 QTLPAMCNVY IAPYCTIAPF GIFGTN (SEQ ID NO: 1928)

**Figure 9**

Group	Predicted epitope "core(s)"	SEQ ID NO:	Sequences	SEQ ID NO:	Response (SFC)	
					A	B
1	QQPTPIQPQ	1699	PFTQPQQPTPIQPQQPFQ	1722	70	18
2	QQPFPQPQ or QQPFPWQPQ or QQPFPQSQQ	1700 1701 1702	QQQFIQPQQPFPQQPQTYF	1723	57	21
			PFPQQPQQPFPQQPQQSFQ	1724	53	23
			TPIQPQQPFPQQPQQPQQPF	1725	64	16
			QTQQPQQPFPQQPQQPFPQT	1726	52	17
			QQFLQPQQPFPQQPQQPYFQ	1727	44	16
			PQQPFPQQPQQPQQPFPQFQ	1728	51	14
			QQPFPQQPQQPFPQFQQPIF	1729	81	10
			PQQPFLQPQQPFPQQPQQPF	1730	45	9
			QFPQPQQPFPWQPQQPFPQ	1731	19	8
			QPQQPFPQSQQPQQPFPQFQ	1732	41	15
			PQTQQPQQPFPQSQQPQQPF	1733	36	9
3	QQPFLQPQ or QQPFPQLQQ	1703 1704	SEQIIPQQQLQQPFPQLQPQQP	1734	12	3
			PFPQTQQPQQPFPQLQQPQQ	1735	25	13
4	QQPIPVQPQ or QQPIPQQPQ or QQPYPQQPQ	1705 1706 1707	QPQQPIPVQPQQSFQQSQ	1736	60	12
			FPELQQPIPQQPQQPFPQLQF	1737	22	7
			FQQQPQQPYQQPQQPFPQT	1738	19	4
			PRQFPQQPQQPYQQPQQP	1739	19	13
5	PQQPQQSFQQQ or PQQPQQPFPQQQ	1708 1709	PFPQPQQPQQSFQQQQPLI	1740	29	15
			LPQPQQPQQSFQQQRPFQ	1741	37	12
			QPQQPQQPFPQQQQPLIQPY	1742	49	17
6	QGSFQPSQQ	1710	QPQQQYPSGQGSFQPSQQNP	1743	54	5
			QYPSSQGSFQPSQQNPQAQG	1744	32	7
			GQGFQPSQQNPQAQGSFQF	1745	7	3
7	PQQPFPQPQQ or PQQPFPQTQQ or	1711 1712	PQTQQPQQPFPQPQQTFPQQ	1746	21	9
			QQPQQPFPQPQLPFPQQSEQ	1747	15	2
			FPWQPQQPFPQTQQSFPLQF	1748	25	7
8	QQPQQPFPQ or QQPQQPYPQ	1713 1714	PFPQTQQPQQPFPQLQQPQQ	1749	25	13
			QQPLPQPQQPQQPFPQSQQP	1750	54	20
			PFPQLQQPQQPFPQPQQQLP	1751	36	5
			PRQFPQQPQQPYQQPQQP	1752	19	13
9	PFPQPQQPQ or PFPQSQQPQ or PFPQPQQAQ or QFPQTQQPQ	1715 1716 1717 1718	PQQPFPQPQQPQQPFPQLQQ	1753	37	8
			PQTQQPQQPFPQSQQPQQPF	1754	36	9
			QPQQPFPQSQQPQQPFPQPQ	1755	41	15
			PQQPQQPFPQPQQQLPFPQ	1756	16	7
			HQPQQQFPQTQQPQQPFPQF	1757	30	14
10	PQQQFIQPQ	1719	FSQPQQPQQQFIQPQQPFPQ	1758	45	8
11	QQPQLPFPQ or LQPQQPFPQ	1720 1721	PQPQQPQLPFPQQPQQPFPQ	1759	79	7
			PQQQFLQPQQPFPQQPRQPY	1760	35	14
12			QTLPAMCNVYIIPHCSTTIA	1761	35	7
13			NPSQQQPOEQVPLVQEQQFQ	1762	5	16
14			HHFRSNSNHFFHSNNNQFYR	1763	14	3

专利名称(译)	表位与乳糜泻有关		
公开(公告)号	<a href="#">EP1755639A2</a>	公开(公告)日	2007-02-28
申请号	EP2005738143	申请日	2005-04-28
[标]申请(专利权)人(译)	BTG INT NO 2664412		
申请(专利权)人(译)	BTG国际有限公司 ( 公司编号2664412 )		
当前申请(专利权)人(译)	BTG国际有限公司 ( 公司编号2664412 )		
[标]发明人	BEISSBATH TIM		
发明人	ANDERSON, ROBERT, THE WALTER AND ELIZA HALL INST. BEISSBATH, TIM DIN, JASON TYE, THE WALTER AND ELIZA HALL INST.		
IPC分类号	A61K38/16 A23L7/10 A61K38/00 A61K38/10 A61K39/00 A61P1/00 C07K14/415 C12N15/11 C12N15/29 G01N33/53		
CPC分类号	A61K38/168 A61P1/00 A61P37/00 A61P37/04 A61P37/06 A61P37/08 A61K39/00		
代理机构(译)	DOLAN , ANTHONY PATRICK		
优先权	2004201774 2004-04-28 AU 2005900650 2005-02-11 AU		
其他公开文献	EP1755639B1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本文公开的发明涉及可用于诊断，治疗和预防乳糜泻的方法中的表位。提供了包含至少一个表位的治疗组合物。